1. Introduction {#sec1-antibiotics-09-00500}
===============

Antimicrobial resistance (AMR) is a health issue of global concern, burdened with elevated costs and high morbidity and mortality rates. Limited therapeutic options and the increasing occurrence of resistance to last-resort antibiotics, i.e., colistin or carbapenems, make it necessary to reassess the role of "old" drugs while waiting for new antibiotics available on the market.

Fosfomycin (FOS) is an inhibitor of the synthesis of the bacterial wall acting with a unique mechanism of action. To carry out its action, FOS enters in the bacterial cell through the L-alpha-glycerophosphate and the hexose-6-phosphate transporter systems, interfering with the formation of the peptidoglycan precursor uridine diphosphate N-acetylmuramic acid (UDP-MurNAc) \[[@B1-antibiotics-09-00500]\].

FOS, after being discovered in 1969 \[[@B2-antibiotics-09-00500]\], has long been prescribed orally for low urinary tract infections (UTIs) and only recently has been repurposed, also intravenously and in combination, as a meropenem- and colistin-sparing agent to treat other infections (complicated UTIs, severe soft tissue infections, osteomyelitis, prostatitis, etc.) \[[@B1-antibiotics-09-00500],[@B3-antibiotics-09-00500],[@B4-antibiotics-09-00500],[@B5-antibiotics-09-00500]\]. The excellent distribution in body sites, the safety and tolerability profile, as well as its affordability, make FOS a therapeutic option worth considering to treat multidrug-resistant (MDR) bacterial infections \[[@B6-antibiotics-09-00500],[@B7-antibiotics-09-00500]\].

FOS is generally prescribed in association with at least another active agent. The association benefits from increase in the bactericidal effect of FOS, prevention of AMR, limitation of side effects thanks to lower dosages. Examples of commonly used empirical combination regimens including FOS are: Carbapenems + FOS, colistin + FOS, ceftolozane/tazobactam + FOS and tigecycline (TIG) + FOS.

We performed a systematic literature review concerning in vitro and in vivo studies to evaluate the synergistic effect of FOS in combination with other antibiotics and offer an overall view with clinically practical tables divided by antibiotic class.

2. Materials and Methods {#sec2-antibiotics-09-00500}
========================

This systematic review was carried out following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA).

On 14 April 2020 we performed a MEDLINE/PubMed search using the search string "Fosfomycin\"\[Tw\] AND (synerg\*\[Tw\] OR association\*\[Tw\] OR combin\*\[Tw\] OR "together"\[Tw\] OR "additive"\[Tw\] OR "addition"\[Tw\] OR "checkerboard"\[Tw\] OR "chequerboard"\[Tw\] OR "time kill"\[Tw\] OR "time--kill"\[Tw\] OR "time--killing"\[Tw\] OR "time killing"\[Tw\])".

1232 papers, from inception to 14 April 2020, were identified. Of these, 870 were excluded by title screening, 84 by abstract screening, 28 after full-text reading. Fifty-eight papers were excluded because written in a language different from English. 7 papers were excluded because full text was not available either online or in paper version. 185 papers were reviewed and discussed independently by seven authors (RMA, RP, AL, SDB, VV, LP, MF).

Common criteria for the evaluation of susceptibility and synergism were adopted by all authors.

*Susceptibility*. Susceptibility to FOS for Enterobacterales and *Staphylococcus* spp. was determined, according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, when the minimum inhibitory concentration (MIC) was ≤ 32 µg/mL. *Enterococcus* spp. were considered susceptible when exhibiting a MIC ≤ 64 µg/mL, according to the Clinical & Laboratory Standards Institute (CLSI) breakpoints. FOS breakpoints are not defined either by EUCAST or CLSI for *Pseudomonas* spp., *Acinetobacter* spp. and *Streptococcus* spp. Based on literature data, susceptibility was defined as a MIC ≤ 128 µg/mL for *Pseudomonas* spp. (ECOFF value), MIC ≤ 32 for *Acinetobacter* spp. and ≤64 µg/mL for *Streptococcus* spp. \[[@B8-antibiotics-09-00500],[@B9-antibiotics-09-00500]\].

For all the antibiotics tested in combination, EUCAST breakpoints was considered at first and CLSI breakpoints were considered when EUCAST breakpoints were not available. Breakpoints adopted are specified in each paragraph.

*Synergistic effect.* Checkerboard assay: fractional inhibitory concentration index (FICI) ≤ 0.5. FICI is defined as follows: $$FICI = \frac{MIC\ FOS\ in\ combination}{MIC\ FOS\ alone} + \frac{MIC\ other\ antibiotic\ in\ combination}{MIC\ other\ antibiotic\ alone}$$.

Time--kill assay: ratio of effective concentrations concordant with FICI or ≥2 log kill.

*Additive effect.* Checkerboard assay: 0.5 \< FICI ≤ 1. Time--kill assay: ratio of effective concentrations concordant with FICI or 1 \< log kill \< 2.

*Indifferent effect.* Checkerboard assay: 1 \< FICI \< 4. Time--kill assay: ratio of effective concentrations concordant with FICI or ± 1 log kill.

*Antagonistic effect.* Checkerboard assay: FICI ≥ 4. Time--kill assay: ratio of effective concentrations concordant with FICI or \< 1 log kill.

For in vitro studies using a method different from checkerboard or time--kill assay, or in case data on effective concentrations were not available, synergism was evaluated according to the authors' judgment.

For studies performed in vivo, synergism was established with the same ratio of effective concentrations considered for checkerboard assays or with the same log kill considered for time--kill assays. When these data were not reported in the paper, synergism was evaluated according to the authors' judgment.

3. Results {#sec3-antibiotics-09-00500}
==========

For a better comprehension, a table with reviewed papers and a summary of most relevant results is proposed for each antibiotic class.

3.1. Penicillins {#sec3dot1-antibiotics-09-00500}
----------------

Twenty-eight papers evaluating FOS in combination with penicillins, penicillins + β-lactamase inhibitors, penicillinase-resistant penicillins were reviewed ([Table 1](#antibiotics-09-00500-t001){ref-type="table"}). Breakpoints for penicillins were inferred from EUCAST breakpoints \[[@B10-antibiotics-09-00500]\]. Penicillins are β-lactam antibiotics that acts through the inhibition of enzymes needed for peptidoglycans cross linking. Effect of FOS in combination with penicillins varied greatly according with the bacterial species considered. The highest rates of synergistic effect were observed against Enterobacterales and *Acinetobacter* spp. Despite this, Avery et al. \[[@B11-antibiotics-09-00500]\] reported high rates of indifferent effect of FOS + piperacillin/tazobactam (PIP/TAZ) against PIP/TAZ-resistant Enterobacterales. Antagonistic effect was observed against one isolate of *S. aureus* with the combination FOS + methicillin \[[@B12-antibiotics-09-00500]\] and against 6 biofilm-producer *Enterococcus faecalis* isolates with the combination FOS + ampicillin \[[@B13-antibiotics-09-00500]\]. Four studies \[[@B14-antibiotics-09-00500],[@B15-antibiotics-09-00500],[@B16-antibiotics-09-00500],[@B17-antibiotics-09-00500]\] performed in vivo experiments, with no substantial differences in results when compared with results obtained in vitro.

The combination of penicillin + FOS retains additive/synergistic effects against \~50% of Enterobacterales, *Acinetobacter* spp., *Staphylococcus* spp., and *Streptococcus* spp. strains.

3.2. Cephalosporins {#sec3dot2-antibiotics-09-00500}
-------------------

Forty-one papers evaluating FOS in combination with cephalosporins and cephalosporins + β-lactamase inhibitors were reviewed ([Table 2](#antibiotics-09-00500-t002){ref-type="table"}). Breakpoints for cephalosporins were inferred from EUCAST breakpoints \[[@B10-antibiotics-09-00500]\]. Cephalosporins are β-lactam antibiotics that acts disrupting the peptidoglycan synthesis like penicillins, but are less susceptible to β-lactamases. Some studies reported discordant results on the effect of FOS in combination with a cephalosporin against clinical isolates, particularly against *Staphylococcus* spp. \[[@B18-antibiotics-09-00500],[@B19-antibiotics-09-00500],[@B20-antibiotics-09-00500]\] and Enterobacterales isolates \[[@B11-antibiotics-09-00500],[@B14-antibiotics-09-00500],[@B21-antibiotics-09-00500]\]. Antagonistic effect was observed against 4 *Pseudomonas aeruginosa* isolates with the combination FOS + ceftazidime \[[@B22-antibiotics-09-00500]\], 1 *S. aureus* and 1 *Staphylococcus epidermidis* isolates with the combination FOS + ceftriaxone \[[@B19-antibiotics-09-00500]\]. 9 in vivo studies \[[@B17-antibiotics-09-00500],[@B23-antibiotics-09-00500],[@B24-antibiotics-09-00500],[@B25-antibiotics-09-00500],[@B26-antibiotics-09-00500],[@B27-antibiotics-09-00500],[@B28-antibiotics-09-00500],[@B29-antibiotics-09-00500],[@B30-antibiotics-09-00500]\] performed with different strains (*Escherichia coli*, *P. aeruginosa*, *S. aureus*, *Streptococcus pneumoniae*, *Streptococcus sanguis*) confirmed results obtained in vitro or resulted in higher synergistic effect (additive effect only against 3 *S. aureus* isolates \[[@B25-antibiotics-09-00500],[@B26-antibiotics-09-00500]\]).

Cephalosporins + β-lactamase inhibitors, often chosen by clinicians to treat MDR infections, resulted in moderate rates of synergistic effect in combination with FOS. Against Enterobacterales, the combination ceftolozane/tazobactam + FOS resulted synergistic in 16.3% of cases (49 isolates tested \[[@B11-antibiotics-09-00500]\]), while the combination ceftazidime/avibactam + FOS was synergistic in 28.8% of cases (66 isolates tested \[[@B11-antibiotics-09-00500],[@B21-antibiotics-09-00500],[@B31-antibiotics-09-00500]\]). Against *P. aeruginosa*, the combination ceftolozane/tazobactam + FOS resulted synergistic in 71.1% of cases (45 isolates tested \[[@B32-antibiotics-09-00500],[@B33-antibiotics-09-00500],[@B34-antibiotics-09-00500]\]), while the combination ceftazidime/avibactam + FOS was synergistic in 31.6% of cases (38 isolates tested \[[@B21-antibiotics-09-00500],[@B29-antibiotics-09-00500],[@B33-antibiotics-09-00500]\]).

The combination of cephalosporins or cephalosporins + β-lactamase inhibitors + FOS appears to be clinically appealing especially against infections sustained by Enterobacterales and *Pseudomonas* spp.

3.3. Carbapenems {#sec3dot3-antibiotics-09-00500}
----------------

Forty-four papers evaluating FOS in combination with carbapenems were reviewed ([Table 3](#antibiotics-09-00500-t003){ref-type="table"}). Carbapenems are β-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins. Carbapenems are β-lactams "last-resort" used intravenously to treat severe infections. Imipenem (IMI) breakpoints are ≤ 2 µg/mL for Enterobacterales, *Acinetobacter* spp., *S. pneumoniae* and ≤ 0.001 µg/mL for *Pseudomonas* spp. and *Staphylococcus* spp. Meropenem breakpoints are ≤2 µg/mL for Enterobacterales, *Acinetobacter* spp., *Pseudomonas* spp., *S. pneumoniae* and ≤4 µg/mL for *Staphylococcus* spp. Ertapenem (ERT) breakpoints are ≤0.5 µg/mL for Enterobacterales, *S. pneumoniae* and ≤4 µg/mL for *Staphylococcus* spp. \[[@B10-antibiotics-09-00500]\].

Synergism rates were not unanimous on all studies, but antagonistic effect was observed only in 2 isolates of *P. aeruginosa* in the study by Pruekprasert et al. \[[@B22-antibiotics-09-00500]\] and in 1 isolate of *S. aureus* in the study by Quentin et al. \[[@B35-antibiotics-09-00500]\]. No evident differences in the synergistic effect was observed depending on the carbapenem tested. The association FOS + carbapenem often resulted, when reported, in FOS- and/or carbapenem-susceptibility restoration. Three authors performed in vivo experiments using methicillin-resistant Staphylococcus aureus (MRSA) isolates: in two studies \[[@B28-antibiotics-09-00500],[@B36-antibiotics-09-00500]\] the results in vivo were concordant with those found in vitro, while in the third study the combination in vivo resulted less effective \[[@B37-antibiotics-09-00500]\].

From the clinical point of view the combination of carbapenems + FOS against Enterobacterales, *P. aeruginosa* end *Acinetobacter* spp. appears appealing.

3.4. Monobactams {#sec3dot4-antibiotics-09-00500}
----------------

Five papers evaluating FOS in combination with aztreonam (ATM) were reviewed ([Table 4](#antibiotics-09-00500-t004){ref-type="table"}). ATM is a synthetic antibiotic whose susceptibility is often preserved also in those strains which are resistant to other β-lactam antibiotics. The mechanism of action is similar to penicillins. ATM breakpoints are ≤1 µg/mL for Enterobacterales and ≤0.001 µg/mL for *Pseudomonas* spp. \[[@B10-antibiotics-09-00500]\].

The largest study evaluating FOS in combination with ATM on Enterobacterales isolates \[[@B33-antibiotics-09-00500]\] reported an indifferent effect on most (64.6%) isolates. The combination was reported to have an additive effect on most isolates of *P. aeruginosa* \[[@B33-antibiotics-09-00500],[@B38-antibiotics-09-00500]\], sometimes leading to ATM susceptibility restoration \[[@B33-antibiotics-09-00500],[@B39-antibiotics-09-00500]\]. There were no in vivo studies evaluating this combination.

3.5. Quinolones {#sec3dot5-antibiotics-09-00500}
---------------

Twenty-nine papers evaluating FOS in combination with quinolones were reviewed ([Table 5](#antibiotics-09-00500-t005){ref-type="table"}). Quinolones are bactericidal antibiotics that directly inhibit bacterial DNA synthesis. Breakpoints for quinolones were inferred from EUCAST breakpoints \[[@B10-antibiotics-09-00500]\]. Synergism rates were not unanimous on all studies for isolates of *P. aeruginosa*. In 1 in vivo study synergism rate was 100% according to Mikuniya et al. \[[@B40-antibiotics-09-00500]\]. Antagonism was observed in 1 in vivo \[[@B41-antibiotics-09-00500]\] and 1 in vitro studies \[[@B39-antibiotics-09-00500]\]. For *E. coli* isolates there was a weak synergism. In a recent in vitro study there was complete FOS and ciprofloxacin susceptibility restoration \[[@B42-antibiotics-09-00500]\]. The combinations showed different synergistic rates for *Staphylococcus* spp. isolates with 100% synergistic rate in 1 in vitro study \[[@B43-antibiotics-09-00500]\] and in 1 in vivo study \[[@B44-antibiotics-09-00500]\]. No antagonism was observed for *E. coli* and *Staphylococcus* spp. isolates. There were some differences in the synergistic effect depending on the quinolone tested. The most frequent effect of FOS + ciprofloxacin was indifferent even though it showed in vitro 95% synergistic effect with *S. aureus* \[[@B45-antibiotics-09-00500]\] The combination with levofloxacin showed mainly an additive effect in *P. aeruginosa* \[[@B38-antibiotics-09-00500],[@B39-antibiotics-09-00500],[@B46-antibiotics-09-00500]\] and in *Acinetobacter* spp. \[[@B38-antibiotics-09-00500]\] isolates.

In summary good additive/synergistic effect rates are reported when quinolones + FOS are used against *S. aureus* and *P. aeruginosa* isolates.

3.6. Aminoglycosides {#sec3dot6-antibiotics-09-00500}
--------------------

Aminoglycosides (AMG) act through inhibition of protein synthesis, resulting in a potent and broad-spectrum antibacterial activity but with a potential high nephro- and oto-toxicity \[[@B47-antibiotics-09-00500]\]. In the attempt to overcome increasing aminoglycosides resistance, development of novel AMG (such as arbekacin and plazomicin) has occurred, but combination strategies are important opportunities to treat resistant bacteria and to reduce toxicity. Inhaled delivery of tobramycin, allowing for greater exposure within the lungs and reducing systemic toxicity, is also approved for the treatment of patients with chronic *P. aeruginosa* lung infection associated with cystic fibrosis (CF) in United States and Europe \[[@B47-antibiotics-09-00500]\]. Overall, 41 papers evaluating FOS in combinations with AMG were reviewed ([Table 6](#antibiotics-09-00500-t006){ref-type="table"}). Available EUCAST aminoglycosides breakpoints were applied in all studies except one \[[@B48-antibiotics-09-00500]\]. Due to the peculiarity of possible AMG therapeutic use (e.g. inhaled formulation in cystic fibrosis), many studies investigated the AMG + FOS combination also when administered by inhaled topical use; moreover, the activity of this combination on biofilm formation and in anaerobic conditions was also evaluated. Different AMG were tested as partner of FOS towards several bacterial species in a total of 67 evaluations: mainly gentamicin (31.3%, n = 21), amikacin (23.9%, n = 16) and tobramycin (22.4%, n = 15) were used. Synergism rates were not unanimous on all studies, considering the different bacteria analyzed and the different types of aminoglycosides tested. Overall, a synergistic effect of FOS together with different AMG, even if with different percentages, was revealed in 51 evaluations (74.6%). No synergism was reported in 16 cases (23.9%), even regarding effects on *P. aeruginosa* and *Acinetobacter* spp. In one study, data on synergism were not available \[[@B49-antibiotics-09-00500]\]: however, a potential beneficial effect was indeed reported, demonstrating that FOS enhanced the activity of tobramycin with a 100% additive effect during in vitro evaluation on *P. aeruginosa* biofilms on cystic fibrosis airway epithelial cells. An antagonistic effect, testing the combination of FOS with gentamicin, was reported in 1985 by Alvarez et al. in 2.7% of 148 MRSA isolates \[[@B12-antibiotics-09-00500]\] and in 2005 by Pruekprasert et al. in 27% of 22 *P. aeruginosa* strains \[[@B22-antibiotics-09-00500]\].

Focusing on different bacterial strains, generally a synergistic or additive effect of FOS + AMG was demonstrated on KPC-producing *K. pneumoniae* \[[@B50-antibiotics-09-00500],[@B51-antibiotics-09-00500],[@B52-antibiotics-09-00500]\]; however, Souli et al. observed an indifferent effect of FOS + gentamycin combination in all of their tested KPC+ strains \[[@B53-antibiotics-09-00500]\].

When tested, a generally positive effect of FOS and AMG combination on biofilm formation and an improved AMG activity in anaerobic conditions were also reported for *P. aeruginosa* and *Acinetobacter* spp., resulting moreover in lower required AMG doses.

Activity of FOS plus an AMG was also evaluated against *Streptococcus* spp. (streptomycin) and *Neisseria gonorrhoeae* (both, gentamicin) in two studies \[[@B14-antibiotics-09-00500],[@B54-antibiotics-09-00500]\]: No synergistic effect was revealed but antagonism was not even reported. Interestingly, synergistic activity (assessed as a fourfold reduction of MIC when fosfomycin was combined with gentamicin 1 mcg/mL) and additive effect were revealed for 8 vancomycin-resistant *E. faecium* (VRE) isolates (63% and 13%, respectively) \[[@B55-antibiotics-09-00500]\].

The combination of AMG + FOS against *P. aeruginosa* appears to be the most clinically appealing.

3.7. Macrolides {#sec3dot7-antibiotics-09-00500}
---------------

Six papers evaluating FOS in combination with macrolides, in particular with erythromycin (ERY), azithromycin (AZT), clarithromycin (CLT), or midecamycin (MDM), were reviewed ([Table 7](#antibiotics-09-00500-t007){ref-type="table"}). Macrolides are a large class of antibiotics that act binding 50S ribosomal subunit, inhibiting bacterial proteins synthesis. They have broad-spectrum activity, mainly against many Gram-positive bacteria and some Gram-negative bacteria \[[@B56-antibiotics-09-00500]\]. Only one in vitro study evaluated FOS + ERY combination against Enterobacterales (87 strains of *E. cloacae, E. coli*, *Proteus* spp. and *Klebsiella pneumoniae*), reporting synergistic effect against 52% of isolates and additive effect against 30% \[[@B14-antibiotics-09-00500]\]; in the same study FOS + ERY combination was also tested against *P. aeruginosa* and *S. aureus*, proving in most cases additive effect or, less frequently, synergistic effect \[[@B14-antibiotics-09-00500]\]. When this combination was tested against *Streptococcus* spp. synergistic effect was observed against 15% of isolates, while additive (27%) or indifferent (58%) was seen against the remaining \[[@B14-antibiotics-09-00500]\]. Some studies evaluated FOS + AZT combination, reporting indifferent effect in 100% of cases, either when tested against *N. gonorrhoeae* (2 studies) \[[@B54-antibiotics-09-00500],[@B57-antibiotics-09-00500]\] or against *S. epidermidis* (1 study) \[[@B58-antibiotics-09-00500]\]. Finally, FOS + CLT and FOS + MDM combinations were evaluated against *S. pseudointermedius* and *P. aeruginosa* respectively; in both cases additive or synergistic effect was demonstrated in vitro or in vivo experiments \[[@B59-antibiotics-09-00500],[@B60-antibiotics-09-00500]\]. No antagonistic effect was observed for any combination against any isolate.

From the clinical point of view the combination of macrolides + FOS appears the less appealing.

3.8. Glycopeptides {#sec3dot8-antibiotics-09-00500}
------------------

Eighteen articles evaluating FOS in combination with glycopeptides (vancomycin and teicoplanin) have been reviewed ([Table 8](#antibiotics-09-00500-t008){ref-type="table"}). Articles were from Spain (n = 5), Taiwan (n = 3), China (n = 2), France (n = 2), Germany (n = 2), Italy (n = 2), Austria (n = 1), and Brazil (n = 1).

Glycopeptides possess an antimicrobial activity selectively directed against Gram-positive bacteria, while Gram-negatives are protected by the outer membrane that is impermeable to these antibiotics. Glycopeptides inhibit the peptidoglycan synthesis by interacting with the terminal D-alanyl-D-alanine present on the pentapeptide side chains of the peptidoglycan precursors.

384 strains have been studied, belonging to several species as *S. aureus* (n = 219), *S. epidermidis* (n = 52), *E. faecalis* (n = 39), *S. pneumoniae* (n = 28), *Acinetobacter baumannii* (n = 20), *Enterococcus faecium* (n = 16) and other coagulase-negative staphylococci (CoNS) (n = 10). Synergy was detected with FOS-vancomycin (VAN) combination (40 out of 308 strains tested, 13%) in 33.3% of *E. faecalis*, 30% of *E. faecium*, 16.7% of *S. aureus*, 13.5% of *S. epidermidis*, and 3.6% of *S. pneumoniae*. Higher rates of synergistic interactions were detected with FOS-teicoplanin (TEC) combination (63 out of 130 strains tested, 48.5%) in 71.8% of *E. faecalis*, 43.7% of *E. faecium*, 60% of other CoNS, 34.3% of *S. aureus* and 33.3% *S. epidermidis*. Synergistic concentration ranges were 1-64 mg/L for FOS, 1-7.5 mg/L for VAN and only 8 mg/L for TEC. Regarding resistant isolates, FOS-VAN synergy was detected in one heterogeneous glycopeptide-intermediate *Staphylococcus aureus* (hGISA), 27 MRSA, 5 *S. aureus* strains with borderline MIC values for VAN (2 mg/L) and in 6 VRE strains, while FOS-TEC in 10 MRSA and 11 VRE strains. Antagonism FOS-VAN was detected in 5 *S. aureus* and one *S. epidermidis* strains. Only in 8 FOS-resistant *S. aureus* strains the activity of FOS was restored in combination with VAN. In vivo application of FOS-VAN combinations showed significant survival of ≥50% of treated animals or patients with infections caused by *S. aureus* or *S. epidermidis* \[[@B24-antibiotics-09-00500],[@B36-antibiotics-09-00500],[@B61-antibiotics-09-00500],[@B62-antibiotics-09-00500],[@B63-antibiotics-09-00500]\].

In summary the combination of VAN + FOS resulted in good synergistic effect rates against *Enterococcus* spp. isolates and seems to be the most clinically relevant combination.

3.9. Tetracyclines {#sec3dot9-antibiotics-09-00500}
------------------

Ten papers evaluating FOS in combination with tetracyclines, mostly with minocycline (MIN) and in few cases with doxycycline (DOX) or tetracycline (TEC), were reviewed ([Table 9](#antibiotics-09-00500-t009){ref-type="table"}). Tetracyclines are a large class of antibiotics that acts binding the 30S ribosomal subunits, inhibiting bacterial proteins synthesis. They have broad-spectrum activity, being active against many Gram-positive bacteria, Gram-negative, and atypical bacteria \[[@B64-antibiotics-09-00500]\]. Almost all studies evaluated in vitro FOS + MIN combination against different bacterial species. When evaluated against Enterobacterales (20 strains), FOS + MIN proved to have additive effect most of the time (65% of isolate), but only in few cases synergistic effect \[[@B38-antibiotics-09-00500]\]. Similar results were observed when it was tested against multidrug-resistant *P. aeruginosa* \[[@B38-antibiotics-09-00500]\] and *A. baumannii* isolates; furthermore, in the last case, complete restoration of susceptibility of MIN was reported \[[@B65-antibiotics-09-00500]\]. Only one study evaluated FOS + TEC combination against Enterobacterales (100 isolates), observing indifference in almost 100% of cases \[[@B66-antibiotics-09-00500]\]. 2 studies evaluated FOS + MIN combination against vancomycin-resistant *E. faecium* or *E. faecalis* (51 strains), reporting most often indifferent effect and some sporadic case of synergism \[[@B13-antibiotics-09-00500],[@B67-antibiotics-09-00500]\]. Otherwise, FOS + DOX combination was tested once against 24 isolates of vancomycin-resistant *E. faecium*, demonstrating to have synergistic or additive effect in most of cases \[[@B68-antibiotics-09-00500]\]. Finally, when FOS + MIN was tested against MRSA (152, strains, 3 studies) proved to have synergistic effect in numerous cases \[[@B18-antibiotics-09-00500],[@B69-antibiotics-09-00500],[@B70-antibiotics-09-00500]\]. No study reported any case of antagonism.

The combination of minocycline + FOS against *A. baumannii* appears interesting.

3.10. Polymyxins {#sec3dot10-antibiotics-09-00500}
----------------

Thirty-two papers evaluating FOS in combination with polymyxins were reviewed ([Table 10](#antibiotics-09-00500-t010){ref-type="table"}). Polymyxins are bactericidal drugs that bind to lipopolysaccharide (LPS) and phospholipids in the outer cell membrane of Gram-negative bacteria and leads to disruption of this. Twenty-eight papers evaluated colistin. Colistin breakpoints are ≤ 2 µg/mL for Enterobacterales, *Acinetobacter* spp. and *Pseudomonas* spp. according to the EUCAST \[[@B10-antibiotics-09-00500]\]. Synergism rates were not unanimous on all studies but was reported in 23/29 papers. Synergisms rate were 100% in 2 in vitro studies against *K. pneumoniae* \[[@B50-antibiotics-09-00500],[@B71-antibiotics-09-00500]\] and 2 in vivo studies respectively against *A. baumannii* and *E.coli* \[[@B72-antibiotics-09-00500],[@B73-antibiotics-09-00500]\]. The overall effect was indifferent on most isolates of *P. aeruginosa* and Enterobacterales. Antagonism was reported in vitro against *K. pneumoniae* and *A. baumannii*. In particular the combination was antagonist in 100% of all *K. pneumoniae* OXA-48 isolates according to Evren et al. \[[@B74-antibiotics-09-00500]\].

Four papers evaluated polymyxin B. Polymyxin B breakpoints for Enterobacterales, *Acinetobacter* spp. and *Pseudomonas* spp. are ≤ 2 µg/mL according to CLSI. Synergism was observed in 100% of in vitro isolates of CP *K. pneumoniae* according to Bulman et al. \[[@B75-antibiotics-09-00500]\]. FOS + polymyxin had a prevalent addictive effect in vitro against *Pseudomonas* spp. \[[@B76-antibiotics-09-00500]\] and *A. baumannii* \[[@B65-antibiotics-09-00500]\]. In a study there was a complete polymyxin B susceptibility restoration \[[@B65-antibiotics-09-00500]\]. No antagonistic effect was observed either in in vitro or in vivo studies.

The combination of polymyxins and FOS appears a good option against Enterobacterales and *P. aeruginosa* strains.

3.11. Daptomycin {#sec3dot11-antibiotics-09-00500}
----------------

Thirteen papers evaluating FOS in combination with daptomycin (DAP) were reviewed ([Table 11](#antibiotics-09-00500-t011){ref-type="table"}). DAP is a cyclic lipopeptide administered intravenously for Gram-positive infections, acting through bacterial membrane depolarization \[[@B77-antibiotics-09-00500]\]. Its breakpoints are ≤1 µg/mL for *Staphylococcus* spp. and ≤2 µg/mL for *Enterococcus* spp. \[[@B10-antibiotics-09-00500],[@B78-antibiotics-09-00500]\].

When evaluated against *S. aureus* isolates, the combination FOS + DAP had a synergistic effect in vitro against 37--100% of isolates (synergistic effect of the combination against 100% of the tested isolates was reported in 4 in vitro studies \[[@B63-antibiotics-09-00500],[@B79-antibiotics-09-00500],[@B80-antibiotics-09-00500],[@B81-antibiotics-09-00500]\] and 2 in vivo studies \[[@B37-antibiotics-09-00500],[@B79-antibiotics-09-00500]\]). DAP showed excellent synergistic activity in association with FOS against *Enterococcus* spp., resulting in synergistic effect in all 34 tested isolates (4 studies). FOS + DAP also exhibited a greater efficacy against *E. faecalis* biofilm formation than FOS or DAP alone. Efficacy in vivo sometimes differed from the results obtained in vitro, resulting in greater \[[@B37-antibiotics-09-00500]\] or less \[[@B82-antibiotics-09-00500]\] efficacy. No antagonistic effect was observed either in in vitro or in vivo studies.

The combination of daptomycin + FOS has good synergistic effect rates against *S. aureus* and *Enterococcus* spp. and deserves clinical interest.

3.12. Tigecycline {#sec3dot12-antibiotics-09-00500}
-----------------

Fourteen papers evaluating FOS in combination with TIG were reviewed ([Table 12](#antibiotics-09-00500-t012){ref-type="table"}). TIG is the first glycylcycline antibiotic, a broad-spectrum class of bacteriostatic derivate from tetracyclines, that acts binding the 30S ribosomal subunits, inhibiting bacterial proteins synthesis. It is only available for intravenous administration and shows activity against either Gram-positive or Gram-negative or atypical bacteria \[[@B64-antibiotics-09-00500]\]. Its breakpoint are ≤0.5 mg/L both for *S. aureus* and Enterobacterales and ≤0.25 mg/L for *Enterococcus* spp. \[[@B10-antibiotics-09-00500]\].

When evaluated in vitro against Enterobacterales or *A. baumannii* (10 studies, 338 isolates) FOS + TIG had synergistic effect approximately in 17% of cases and additive effect in the 43%, while indifference was reported for all remaining cases \[[@B38-antibiotics-09-00500],[@B73-antibiotics-09-00500],[@B74-antibiotics-09-00500],[@B83-antibiotics-09-00500],[@B84-antibiotics-09-00500],[@B85-antibiotics-09-00500],[@B86-antibiotics-09-00500],[@B87-antibiotics-09-00500],[@B88-antibiotics-09-00500],[@B89-antibiotics-09-00500]\]. Furthermore, indifferent effect against all isolates was observed in one in vivo experiment against *E. coli* \[[@B73-antibiotics-09-00500]\]. Mostly indifference was observed also when it was tested against *N. gonorrhoeae* or *P. aeruginosa* \[[@B54-antibiotics-09-00500],[@B86-antibiotics-09-00500]\]. When tested against 61 isolates of *Enterococcus* spp. (3 studies) many cases of synergistic effect was reported in vitro (about 40% of cases) \[[@B55-antibiotics-09-00500],[@B90-antibiotics-09-00500],[@B91-antibiotics-09-00500]\] and in vivo against *E. faecalis* \[[@B90-antibiotics-09-00500]\]. Finally, 2 studies evaluated FOS + TIG combination in vitro against MRSA, but with inconclusive results (total indifference or almost total synergism) \[[@B69-antibiotics-09-00500],[@B90-antibiotics-09-00500]\]. In all in vitro studies only 2 cases of antagonism were reported, against *K. pneumoniae* \[[@B89-antibiotics-09-00500]\].

According to the literature the combination of TIG + FOS appears to be particularly interesting (good synergistic effect rates) against Enterobacterales and *Enterococcus* spp.

3.13. Linezolid {#sec3dot13-antibiotics-09-00500}
---------------

Thirteen papers evaluating FOS in combination with linezolid (LZD) were reviewed ([Table 13](#antibiotics-09-00500-t013){ref-type="table"}). LZD is a synthetic antibiotic which binds rRNA on both 30S and 50S ribosomal subunits, inhibiting bacterial proteins synthesis \[[@B92-antibiotics-09-00500]\]. It is used for Gram-positive infections treatment, including MRSA and *E. faecium* vancomycin-resistant (VREF) infections \[[@B93-antibiotics-09-00500]\]. Its breakpoint is ≤4 µg/mL both for *S. aureus* and *E. faecium*.

When evaluated against *S. aureus* isolates (9 studies), combination FOS + LZD had a synergistic effect in vitro approximately in 95% of cases (synergistic effect of the combination against 100% of the tested isolates was reported in 6 in vitro studies \[[@B36-antibiotics-09-00500],[@B43-antibiotics-09-00500],[@B63-antibiotics-09-00500],[@B94-antibiotics-09-00500],[@B95-antibiotics-09-00500]\]) and even against staphylococcal biofilm cultures \[[@B69-antibiotics-09-00500]\]; furthermore, the only 2 in vivo studies performed proved FOS + LZD combination to have higher efficacy than FOS or LZD alone \[[@B36-antibiotics-09-00500],[@B95-antibiotics-09-00500]\]. One study evaluated the combination on 2 strains of *S. epidermidis* proving synergism on both \[[@B43-antibiotics-09-00500]\]. Otherwise, in the 4 studies in which it was tested against *E. faecium*, this combination showed in most cases additive effect and only few cases of synergism. In no case was reported synergistic effect against *E. faecalis* (2 studies). No antagonistic effect was observed either in in vitro or in vivo studies.

The good synergistic effects reported make LZD + FOS a promising combination against *staphylococci*.

3.14. Rifampin {#sec3dot14-antibiotics-09-00500}
--------------

Fourteen papers evaluating FOS in combinations with rifampin were reviewed ([Table 14](#antibiotics-09-00500-t014){ref-type="table"}). Rifampin breakpoints are ≤0.06 µg/mL for *Staphylococcus* spp., *Streptococcus* spp. and ≤0.125 µg/mL for *S. pneumoniae*. Rifampin inhibits bacterial DNA-dependent RNA polymerase with a concentration related effect. It is used for the treatment of intracellular pathogens and it has a broad-spectrum antibacterial activity. Rifampin breakpoints are not defined either by EUCAST or by CLSI for *Acinetobacter* spp., Enterobacterales and *Enterococcus* spp. Based on literature data, susceptibility was defined as a MIC ≤ 1 µg/mL for *Enterococcus* spp. \[[@B71-antibiotics-09-00500]\]. Rifampin showed synergistic activity in association with FOS against *Enterococcus* spp., resulting in synergistic effect in 20−100% of cases. High activity was reported in vitro and in vivo in a recent paper where FOS + RIFA also exhibited a greater efficacy against *E. faecalis* biofilm formation \[[@B90-antibiotics-09-00500]\]. When evaluated against *S. aureus* isolates, the combination FOS + rifampin had a synergistic effect in vitro against 34−100% of isolates. Synergistic effect of the combination against 100% of the tested isolates was reported in 3 in vitro studies \[[@B43-antibiotics-09-00500],[@B90-antibiotics-09-00500],[@B96-antibiotics-09-00500]\] and 2 in vivo studies \[[@B37-antibiotics-09-00500],[@B96-antibiotics-09-00500]\]. Antagonistic effect was observed only in 33% of isolates in the study by Quentin et al. \[[@B35-antibiotics-09-00500]\] where the antibiotic combination was antagonist for the isolates susceptible and intermediate to rifampin and indifferent for those resistant. No antagonistic effect was observed in other studies.

In clinics RIF + FOS should be considered (usually with a third agent) against *S. aureus* sustained infections, especially when biofilm production is likely.

3.15. Miscellanea {#sec3dot15-antibiotics-09-00500}
-----------------

Two papers evaluating FOS in combination with metronidazole (MTZ) were reviewed ([Table S1](#app1-antibiotics-09-00500){ref-type="app"}). MTZ is a bacteriostatic antimicrobial, active on bacteria (mainly anaerobic) and parasites. When evaluated in vitro against *Helicobacter pylori*, combination FOS + MTZ had a prevalent indifferent effect, an additive effect in only 21% of cases and an antagonist effect in 4% \[[@B97-antibiotics-09-00500]\]. In vivo study showed a significantly decrease mortality and increase cure rates if the animal treated with MTZ + FOS \[[@B98-antibiotics-09-00500]\].

One paper evaluating FOS in combination with spectinomycin (SCM) was reviewed ([Table S1](#app1-antibiotics-09-00500){ref-type="app"}). SCM is an aminocyclitol aminoglycoside antibiotic with bacteriostatic activity, used to treat gonorrhea. In vitro study reported that antimicrobial combinations of SMC + FOS no synergistic effect was found \[[@B54-antibiotics-09-00500]\].

One paper evaluating FOS in combination with sulbactam (SLB) was reviewed ([Table S1](#app1-antibiotics-09-00500){ref-type="app"}). SLB is an irreversible β-lactamase inhibitor capable to binding to penicillin-binding proteins and with weak antimicrobial activity. When evaluated in vitro against *A. baumannii* OXA-23, combination FOS + SLB had a synergistic effect in 75% of case, and an indifferent effect in 25% of cases \[[@B99-antibiotics-09-00500]\].

One paper evaluating FOS in combination with lincomycin (LNM) was reviewed ([Table S1](#app1-antibiotics-09-00500){ref-type="app"}). LMN is a protein synthesis inhibitor with activity against gram positive and anaerobic bacteria. When evaluated in vitro against *S. aureus*, combination FOS + LNM had a synergistic effect in 81% of case and an additive effect in 25% of cases \[[@B14-antibiotics-09-00500]\].

One paper evaluating FOS in combination with nitroxoline (NTX) was reviewed ([Table S1](#app1-antibiotics-09-00500){ref-type="app"}). NTX is a urinary antibacterial agent active against susceptible Gram-positive and Gram-negative organisms. In vitro study, NTX was synergistic with FOS in only 12% of cases and in other cases shoed an indifferent effect (88%) \[[@B66-antibiotics-09-00500]\].

Two papers evaluating FOS in combination with quinupristin/dalfopristin (Synercid) were reviewed ([Table S1](#app1-antibiotics-09-00500){ref-type="app"}). Synercid is a protein synthesis inhibitor used to treat infections by staphylococci and by vancomycin-resistant strain. When evaluated in vitro against methicillin resistant or susceptible *Staphyloccoccus* spp., combination FOS + Synercid had a synergistic effect in 100% of case \[[@B43-antibiotics-09-00500],[@B100-antibiotics-09-00500]\].

Three papers evaluating FOS in combination with fusidic acid (FSA) were reviewed ([Table S1](#app1-antibiotics-09-00500){ref-type="app"}). FSA is a bacteriostatic antibiotic with acts as a bacterial protein synthesis inhibitor. When evaluated in vitro against MRSA, combination FOS + FSA had a various behavior, showing a synergistic effect in 88--100% of case or an indifferent effect in 100% of cases. No antagonism was found \[[@B69-antibiotics-09-00500],[@B101-antibiotics-09-00500],[@B102-antibiotics-09-00500]\].

Four papers evaluating FOS in combination with chloramphenicol (CHL) were reviewed ([Table S1](#app1-antibiotics-09-00500){ref-type="app"}). CHL is a synthetic broad-spectrum antimicrobial, mainly bacteriostatic, active on numerous Gram-positive and Gram-negative, aerobic and anaerobic bacteria; it acts binding 50S ribosomal subunit, inhibiting bacterial protein synthesis \[[@B103-antibiotics-09-00500]\]. Its breakpoint is ≤ 8 mg/L both for *S. aureus* and Enterobacterales \[[@B10-antibiotics-09-00500]\]. When evaluated in vitro against either Enterobacterales (468 isolates, 4 studies), combination FOS + CHL had synergistic effect approximately in 40% of cases, while additive effect in 35% and indifferent effect in the remaining cases \[[@B14-antibiotics-09-00500],[@B66-antibiotics-09-00500],[@B104-antibiotics-09-00500],[@B105-antibiotics-09-00500]\]. Furthermore, one study tested this combination against *S. aureus*, with similar results (synergistic effect against 44% of isolates) \[[@B14-antibiotics-09-00500]\]. No antagonistic effect was observed.

Three papers evaluating FOS in combination with trimethoprim-sulfamethoxazole (TMP-SMX) were reviewed ([Table S1](#app1-antibiotics-09-00500){ref-type="app"}). TMP-SMX is a fixed combination of 2 antimicrobials that inhibits bacterial synthesis of tetrahydrofolate, a necessary cofactor for bacterial DNA synthesis. It is available in oral or intravenous preparation and it is mainly used for treatment of urinary and respiratory infections \[[@B106-antibiotics-09-00500]\]. Its breakpoint is ≤ 2 µg/mL both *S. aureus* and Enterobacterales \[[@B10-antibiotics-09-00500]\]. When evaluated in vitro against either *S. aureus* (148 isolates) or Enterobacterales (120 isolates), combination FOS + TMP-SMX had indifferent effect approximately against 92% of isolates \[[@B12-antibiotics-09-00500],[@B38-antibiotics-09-00500],[@B66-antibiotics-09-00500]\]. Only in few cases, against Enterobacterales, was reported synergistic or additive effect (1 study) \[[@B38-antibiotics-09-00500]\] and even antagonistic effect was reported in 4 cases when tested against *S. aureus* \[[@B12-antibiotics-09-00500]\].

Two papers evaluating FOS in combination with nitrofurantoin (NTF) were reviewed ([Table S1](#app1-antibiotics-09-00500){ref-type="app"}). NTF is a synthetic antibiotic administered orally mainly for treatment of lower urinary tract infections. Its breakpoint is ≤ 64 µg/mL both *E. faecalis* and Enterobacterales \[[@B10-antibiotics-09-00500]\]. When evaluated in vitro against either vancomycin-resistant *E. faecium* (32 isolates) or Enterobacterales (100 isolates), combination FOS + NTF had indifferent effect against 100% of isolates \[[@B66-antibiotics-09-00500],[@B67-antibiotics-09-00500]\]. No synergistic, additive or antagonistic effect was observed.

3.16. Non-Antibiotic Molecules {#sec3dot16-antibiotics-09-00500}
------------------------------

One paper evaluating FOS in combination with auranofin (AF) was reviewed ([Table S2](#app1-antibiotics-09-00500){ref-type="app"}). AF is an orally active gold compound for the treatment of rheumatoid arthritis. When evaluated in vitro against *Staphyloccoccus* spp., combination FOS + AF had showed a reduction of bacterial load for both MSSA and MRSA strains. In vivo, this combination had showed a synergistically inhibition of abscess and inflammation formation. No interactions were showed against *S. epidermidis* MS \[[@B107-antibiotics-09-00500]\]. Three paper evaluating FOS in combination with dilipid ultrashort cationic lipopeptides, tobramycin-efflux pump inhibitor (TOB-EPI) conjugates or amphiphilic lysine-tobramycin conjugates (ALT) against *P. aeruginosa*, were reviewed ([Table S2](#app1-antibiotics-09-00500){ref-type="app"}). For all combinations, in vitro studies had showed a synergistic effect (100%). Furthermore, in presence of TOB-EPI or ALT conjugates MICs of FOS were dramatically reduced \[[@B108-antibiotics-09-00500],[@B109-antibiotics-09-00500],[@B110-antibiotics-09-00500]\]. One paper evaluating FOS in combination with β-chloro-L-alanine (β-CLA) was reviewed ([Table S2](#app1-antibiotics-09-00500){ref-type="app"}). β-CLA is an amino acid analog of FOS. When evaluated in vitro against MRSA, combination FOS + β-CLA had showed a synergistic effect on biofilm production \[[@B111-antibiotics-09-00500]\]. One paper evaluating FOS in combination with plectasin NZ2114, compound capable to inhibits a cell wall biosynthesis, was reviewed ([Table S2](#app1-antibiotics-09-00500){ref-type="app"}). When plectasin NZ2114 evaluated in vitro against *E. faecalis*, in combination with FOS it no show a synergistic effect \[[@B112-antibiotics-09-00500]\]. One paper evaluating FOS in combination with 2 quinolone derivatives (A and B) was reviewed ([Table S2](#app1-antibiotics-09-00500){ref-type="app"}). When evaluated in vitro against *E. faecalis* VRE and MRSA, combination FOS + A had always showed a synergistic effect, while FOS + B had showed a synergistic effect in 64% of cases and in other cases shoed an additive effect (36%) \[[@B113-antibiotics-09-00500]\]. One paper evaluating FOS in combination with N-acetylcysteine (NAC), a mucolytic agent, was reviewed ([Table S2](#app1-antibiotics-09-00500){ref-type="app"}). The in vitro analysis against *E. coli*, had showed a capable of NAC to reduce biofilm if used in combination with FOS. The most effective combination was that obtained using FOS at 2000 mg/L and NAC at 2 mg/mL \[[@B114-antibiotics-09-00500]\]. One paper evaluating FOS in combination with sophoraflavanone G (SFG), a phytoalexins, was reviewed ([Table S2](#app1-antibiotics-09-00500){ref-type="app"}). When evaluated in vitro against MRSA, combination FOS + SFG had showed a synergistic effect (100%) \[[@B115-antibiotics-09-00500]\]. One paper evaluating FOS in combination with arenaemycin (ARM), also called pentalenolactones, was reviewed ([Table S2](#app1-antibiotics-09-00500){ref-type="app"}). When evaluated in vitro against *P. vulgaris* and *S. gallinarum*, combination FOS + ARM had showed a synergistic effect (100%) \[[@B116-antibiotics-09-00500]\]. One paper evaluating FOS in combination with chlorogenic acid (CHA) and caffeic acid (CFA) was reviewed ([Table S2](#app1-antibiotics-09-00500){ref-type="app"}). When evaluated in vitro against *Resistant Listeria monocytogenes*, combination FOS + CHA had showed a reduction in the cell growth equal to 98% and FOS + CFA as to 85,2%. Moreover, CHA restored a FOS susceptibility in 100%, if 3 mg/L \[[@B117-antibiotics-09-00500]\]. One paper evaluating FOS in combination with silver (AgNPs) and zinc oxide (ZnONPs) nanoparticles, are molecules known to affect bacterial membranes, was reviewed ([Table S2](#app1-antibiotics-09-00500){ref-type="app"}). When evaluated in vitro against *S. aureus*, *S. enterica*, and *E. coli*, combination FOS + AgNPs or ZnONPs had showed a synergistic effect (100%) \[[@B118-antibiotics-09-00500]\].

4. Discussion {#sec4-antibiotics-09-00500}
=============

FOS is an inhibitor of bacterial wall synthesis with a unique mechanism of action. Its use in clinic is increasing as is often active against MDR bacteria. Intravenous FOS is often administered in combination with other antibiotics therefore the knowledge of pharmacodynamic interactions is of fundamental importance. In this review, we have investigated the role of FOS as partner drug, by analyzing literature studies in which it has been used in vitro and in vivo in combination with other antibiotics and evaluating the antimicrobial activity of combinations against the most common bacterial pathogens. From this huge data collection, no clinically significant antagonistic effect came out between FOS and any most common used antibiotics for the treatment of nosocomial infections.

FOS has been studied in combination with the major antibiotic classes (penicillins, cephalosporins, carbapenems, monobactams, quinolones, aminoglycosides, macrolides, glycopeptides, tetracyclines, polimyxins, lipopeptides, oxazolydinones, and rifampicin) against both Gram-negative and Gram-positive bacteria. A total of 185 literature reports accounted for 9,927 study isolates. FOS-based synergistic interactions were detected in 33.7% of total isolates, although additive and indifferent interactions were more prevalent (65.4%). Antagonism occurred sporadically (0.9% of total isolates).

Clinically significant synergistic interactions were mostly distributed in combination with penicillins (51%), carbapenems (43%), chloramphenicol (39%), and cephalosporins (33%) in *Enterobactaerales*; with linezolid (74%), tetracyclines (72%), and daptomycin (56%) in *S. aureus*; with chloramphenicol (53%), aminoglycosides (43%) and cephalosporins (36%) against *P. aeruginosa*; with daptomycin (97%) in *Enterococcus* spp. and with sulbactam (75%) and penicillins (60%) and in *Acinetobacter* spp.

Notably, 31.2% of synergistic interactions occurred in Enterobacterales (FOS in combination with 3 different antibiotics), followed by 31% occurred in *S. aureus* (FOS in combination with 4 different antibiotics) and 7.6% occurred *Enterococcus* spp. (FOS in combination with 5 different antibiotics).

From a clinical point of view, taking into account the antimicrobial stewardship principles and the priorities in terms of MDR impact, our work points out good pharmacodynamic interactions rates (additive/synergistic effects) when FOS is especially combined with: (1)Cephalosporins and cephalosporins + β-lactamase inhibitors, including ceftazidime/avibactam and ceftolozane/tazobactam, for Enterobacterales and *P. aeruginosa*;(2)carbapenems for *K. pneumoniae* and *P. aeruginosa*;(3)quinolones for *P. aeruginosa*;(4)polymyxins for *K. pneumoniae*;(5)daptomycin for *Staphylococcus* spp (MRSA included), and *Enterococcus* spp.;(6)linezolid for *Staphylococcus* spp.; and(7)sulbactam for *A. baumannii*.

When FOS is combined with molecules other than antibiotics, chlorogenic acid and caffeic acid appeared to be good partner drugs against *L. monocytogenes*.

Our tables (including the summarizing [Table 15](#antibiotics-09-00500-t015){ref-type="table"}) could act as a useful consultation tool for clinicians using FOS both as empirical or targeted antibiotic regimen.

5. Conclusions {#sec5-antibiotics-09-00500}
==============

In conclusion, taken together, these data, the pharmacological characteristics (i.e., excellent distribution in body sites, the safety and tolerability profile) and the encouraging positive clinical outcome of treated patients highlight the role of FOS as partner drug (mostly intravenously) for the treatment of infections caused by common (including MDR) pathogens. In particular, the presence of synergistic interactions and the almost total absence of antagonisms, make FOS a good partner drug in clinical practice. Moreover, improving FOS-based combinations could act as a meropenem- and colistin-sparing agent, mostly contributing to prevent AMR, especially related to last resource antibiotics.

antibiotics-09-00500-t001_Table 1

###### 

Studies on combination between fosfomycin and penicillins, penicillins + β-lactamase inhibitors, penicillinase-resistant penicillins. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strain                 Year and Country   Author                      Penicillin                                                                                                                                                                   Number of Isolates                                 Known Resistance Mechanisms or Determinants (%)                                                                                                                                                                                                            Fosfomycin-Resistant (%)   penicillin-Resistant (%)                            In Vitro (methods)/In Vivo (Animal and Site of Infection)   Synergistic Effect (%)                          Additive Effect (%)                            Indifferent Effect (%)   Antagonistic Effect (%)   Fosfomycin Susceptibility Restoration (%)   Penicillin Susceptibility Restoration (%)                                                                                                                                                                               Comments                                                                                                                                                                                                                                                                                        Reference
  ---------------------- ------------------ --------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- --------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------- ---------------------------------------------- ------------------------ ------------------------- ------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  Enterobacterales       2019, USA          Avery                       piperacillin/tazobactam                                                                                                                                                      49                                                 8 *E. coli*: KPC (25%), NDM (75%), ESBL (62.5%); 35 *Klebsiella* spp: KPC (45.7%), NDM (40%); OXA (14.3%), VIM (8.6%), ESBL (88.6%), fosA (44%); 2 *Citrobacter* spp: KPC (50%), NDM (50%), ESBL (50%), 4 *E. cloacae*: KPC (75%), NDM (25%), ESBL (75%)   20 (40.8%)                 49 (100%)                                           in vitro (ET)                                               1 (2%)                                          2 (4%)                                         46 (94%)                 0%                        \-                                          \-                                                                                                                                                                                                                      Data on synergism reported without distinction for bacterial strains. % of FOS-R isolates estimated on the basis of the reported MIC50.                                                                                                                                                         \[[@B11-antibiotics-09-00500]\]
  2019, USA              Flamm              piperacillin/tazobactam     20                                                                                                                                                                           \-                                                 \-                                                                                                                                                                                                                                                         \-                         in vitro (CB, TK)                                   12 (60%)                                                    7 (35%)                                         0%                                             0%                       \-                        \-                                          For 1 isolate the efficacy of FOS + PIP/TAZ remained indeterminate.                                                                                                                                                     \[[@B38-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                 
  1978, Spain            Olay               ampicillin, carbenicillin   Ampicillin: 17 *E. coli*, 11 *Klebsiella* spp., 7 *E. cloacae*, 14 *Proteus* spp., 22 *Salmonella* spp. Carbenicillin: 16 *E. coli*, 32 *S. marcescens*, 26 *Proteus* spp.   \-                                                 \-                                                                                                                                                                                                                                                         \-                         in vitro (CB)                                       ampicillin: 31 (43%); carbenicillin: 24 (32%)               ampicillin: 31 (43%); carbenicillin: 31 (41%)   ampicillin: 9 (12%); carbenicillin: 19 (25%)   0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B14-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                 
  *E. coli*              2020, Korea        Seok                        piperacillin/tazobactam                                                                                                                                                      2                                                  ESBL (100%)                                                                                                                                                                                                                                                0%                         1 (50%)                                             in vitro (TK)                                               0%                                              0%                                             2 (100%)                 0%                        \-                                          \-                                                                                                                                                                                                                      \-                                                                                                                                                                                                                                                                                              \[[@B119-antibiotics-09-00500]\]
  2018, France           Berleur            temocillin                  3                                                                                                                                                                            KPC (33.3%), OXA (33.3%)                           0%                                                                                                                                                                                                                                                         Breakpoints NA             in vitro (CB, TK); in vivo (mouse, peritonitis)     0%                                                          in vitro: 3 (100%); in vivo: 3 (100%)           0%                                             0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B15-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                 
  2014, Sweden           Hickam             mecillinam                  2                                                                                                                                                                            ESBL, OXA (50%)                                    0%                                                                                                                                                                                                                                                         0%                         in vitro (CB, TK)                                   2 (100%)                                                    0%                                              0%                                             0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B120-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                
  1977, Poland           Borowski           ampicillin                  10                                                                                                                                                                           \-                                                 \-                                                                                                                                                                                                                                                         \-                         in vitro (CB)                                       7 (70%)                                                     1 (10%)                                         2 (20%)                                        0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B121-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                
  *K. pneumoniae*        2014, Sweden       Hickam                      mecillinam                                                                                                                                                                   1                                                  ESBL, OXA (100%)                                                                                                                                                                                                                                           0%                         0%                                                  in vitro (CB, TK)                                           1 (100%)                                        0%                                             0%                       0%                        \-                                          \-                                                                                                                                                                                                                      \-                                                                                                                                                                                                                                                                                              \[[@B120-antibiotics-09-00500]\]
  *Salmonella* spp.      1977, Spain        Perea                       ampicillin                                                                                                                                                                   90                                                 \-                                                                                                                                                                                                                                                         17 (18.9%)                 11 (12%)                                            in vitro (CB, TK)                                           74 (82%)                                        7 (7%)                                         7 (7%)                   0%                        \-                                          \-                                                                                                                                                                                                                      For 2 isolates the effect of FOS + ampicillin remained indeterminate. The authors considered synergistic the effect for FICI up to 0.75.                                                                                                                                                        \[[@B104-antibiotics-09-00500]\]
  1977, Spain            Figueroa           ampicillin                  16                                                                                                                                                                           \-                                                 \-                                                                                                                                                                                                                                                         \-                         in vitro (CB)                                       15 (93%)                                                    1 (6%)                                          0%                                             0%                       \-                        \-                                          *S. typhi*. The authors considered synergistic the effect for FICI up to \< 1. They also evaluated different antibiotic combinations on patients with typhoid fever: FOS + AMP resulted in the highest rate of cures.   \[[@B105-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                
  *Shigella* spp.        1977, Spain        Perea                       ampicillin                                                                                                                                                                   50                                                 \-                                                                                                                                                                                                                                                         27 (54%)                   30 (60%)                                            in vitro (CB, TK)                                           27 (54%)                                        9 (18%)                                        14 (28%)                 0%                        \-                                          \-                                                                                                                                                                                                                      The authors considered synergistic the effect for FICI up to 0.75.                                                                                                                                                                                                                              \[[@B104-antibiotics-09-00500]\]
  *P. aeruginosa*        2019, USA          Avery                       piperacillin/tazobactam                                                                                                                                                      103                                                \-                                                                                                                                                                                                                                                         NA (at least 71)           103 (100%)                                          in vitro (ET)                                               3 (2%)                                          26 (25%)                                       74 (71%)                 0%                        \-                                          15 (14.6%)                                                                                                                                                                                                              \-                                                                                                                                                                                                                                                                                              \[[@B33-antibiotics-09-00500]\]
  2019, USA              Flamm              piperacillin/tazobactam     5                                                                                                                                                                            \-                                                 \-                                                                                                                                                                                                                                                         \-                         in vitro (CB, TK)                                   0%                                                          5 (100%)                                        0%                                             0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B38-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                 
  2013, Brazil           dos Santos         piperacillin/tazobactam     4                                                                                                                                                                            \-                                                 4 (100%)                                                                                                                                                                                                                                                   2 (50%)                    in vitro (CB)                                       4 (100%)                                                    0%                                              0%                                             0%                       2 (50%)                   1 (50%)                                     \-                                                                                                                                                                                                                      \[[@B48-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                 
  2002, Japan            Okazaki            piperacillin                30                                                                                                                                                                           \-                                                 15 (50%)                                                                                                                                                                                                                                                   30 (100%)                  in vitro (efficacy time index)                      3 (10%)                                                     6 (20%)                                         21 (70%)                                       0%                       0%                        15 (50%)                                    \-                                                                                                                                                                                                                      \[[@B39-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                 
  1984, Japan            Takahashi          piperacillin                20                                                                                                                                                                           \-                                                 \-                                                                                                                                                                                                                                                         \-                         in vitro (CB)                                       4 (20%)                                                     16 (80%)                                        0%                                             0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B122-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                
  1978, Spain            Olay               carbenicillin               in vitro: 73; in vivo: 2                                                                                                                                                     \-                                                 \-                                                                                                                                                                                                                                                         \-                         in vitro (CB); in vivo (mouse, peritonitis)         in vitro: 21 (28%); in vivo: 2 (100%)                       in vitro: 40 (54%)                              in vitro: 12 (16%)                             0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B14-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                 
  *Acinetobacter* spp.   2019, USA          Flamm                       piperacillin/tazobactam                                                                                                                                                      5 (*A. baumannii-calcoaceticus* species complex)   \-                                                                                                                                                                                                                                                         \-                         \-                                                  in vitro (CB, TK)                                           3 (60%)                                         1 (20%)                                        0%                       0%                        \-                                          \-                                                                                                                                                                                                                      For 1 isolate the efficacy of FOS + PIP/TAZ remained indeterminate.                                                                                                                                                                                                                             \[[@B38-antibiotics-09-00500]\]
  *S. aureus*            2015, Spain        del Río                     amoxicillin + clavulanic acid                                                                                                                                                10                                                 Methicillin-resistant *Staphylococcus aureus* (MRSA) (100%)                                                                                                                                                                                                1 (10%)                    10 (100%)                                           in vitro (TK)                                               in vitro: 8 (80%); in vivo: 2 (100%)            in vitro: 2 (20%)                              0%                       0%                        \-                                          \-                                                                                                                                                                                                                      \-                                                                                                                                                                                                                                                                                              \[[@B28-antibiotics-09-00500]\]
  2003, Japan            Nakazawa           ampicillin                  32                                                                                                                                                                           MRSA (100%)                                        29 (91%)                                                                                                                                                                                                                                                   31 (96%)                   in vitro (efficacy time index)                      4 (12%)                                                     2 (6%)                                          26 (81%)                                       0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B18-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                 
  1997, Italy            Ferrara            oxacillin                   16                                                                                                                                                                           MRSA (100%)                                        NA (at least 8)                                                                                                                                                                                                                                            16 (100%)                  in vitro (TK)                                       3 (18%)                                                     3 (18%)                                         4 (25%)                                        \-                       \-                        \-                                          Addition or indifference was observed for the remaining 6 strains (data not shown).                                                                                                                                     \[[@B123-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                
  1994, Japan            Komatsuzawa        oxacillin                   38                                                                                                                                                                           MRSA (60.5%)                                       33 (86.8%)                                                                                                                                                                                                                                                 23 (60%)                   in vitro (CB)                                       20 (52%)                                                    17 (44%)                                        1 (2%)                                         0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B124-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                
  1985, USA              Alvarez            methicillin                 148                                                                                                                                                                          MRSA (100%)                                        NA (\< 15)                                                                                                                                                                                                                                                 148 (100%)                 in vitro (CB)                                       69 (46%)                                                    \-                                              \-                                             1 (1%)                   \-                        \-                                          For the 78 remaining strains it was not specified if the combination FOS + methicillin acted with an additive or indifferent effect.                                                                                    \[[@B12-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                 
  1978, Spain            Olay               ampicillin, carbenicillin   ampicillin: 27; carbenicillin: 28                                                                                                                                            \-                                                 \-                                                                                                                                                                                                                                                         \-                         in vitro (CB)                                       ampicillin: 15 (55%); carbenicillin: 10 (35.7%)             ampicillin: 9 (33%); carbenicillin: 18 (64%)    ampicillin: 3 (11%); carbenicillin: 0%         0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B14-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                 
  1977, Poland           Borowski           penicillin G                11                                                                                                                                                                           \-                                                 \-                                                                                                                                                                                                                                                         \-                         in vitro (CB)                                       5 (45%)                                                     2 (18%)                                         4 (36%)                                        0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B121-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                
  *S. epidermidis*       1997, Italy        Ferrara                     oxacillin                                                                                                                                                                    12                                                 MRSE (100%)                                                                                                                                                                                                                                                NA (at least 6)            12 (100%)                                           in vitro (TK)                                               6 (50%)                                         1 (8%)                                         1 (8%)                   \-                        \-                                          \-                                                                                                                                                                                                                      Data of the other 4 strains are not shown.                                                                                                                                                                                                                                                      \[[@B123-antibiotics-09-00500]\]
  *Streptococcus* spp.   2017, Germany      Gonzalez Moreno             benzylpenicillin                                                                                                                                                             3                                                  \-                                                                                                                                                                                                                                                         1 (33.3%)                  0%                                                  in vitro (microcalorimetry for biofilms)                    0%                                              0%                                             3 (100%)                 0%                        \-                                          \-                                                                                                                                                                                                                      *S. agalactiae*, *S. pyogenes*, *S. oralis*. High-dose FOS caused a delay of 8 h in the production of heat, compared with untreated controls, suggesting that the treatment could result in a reduction in the number of viable sessile cells, although not in complete biofilm eradication.    \[[@B9-antibiotics-09-00500]\]
  1981, Spain            Vicente            penicillin G                17                                                                                                                                                                           \-                                                 9 (53%)                                                                                                                                                                                                                                                    5 (29%)                    in vitro (CB, TK); in vivo (rabbit, endocarditis)   in vitro: 4 (23%)                                           in vitro: 12 (71%); in vivo: 100%               in vitro: 1 (6%)                               0%                       \-                        \-                                          *S. sanguis*. The mean log10 CFU per gram of vegetations in the FOS + penicillin groups was significantly lower than that in the FOS groups but was not significantly lower than that in the penicillin group.          \[[@B17-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                 
  1978, Spain            Olay               ampicillin                  37                                                                                                                                                                           \-                                                 \-                                                                                                                                                                                                                                                         \-                         in vitro (CB)                                       12 (32%)                                                    11 (29%)                                        14 (37%)                                       0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B14-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                 
  *S. pneumoniae*        2001, Spain        Bañón Arias                 penicillin                                                                                                                                                                   10                                                 \-                                                                                                                                                                                                                                                         1 (10%)                    8 (80%)                                             in vitro (TK)                                               10 (100%)                                       0%                                             0%                       0%                        \-                                          \-                                                                                                                                                                                                                      Synergistic effect difficult to determine. It is reported as synergistic against all isolates based on authors' considerations and on the comparison between cumulative efficacy of MIC + MIC and MIC/4 + MIC/4.                                                                                \[[@B125-antibiotics-09-00500]\]
  1996, France           Chavanet           amoxicillin                 1                                                                                                                                                                            \-                                                 0%                                                                                                                                                                                                                                                         1 (100%)                   in vivo (rabbit, fibrin clot infection)             1 (100%)                                                    0%                                              0%                                             0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B23-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                 
  1995, Japan            Kikuchi            benzylpenicillin            51                                                                                                                                                                           \-                                                 0%                                                                                                                                                                                                                                                         51 (100%)                  in vitro (CB, TK)                                   9 (17%)                                                     42 (82%)                                        0%                                             0%                       \-                        \-                                          \-                                                                                                                                                                                                                      \[[@B126-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                
  *Enterococcus* spp.    2013, Taiwan       Tang                        ampicillin                                                                                                                                                                   10 *E. faecium*, 9 *E. faecalis*                   VRE (100%)                                                                                                                                                                                                                                                 13 (68%)                   9 (47%)                                             in vitro (TK, biofilm)                                      TK: 3 (15%)                                     \-                                             \-                       biofilm: 6 (31%)          \-                                          \-                                                                                                                                                                                                                      The 3 isolates exhibiting synergistic effect were all *E. faecium*. The 6 isolates exhibiting antagonistic effect on biofilm formation were all *E. faecalis*. From the data reported in the paper it was not possible to establish the effect of the combination against the other isolates.   \[[@B13-antibiotics-09-00500]\]
  1995, France           Pestel             penicillin                  10                                                                                                                                                                           \-                                                 10 (100%)                                                                                                                                                                                                                                                  6 (60%)                    in vitro (CB, TK)                                   6 (60%)                                                     \-                                              \-                                             0%                       \-                        \-                                          *E. faecalis*, *E. faecium*, *E. casseliflavus*, *E. durans*. The authors did not distinguish between additive and indifferent effect.                                                                                  \[[@B127-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                
  *E. faecalis*          2011, Italy        Farina                      ampicillin                                                                                                                                                                   27                                                 \-                                                                                                                                                                                                                                                         2 (7%)                     0%                                                  in vitro (ET)                                               2 (7%)                                          0%                                             25 (92%)                 0%                        \-                                          \-                                                                                                                                                                                                                      The Authors considered 0.5 \< FICI ≤ 4 as indifferent.                                                                                                                                                                                                                                          \[[@B128-antibiotics-09-00500]\]
  *E. faecium*           2013, USA          Descourouez                 amoxicillin                                                                                                                                                                  4                                                  VRE (100%)                                                                                                                                                                                                                                                 0%                         4 (100%)                                            in vitro (TK)                                               100%                                            0%                                             0%                       0%                        \-                                          \-                                                                                                                                                                                                                      The combination resulted also strongly bactericidal.                                                                                                                                                                                                                                            \[[@B67-antibiotics-09-00500]\]
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###### 

Studies on combination between fosfomycin and cephalosporins, cephalosporins + β-lactamase inhibitors. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strain                  Year and Country    Author                                                                                         Cephalosporin                                                                                                     Number of Isolates                                                                                             Known Resistance Mechanisms or Determinants (%)                                                                                                                                                                                                  FOS-Resistant (%)                                          cephalosporin-Resistant (%)                                In Vitro (Methods)/In Vivo (Animal and Site of Infection)      Synergistic Effect (%)                                                                Additive Effect (%)                                           Indifferent Effect (%)                                       Antagonistic Effect (%)       FOS Susceptibility Restoration (%)                           Cephalosporin Susceptibility Restoration (%)                                                                                                                                                                                                                                                                                                                                         Comments                                                                                                                                                                                                                                                                         Reference
  ----------------------- ------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------ ----------------------------- ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  Enterobacterales        2019, USA           Avery                                                                                          cefepime (FEP), ceftolozane/tazobactam (C/T), ceftazidime (CTZ), ceftazidime/avibactam (CZA)                      49 (26 tested for CZA)                                                                                         8 *E. coli*: KPC (25%), NDM (75%), ESBL (62%); 35 *Klebsiella* spp: KPC (45%), NDM (40%); OXA (14%), VIM (8%), ESBL (88%), fosA (44%); 2 *Citrobacter* spp: KPC (50%), NDM (50%), ESBL (50%), 4 *E. cloacae*: KPC (75%), NDM (25%), ESBL (75%)   20 (40%)                                                   49 (100%)                                                  in vitro (ET)                                                  FEP: 2 (4%); C/T: 8 (16%); CTZ: 3 (6%); CZA: 0%                                       FEP: 5 (10%); C/T: 11 (22%); CTZ: 8 (16.3%); CZA: 3 (11.5%)   FEP: 42 (85%); C/T: 30 (61%); CTZ: 38 (77%); CZA: 23 (88%)   0%                            0%                                                           0%                                                                                                                                                                                                                                                                                                                                                                                   Data on synergism reported without distinction for bacterial strains. % of FOS-R isolates estimated on the basis of the reported MIC50.                                                                                                                                          \[[@B11-antibiotics-09-00500]\]
  2019, USA               Flamm               ceftazidime                                                                                    20                                                                                                                \-                                                                                                             \-                                                                                                                                                                                                                                               \-                                                         in vitro (CB, TK)                                          8 (40%)                                                        10 (50%)                                                                              0%                                                            0%                                                           \-                            \-                                                           For 2 isolates the efficacy of FOS + CTZ remained indeterminate.                                                                                                                                                                                                                                                                                                                     \[[@B38-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  1978, Spain             Olay                cephalexin                                                                                     23 *E. coli*, 29 *Salmonella* spp., 8 *Klebsiella* spp., 11 *E. cloacae*, 16 *S. marcescens*, 16 *Proteus* spp.   \-                                                                                                             \-                                                                                                                                                                                                                                               \-                                                         in vitro (CB)                                              42 (40%)                                                       46 (44%)                                                                              15 (14%)                                                      0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B14-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  *E. coli*               2020, Korea         Seok                                                                                           cefixime                                                                                                          4                                                                                                              ESBL (50%)                                                                                                                                                                                                                                       0%                                                         2 (50%)                                                    in vitro (TK)                                                  4 (100%)                                                                              0%                                                            0%                                                           0%                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \-                                                                                                                                                                                                                                                                               \[[@B119-antibiotics-09-00500]\]
  2014, France            Lefort              cefoxitim                                                                                      2                                                                                                                 ESBL (50%)                                                                                                     0%                                                                                                                                                                                                                                               breakpoints NA                                             in vitro (TK); in vivo (mouse, urinary tract infection)    in vitro: 2 (100%); in vivo: 2 (100%)                          0%                                                                                    0%                                                            0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B30-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  *K. pneumoniae*         2019, Poland        Ojdana                                                                                         ceftazidime-avibactam                                                                                             19                                                                                                             NDM (52%); KPC (42%); OXA (5%)                                                                                                                                                                                                                   10 (53%)                                                   10 (53%)                                                   in vitro (ET)                                                  9 (47%)                                                                               7 (36%)                                                       3 (15%)                                                      0%                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \-                                                                                                                                                                                                                                                                               \[[@B31-antibiotics-09-00500]\]
  2019, USA               Mikhail             ceftazidime-avibactam                                                                          21                                                                                                                fosA/fosA-like, KPC, ESBL, OXA (100%)                                                                          15 (71%)                                                                                                                                                                                                                                         0%                                                         in vitro (CB, TK)                                          10 (47%)                                                       9 (42%)                                                                               2 (9%)                                                        0%                                                           \-                            0% (all S)                                                   It is reported only the reduction of CZA in combination and time--kill was performed only on 2 isolates randomly selected, therefore a reduction of at least 4 times was considered as synergistic. A 2-fold reduction was considered as additive. No reduction was considered as indifferent. In increase of MIC in combination was considered antagonistic.                        \[[@B21-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  1977, Spain             Daza                cephapirin                                                                                     33                                                                                                                \-                                                                                                             100%                                                                                                                                                                                                                                             breakpoints NA                                             in vitro (CB)                                              1 (3%)                                                         \-                                                                                    \-                                                            \-                                                           0%                            Breakpoints NA (reduction of MIC from 16 to 4 µg/mL)         The authors reported only the number of isolates on which the combination had a synergistic effect.                                                                                                                                                                                                                                                                                  \[[@B66-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  *P. aeruginosa*         2020, Brazil        Cuba                                                                                           ceftolozane/tazobactam                                                                                            27                                                                                                             carbapenemase-producing (74%)                                                                                                                                                                                                                    26 (96%)                                                   22 (81%)                                                   in vitro (ET, TK)                                              24 (88%)                                                                              3 (11%)                                                       0%                                                           0%                            24 (92%)                                                     \-                                                                                                                                                                                                                                                                                                                                                                                   It is not possible to establish the % of strains with FOS susceptibility restoration because the MIC for all R strains was \> 64 ug/mL and it is not reported the MIC in combination but the MIC fold reduction. It is however strongly reduced (range: 2--16 fold reduction).   \[[@B32-antibiotics-09-00500]\]
  2020, USA               Mullane             cefepime, ceftolozane/tazobactam                                                               28 CEF; 15 C/T                                                                                                    \-                                                                                                             \-                                                                                                                                                                                                                                               \-                                                         in vitro (CB, TK)                                          CEF: 5 (18%); C/T: 5 (33%)                                     CEF: 20 (71%); C/T: 8 (53%)                                                           CEF: 3 (11%); C/T: 2 (14%)                                    0%                                                           \-                            CEF: 1 (4%); C/T: 5 (33%)                                    \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B129-antibiotics-09-00500]\]                                                                                                                                                                                                                                                 
  2019, USA               Mikhail             ceftazidime-avibactam                                                                          21                                                                                                                fosA/fosA-like, KPC, ESBL, OXA (100% at least 1 resistance gene)                                               19 (90%)                                                                                                                                                                                                                                         5 (23%)                                                    in vitro (CB, TK)                                          7 (33%)                                                        6 (28%)                                                                               8 (38%)                                                       0%                                                           \-                            1 (20%)                                                      It is reported only the reduction of CZA in combination and time--kill was performed only on 2 isolates randomly selected, therefore a reduction of at least 4 times was considered as synergistic. A 2-fold reduction was considered as additive. No reduction was considered as indifferent. In increase of MIC in combination was considered antagonistic.                        \[[@B21-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  2019, USA               Papp-Wallace        ceftazidime-avibactam                                                                          1                                                                                                                 \-                                                                                                             0%                                                                                                                                                                                                                                               1 (100%)                                                   in vitro (CB, TK); in vivo (mouse)                         in vitro: 100%; in vivo: 100%                                  0%                                                                                    0%                                                            0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B29-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  2019, USA               Avery               cefepime (FEP), ceftolozane/tazobactam (C/T), ceftazidime (CAZ), ceftazidime/avibactam (CZA)   92 FEP, 14 C/T, 81 CAZ, 16 CZA                                                                                    Carbapenem-resistant (100%)                                                                                    \-                                                                                                                                                                                                                                               100%                                                       in vitro (ET)                                              FEP: 22 (23%); C/T: 7 (50%); CAZ: 42 (51%); CZA: 4 (25%)       FEP: 53 (57%); C/T: 5 (35%); CAZ: 31 (38%); CZA: 12 (75%)                             FEP: 17 (18%); C/T: 2 (14%); CAZ: 8 (9%); CZA: 0%             0%                                                           \-                            FEP: 56 (60%); C/T: 10 (71%); CAZ: 46 (56%); CZA: 11 (68%)   \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B33-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  2019, USA               Flamm               ceftazidime                                                                                    5                                                                                                                 \-                                                                                                             \-                                                                                                                                                                                                                                               \-                                                         in vitro (CB, TK)                                          2 (40%)                                                        3 (60%)                                                                               0%                                                            0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B38-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  2018, USA               Monogue             ceftolozane/tazobactam                                                                         4                                                                                                                 \-                                                                                                             3 (75%)                                                                                                                                                                                                                                          2 (50%)                                                    in vitro (TK)                                              1 (25%)                                                        2 (50%)                                                                               1 (25%)                                                       0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B34-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  2013, Brazil            dos Santos          ceftazidime                                                                                    3                                                                                                                 \-                                                                                                             3 (100%)                                                                                                                                                                                                                                         3 (100%)                                                   in vitro (CB)                                              3 (100%)                                                       0%                                                                                    0%                                                            0%                                                           1 (33%)                       2 (66%)                                                      \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B48-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  2005, Thailand          Pruekprasert        ceftazidime                                                                                    18                                                                                                                \-                                                                                                             \-                                                                                                                                                                                                                                               \-                                                         in vitro (CB)                                              2 (11%)                                                        6 (33%)                                                                               6 (33%)                                                       4 (22%)                                                      \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B22-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  2002, Japan             Okazaki             ceftazidime, cefepime                                                                          30                                                                                                                \-                                                                                                             15 (50%)                                                                                                                                                                                                                                         CAZ: 28 (93%), CEFP: 26 (86.7%)                            in vitro (efficacy time index)                             CAZ: 21 (70%); CEFP: 24 (80%)                                  CAZ: 8 (26%); CEFP: 1 (3.3%)                                                          CAZ: 1 (3%); CEFP: 5 (16%)                                    0%                                                           CAZ: 3 (20%); CEFP: 6 (40%)   CAZ: 19 (67%); CEFP: 26 (100%)                               \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B39-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  1999, Japan             Hayami              ceftazidime                                                                                    26                                                                                                                \-                                                                                                             NA (at least 13)                                                                                                                                                                                                                                 NA (at least 5)                                            in vitro (CB, TK)                                          7 (26%)                                                        14 (53%)                                                                              5 (19%)                                                       0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B130-antibiotics-09-00500]\]                                                                                                                                                                                                                                                 
  1997, France            Tessier             ceftazidime                                                                                    40                                                                                                                \-                                                                                                             21 (52%)                                                                                                                                                                                                                                         14 (35%)                                                   in vitro (CB)                                              0%                                                             8 (20%)                                                                               32 (80%)                                                      0%                                                           20 (95%)                      8 (57%)                                                      Although the combination had a synergistic effect on no tested strains, it is of clinical relevance as it restored FOS and CTZ susceptibility in many resistant isolates.                                                                                                                                                                                                            \[[@B131-antibiotics-09-00500]\]                                                                                                                                                                                                                                                 
  1984, Japan             Takahashi           cefoperazone, cefsulodin                                                                       20 (cefoperazone), 23 (cefsulodin)                                                                                \-                                                                                                             \-                                                                                                                                                                                                                                               \-                                                         in vitro (CB)                                              cefoper: 17 (85%); cefsul: 19 (92%)                            cefoper: 3 (15%); cefsul: 4 (17%)                                                     0%                                                            0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B122-antibiotics-09-00500]\]                                                                                                                                                                                                                                                 
  *A. baumannii*          2019, USA           Flamm                                                                                          ceftazidime                                                                                                       5 (*A. baumannii*-calcoaceticus species complex)                                                               \-                                                                                                                                                                                                                                               \-                                                         \-                                                         in vitro (CB, TK)                                              2 (40%)                                                                               1 (20%)                                                       1 (20%)                                                      0%                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   For 1 isolate the efficacy of FOS + CTZ remained indeterminate.                                                                                                                                                                                                                  \[[@B38-antibiotics-09-00500]\]
  1996, Spain             Martinez-Martinez   ceftazidime                                                                                    34                                                                                                                \-                                                                                                             34 (100%)                                                                                                                                                                                                                                        32 (94%)                                                   in vitro (CB)                                              1 (3%)                                                         NA                                                                                    NA                                                            0%                                                           \-                            \-                                                           Only synergistic and antagonistic effect reported.                                                                                                                                                                                                                                                                                                                                   \[[@B132-antibiotics-09-00500]\]                                                                                                                                                                                                                                                 
  *Staphylococcus* spp.   1995, Italy         Marchese                                                                                       cefdinir                                                                                                          6 *S. aureus*, 8 *S. epidermidis*, 2 *S. hominis*, 2 *S. xylosus*, 5 *S. saprophyticus*, 2 *S. haemolyticus*   Penicillin-resistant (100%)                                                                                                                                                                                                                      \-                                                         \-                                                         in vitro (CB, TK)                                              4 (16%)                                                                               \-                                                            \-                                                           0%                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   The authors considered 0.5 \< FICI ≤ 4 as indifferent, therefore it is not possible to establish if the effect was additive or indifferent for most strains.                                                                                                                     \[[@B114-antibiotics-09-00500]\]
  *S. aureus*             2003, Japan         Nakazawa                                                                                       flomoxef sodium (FS), cefmetazole (CEM), cefotiam (CET), cefoperazone/sulbactam (CS)                              32                                                                                                             MRSA (100%)                                                                                                                                                                                                                                      29 (91%)                                                   FS: 29 (91%); CEM: 16 (50%); CET: 30 (94%); CS: 27 (84%)   in vitro (efficacy time index)                                 FS: 7 (22%); CEM: 26 (81%); CET: 7 (22%); CS: 19 (59%)                                FS: 11 (34%); CEM: 3 (9%); CET: 1 (3%); CS: 8 (25%)           FS: 14 (44%); CEM: 3 (9%); CET: 22 (69%); CS: 5 (15%)        0%                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \-                                                                                                                                                                                                                                                                               \[[@B18-antibiotics-09-00500]\]
  1978, Spain             Olay                cephalexin                                                                                     24                                                                                                                \-                                                                                                             \-                                                                                                                                                                                                                                               \-                                                         in vitro (CB)                                              17 (70.8%)                                                     7 (29.2%)                                                                             0%                                                            0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B14-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  2015, Spain             del Río             ceftriaxone                                                                                    in vitro 10; in vivo 2                                                                                            MRSA (100%)                                                                                                    1 (10%)                                                                                                                                                                                                                                          10 (100%)                                                  in vitro (TK); in vivo (rabbit, endocarditis)              in vitro: 8 (80%); in vivo: 2 (100%)                           in vitro: 2 (20%)                                                                     0%                                                            0%                                                           \-                            \-                                                           \% of sterile vegetations: FOS alone 0%, IMI alone 0%, FOS + CRO 62%.                                                                                                                                                                                                                                                                                                                \[[@B28-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  1985, Germany           Portier             cefotaxime, cephalotin, cefoperazone, cefamandole                                              10                                                                                                                MRSA (100%)                                                                                                    0%                                                                                                                                                                                                                                               10 (100%)                                                  in vitro (CB)                                              cefotaxime, cephalotin, cefoperazone, cefamandole: 10 (100%)   0%                                                                                    0%                                                            0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B20-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  1990, France            Chavanet            cefotaxime                                                                                     1                                                                                                                 MGRSA (100%)                                                                                                   0%                                                                                                                                                                                                                                               1 (100%)                                                   in vivo (rabbit, subcutaneous fibrin clots)                1 (100%)                                                       0%                                                                                    0%                                                            0%                                                           \-                            \-                                                           Synergistic effect was observed when both drugs were administered in two divided doses.                                                                                                                                                                                                                                                                                              \[[@B27-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  1985, France            Kazmierczak         cefotaxime                                                                                     1                                                                                                                 \-                                                                                                             0%                                                                                                                                                                                                                                               1 (100%)                                                   in vivo (rabbit, meningitis)                               0%                                                             1 (100%)                                                                              0%                                                            0%                                                           \-                            \-                                                           Cefotaxime: variable drop in bacterial numbers from one rabbit to another during the first 12 h, then a bacteriostasis. FOS: rapid bactericidal effect during the first 12 h, becoming slower during the following 36 h (0.03% surviving bacteria at 48 h). Cefotaxime + FOS: rapid bactericidal effect remaining steady over the 48-h period (0.001% surviving bacteria at 48 h).   \[[@B26-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  1991, Japan             Matsuda             cefmetazole                                                                                    25                                                                                                                MRSA (100%)                                                                                                    25 (100%)                                                                                                                                                                                                                                        25 (100%)                                                  in vitro (CB, TK)                                          11 (44%)                                                       11 (44%)                                                                              3 (12%)                                                       0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B133-antibiotics-09-00500]\]                                                                                                                                                                                                                                                 
  1986, Japan             Utsui               cefmetazole                                                                                    14 in vitro, 7 in vivo                                                                                            MRSA (100%)                                                                                                    \-                                                                                                                                                                                                                                               14 (100%)                                                  in vitro (CB, TK); in vivo (mouse)                         in vitro: 10 (71%); in vivo: 5 (71%)                           in vitro: 4 (28%); in vivo: 2 (28%)                                                   0%                                                            0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B25-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  1987, France            Courcol             ceftriaxone                                                                                    6                                                                                                                 \-                                                                                                             1 (16.%)                                                                                                                                                                                                                                         6 (100%)                                                   in vitro (CB, TK)                                          CB: 1 (16%); TK: 1 (16%)                                       CB: 0%; TK: -                                                                         CB: 4 (66%); TK: 3 (50%)                                      CB: 1 (16%); TK: -                                           \-                            \-                                                           Different activity of the drug combination with checkerboard assay or time--kill assay. The effect of FOS + ceftriaxone on 2 isolates remained indeterminate. The authors considered the combination antagonistic when the FICI was \> 2.                                                                                                                                            \[[@B19-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  1985, USA               Alvarez             cefamandole                                                                                    148                                                                                                               MRSA (100%)                                                                                                    NA (\<15)                                                                                                                                                                                                                                        \-                                                         in vitro (CB)                                              97 (66%)                                                       \-                                                                                    \-                                                            0%                                                           \-                            \-                                                           For the 78 remaining isolates it was not specified if the combination FOS + cefamandole acted with an additive or indifferent effect.                                                                                                                                                                                                                                                \[[@B12-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  2001, Austria           Grif                cefazolin                                                                                      5                                                                                                                 MRSA (20%), GISA (20%)                                                                                         \-                                                                                                                                                                                                                                               \-                                                         in vitro (CB, TK)                                          5 (100%)                                                       0%                                                                                    0%                                                            0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B43-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  *S. epidermidis*        2001, Austria       Grif                                                                                           cefazolin                                                                                                         2                                                                                                              \-                                                                                                                                                                                                                                               \-                                                         \-                                                         in vitro (CB, TK)                                              0%                                                                                    0%                                                            2 (100%)                                                     0%                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \-                                                                                                                                                                                                                                                                               \[[@B43-antibiotics-09-00500]\]
  1987, France            Courcol             ceftriaxone                                                                                    6                                                                                                                 \-                                                                                                             2 (33.3%)                                                                                                                                                                                                                                        6 (100%)                                                   in vitro (CB, TK)                                          CB: 1 (16%); TK: 5 (83.3%)                                     CB: 0%; TK: -                                                                         CB: 5 (83%); TK: -                                            CB: 1 (16%); TK: -                                           \-                            \-                                                           Different activity of the drug combination with checkerboard assay or time--kill assay. The effect of FOS + ceftriaxone on 1 isolate remained indeterminate. The authors considered the combination antagonistic when the FICI was \> 2.                                                                                                                                             \[[@B19-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  *S. pneumoniae*         2006, Spain         Ribes                                                                                          ceftriaxone                                                                                                       2                                                                                                              \-                                                                                                                                                                                                                                               0%                                                         2 (100%)                                                   in vitro (TK); in vivo (rabbit, meningitis)                    0%                                                                                    in vitro: 1 (50%); in vivo: 2 (100%)                          in vitro: 1 (50%)                                            0%                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \-                                                                                                                                                                                                                                                                               \[[@B24-antibiotics-09-00500]\]
  2001, Spain             Bañón Arias         ceftriaxone                                                                                    10                                                                                                                \-                                                                                                             1 (10%)                                                                                                                                                                                                                                          7 (70%)                                                    in vitro (TK)                                              10 (100%)                                                      0%                                                                                    0%                                                            0%                                                           \-                            \-                                                           Synergistic effect difficult to determine. It is reported as synergistic against all isolates based on authors' considerations and on the comparison between cumulative efficacy of MIC + MIC and MIC/4 + MIC/4.                                                                                                                                                                     \[[@B125-antibiotics-09-00500]\]                                                                                                                                                                                                                                                 
  1994, France            Doit                ceftriaxone                                                                                    26                                                                                                                \-                                                                                                             0%                                                                                                                                                                                                                                               20 (76%)                                                   in vitro (TK)                                              0%                                                             26 (100%)                                                                             0%                                                            0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B134-antibiotics-09-00500]\]                                                                                                                                                                                                                                                 
  1993, France            Barakett            cefotaxime                                                                                     7                                                                                                                 \-                                                                                                             0%                                                                                                                                                                                                                                               2 (28%)                                                    in vitro (TK)                                              3 (42%)                                                        1 (14%)                                                                               3 (42%)                                                       0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B135-antibiotics-09-00500]\]                                                                                                                                                                                                                                                 
  1995, France            Chavanet            cefotaxime, ceftriaxone                                                                        1                                                                                                                 \-                                                                                                             0%                                                                                                                                                                                                                                               1 (100%)                                                   in vitro (TK); in vivo (rabbit, fibrin clot infection)     in vitro: 0%; in vivo: 1 (100%, cefotaxime)                    in vitro: 1 (100%, both cefotaxime and ceftriaxone); in vivo: 1 (100%, ceftriaxone)   0%                                                            0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B23-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  *S. sanguis*            1981, Spain         Vicente                                                                                        cefoxitim                                                                                                         17                                                                                                             \-                                                                                                                                                                                                                                               9 (53%)                                                    3 (16%)                                                    in vitro (CB, TK); in vivo (rabbit, endocarditis)              in vitro: 8 (47%); in vivo: 100%                                                      in vitro: 8 (47%)                                             in vitro: 1 (6%)                                             0%                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   The mean log10 CFU per gram of vegetations in the FOS + cefoxitim groups was significantly lower than that in the FOS groups and in the cefoxitim groups.                                                                                                                        \[[@B17-antibiotics-09-00500]\]
  *Enterococcus* spp.     1995, France        Pestel                                                                                         cefotaxime                                                                                                        50                                                                                                             \-                                                                                                                                                                                                                                               48 (96%)                                                   50 (100%)                                                  in vitro (CB, TK)                                              45 (90%)                                                                              \-                                                            5 (10%)                                                      0%                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   *E. faecalis*, *E. faecium*, *E. casseliflavus*, *E. durans*. The authors did not distinguish between additive and indifferent effect.                                                                                                                                           \[[@B127-antibiotics-09-00500]\]
  *E. faecalis*           2011, Italy         Farina                                                                                         ceftriaxone                                                                                                       27                                                                                                             \-                                                                                                                                                                                                                                               2 (7%)                                                     27 (100%)                                                  in vitro (ET)                                                  15 (55%)                                                                              0%                                                            12 (44%)                                                     0%                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   The authors did not distinguish between additive and indifferent effect, considering 0.5 \< FICI ≤ 4 as indifferent.                                                                                                                                                             \[[@B128-antibiotics-09-00500]\]
  *N. gonorrhoeae*        2015, Switzerland   Hauser                                                                                         ceftriaxone                                                                                                       8                                                                                                              \-                                                                                                                                                                                                                                               0%                                                         1 (12.5%)                                                  in vitro (CB)                                                  0%                                                                                    0%                                                            8 (100%)                                                     0%                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \-                                                                                                                                                                                                                                                                               \[[@B57-antibiotics-09-00500]\]
  2015, The Netherlands   Wind                cefixime, ceftriaxone                                                                          4                                                                                                                 \-                                                                                                             \-                                                                                                                                                                                                                                               \-                                                         in vitro (ET)                                              0%                                                             cefixime: 1 (25%); ceftriaxone: 2 (50%)                                               cefixime: 3 (75%); ceftriaxone: 2 (50%)                       0%                                                           \-                            \-                                                           \-                                                                                                                                                                                                                                                                                                                                                                                   \[[@B54-antibiotics-09-00500]\]                                                                                                                                                                                                                                                  
  2014, USA               Barbee              cefixime, ceftriaxone                                                                          32                                                                                                                \-                                                                                                             0%                                                                                                                                                                                                                                               cefotaxime: 29 (90%), cefixime: 6 (18%), ceftriaxone: 0%   in vitro (ET)                                              0%                                                             0%                                                                                    32 (100%)                                                     0%                                                           \-                            \-                                                           The authors did not distinguish between additive and indifferent effect, considering 0.5 \< FICI ≤ 4 as indifferent.                                                                                                                                                                                                                                                                 \[[@B136-antibiotics-09-00500]\]                                                                                                                                                                                                                                                 
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###### 

Studies on combination between fosfomycin and carbapenems. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strains                                       Year and Country        Author                                      Carbapenem                           Number of Isolates                                 Known Resistance Mechanisms or Determinants (%)                                                                                                                                                                                                  FOS-Resistant (%)              Carbapenem-Resistant (%)                               In Vitro (Methods)/In Vivo (Animal and Site of Infection)                                           Synergistic Effect (%)                                                                             Additive Effect (%)                                      Indifferent Effect (%)       Antagonistic Effect (%)      FOS Susceptibility Restoration (%)   Carbapenem Susceptibility Restoration (%)                                                                                                                                                                                                                                                   Comments                                                                                                                                                                                     Reference
  --------------------------------------------- ----------------------- ------------------------------------------- ------------------------------------ -------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------ ------------------------------------------------------ --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- -------------------------------------------------------- ---------------------------- ---------------------------- ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  Enterobacterales                              2019, USA               Avery                                       meropenem                            49                                                 8 *E. coli*: KPC (25%), NDM (75%), ESBL (62%); 35 *Klebsiella* spp: KPC (45%), NDM (40%); OXA (14%), VIM (8%), ESBL (88%), fosA (44%); 2 *Citrobacter* spp: KPC (50%), NDM (50%), ESBL (50%), 4 *E. cloacae*: KPC (75%), NDM (25%), ESBL (75%)   20 (40.8%)                     49 (100%)                                              in vitro (ET)                                                                                       1 (2%)                                                                                             10 (20%)                                                 38 (77%)                     0%                           \-                                   \-                                                                                                                                                                                                                                                                                          Data on synergism reported without distinction for bacterial strains. % of FOS-R isolates estimated on the basis of the reported MIC50.                                                      \[[@B11-antibiotics-09-00500]\]
  2019, USA                                     Flamm                   meropenem                                   20                                   \-                                                 \-                                                                                                                                                                                                                                               \-                             in vitro (CB, TK)                                      8 (40%)                                                                                             10 (50%)                                                                                           0%                                                       0%                           \-                           \-                                   For 2 isolates the efficacy of FOS + meropenem (MER) remained indeterminate.                                                                                                                                                                                                                \[[@B38-antibiotics-09-00500]\]                                                                                                                                                              
  *E. coli*                                     2020, Egypt             El-Wafa                                     imipenem                             8                                                  \-                                                                                                                                                                                                                                               3 (37.5%)                      7 (87.5%)                                              in vitro (CB, TK)                                                                                   2 (25%)                                                                                            5 (62%)                                                  0%                           0%                           2 (66%)                              6 (87%)                                                                                                                                                                                                                                                                                     For 1 isolate the efficacy of FOS + MER remained indeterminate                                                                                                                               \[[@B42-antibiotics-09-00500]\]
  2019, India                                   Sugathan                meropenem                                   50                                   \-                                                 0%                                                                                                                                                                                                                                               8 (16%)                        in vitro (TK)                                          34 (68%)                                                                                            14 (28%)                                                                                           2 (4%)                                                   0%                           0% (all S)                   2 (25%)                              \-                                                                                                                                                                                                                                                                                          \[[@B137-antibiotics-09-00500]\]                                                                                                                                                             
  2019, Germany                                 Loose                   meropenem, ertapenem                        4                                    \-                                                 1 (25%)                                                                                                                                                                                                                                          3 (75%)                        in vitro (CB)                                          4 (100%)                                                                                            0%                                                                                                 0%                                                       0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B138-antibiotics-09-00500]\]                                                                                                                                                             
  2013, Austria                                 Lingscheid              doripenem                                   10                                   ESBL (80%), AmpC (20%)                             0%                                                                                                                                                                                                                                               \-                             in vitro (CB, TK)                                      8 (80%)                                                                                             \-                                                                                                 .                                                        0%                           \-                           \-                                   The authors reported FICI ranging from 0.5 to 4, without distinction between additive and indifferent effect.                                                                                                                                                                               \[[@B139-antibiotics-09-00500]\]                                                                                                                                                             
  2012, Greece                                  Samonis                 imipenem, meropenem, doripenem              20                                   ESBL (100%)                                        0%                                                                                                                                                                                                                                               0%                             in vitro (ET)                                          IMI: 11 (55%); MER: 5 (25%); DORI: 6 (30%)                                                          IMI: 9 (45%); MER: 15 (75%); DOR: 14 (70%)                                                         0%                                                       0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B86-antibiotics-09-00500]\]                                                                                                                                                              
  2010, Thailand                                Netikul                 ertapenem, imipenem, meropenem, doripenem   8                                    ESBL (87%)                                         0%                                                                                                                                                                                                                                               8 (100%)                       in vitro (ET)                                          0%                                                                                                  ERT: 5 (62%); IMI: 2 (25%); MER: 2 (25%); DOR: 1 (12%)                                             ERT: 3 (37%); IMI: 6 (75%); MER: 6 (75%); DOR: 7 (87%)   0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B140-antibiotics-09-00500]\]                                                                                                                                                             
  *K. pneumoniae*                               2020, India             Bakthavatchalam                             meropenem                            50                                                 OXA (78%), NDM (32%)                                                                                                                                                                                                                             \-                             50 (100%)                                              in vitro (TK)                                                                                       10 (20%)                                                                                           0%                                                       40 (80%)                     0%                           \-                                   \-                                                                                                                                                                                                                                                                                          \-                                                                                                                                                                                           \[[@B141-antibiotics-09-00500]\]
  2020, Turkey                                  Erturk Sengel           meropenem                                   17                                   OXA (70%), NDM (70%)                               7 (41%)                                                                                                                                                                                                                                          17 (100%)                      in vitro (CB, TK)                                      15 (88%)                                                                                            2 (11%)                                                                                            0%                                                       0%                           4 (23%)                      \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B142-antibiotics-09-00500]\]                                                                                                                                                             
  2019, Germany                                 Loose                   meropenem, ertapenem                        3                                    \-                                                 3 (100%)                                                                                                                                                                                                                                         2 (66%)                        in vitro (CB)                                          2 (66%)                                                                                             1 (33%)                                                                                            0%                                                       0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B138-antibiotics-09-00500]\]                                                                                                                                                             
  2019, Brazil                                  Perdigão Neto           meropenem                                   9                                    ESBL, KPC (100%); OXA (4%), fosA (100%)            9 (100%)                                                                                                                                                                                                                                         9 (100%)                       in vitro (CB, TK)                                      8 (88%)                                                                                             0%                                                                                                 1 (11%)                                                  0%                           2 (22%)                      0%                                   \-                                                                                                                                                                                                                                                                                          \[[@B143-antibiotics-09-00500]\]                                                                                                                                                             
  2017, Taiwan                                  Tseng                   meropenem                                   25                                   see comments                                       12 (48%)                                                                                                                                                                                                                                         24 (96%)                       in vitro (CB)                                          25 (100%)                                                                                           0%                                                                                                 0%                                                       0%                           \-                           \-                                   The 25 isolates were randomly selected among 642 isolates with the following resistance determinants: fosA3 (5.5%), foskp96 (4.2%), KPC (10.1%), IMP (0.8%), VIM (0.2%). It is not reported which carbapenemases and fosfomycinases were present in the 25 isolates tested for synergism.   \[[@B144-antibiotics-09-00500]\]                                                                                                                                                             
  2017, China                                   Yu                      imipenem, ertapenem                         136                                  KPC (100%)                                         78 (57%)                                                                                                                                                                                                                                         136 (100%)                     in vitro (CB, TK)                                      IMI: 21 (15%); ERT: 30 (22%)                                                                        IMI: 114 (83%); ERT: 104 (76%)                                                                     IMI: 1 (1%); ERT: 2 (1%)                                 0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B89-antibiotics-09-00500]\]                                                                                                                                                              
  2016, Brazil                                  Albiero                 meropenem                                   18                                   KPC (100%)                                         13 (72%)                                                                                                                                                                                                                                         16 (89%)                       in vitro (CB)                                          12 (66%)                                                                                            3 (16%)                                                                                            3 (16%)                                                  0%                           12 (92.3%)                   4 (25%)                              \-                                                                                                                                                                                                                                                                                          \[[@B145-antibiotics-09-00500]\]                                                                                                                                                             
  2014, Sweden                                  Tängdén                 meropenem                                   4                                    NDM (50%), VIM (50%), ESBL (100%)                  2 (50%)                                                                                                                                                                                                                                          3 (75%)                        in vitro (TK)                                          0%                                                                                                  0%                                                                                                 4 (100%)                                                 0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B146-antibiotics-09-00500]\]                                                                                                                                                             
  2013, Turkey                                  Evren                   imipenem, meropenem                         12                                   OXA-48 (100%)                                      12 (100%)                                                                                                                                                                                                                                        12 (100%)                      in vitro (CB)                                          IMI: 5 (41%); MER: 4 (33%)                                                                          IMI: 6 (50%); MER: 6 (50%)                                                                         IMI: 1 (8%); MER: 2 (16%)                                0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B74-antibiotics-09-00500]\]                                                                                                                                                              
  2013, Austria                                 Lingscheid              doripenem                                   5                                    ESBL (60%), AmpC (100%)                            0%                                                                                                                                                                                                                                               \-                             in vitro (CB, TK)                                      5 (100%)                                                                                            0%                                                                                                 0%                                                       0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B139-antibiotics-09-00500]\]                                                                                                                                                             
  2012, Greece                                  Samonis                 imipenem, meropenem, doripenem              64                                   KPC (78%), ESBL (21%)                              1 (1%)                                                                                                                                                                                                                                           51 (78% )                      in vitro (ET)                                          KPC: IMI: 37 (74%); MER: 35 (70%); DOR: 37 (74%). ESBL: IMI: 11 (78%); MER: 6 (42%); DOR: 6 (42%)   KPC: IMI: 13 (26%); MER: 15 (30%); DOR: 13 (26%). ESBL: IMI: 3 (21%); MER: 8 (57%); DOR: 8 (57%)   0%                                                       0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B86-antibiotics-09-00500]\]                                                                                                                                                              
  2011, Greece                                  Souli                   meropenem                                   17                                   KPC (100%)                                         4 (23%)                                                                                                                                                                                                                                          17 (100%)                      in vitro (TK)                                          11 (64%)                                                                                            0%                                                                                                 6 (35%)                                                  0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B53-antibiotics-09-00500]\]                                                                                                                                                              
  2010, Thailand                                Netikul                 ertapenem, imipenem, meropenem, doripenem   8                                    ESBL (87%)                                         4 (50%)                                                                                                                                                                                                                                          8 (100%)                       in vitro (ET)                                          0%                                                                                                  ERT: 5 (62%); IMI: 2 (25%); MER: 1 (12%); DOR: 2 (25%)                                             ERT: 3 (37%); IMI: 6 (75%); MER: 7 (87%); DOR: 6 (75%)   0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B140-antibiotics-09-00500]\]                                                                                                                                                             
  *E. cloacae*                                  2019, Germany           Loose                                       meropenem, ertapenem                 2                                                  \-                                                                                                                                                                                                                                               2 (100%)                       1 (50%)                                                in vitro (CB)                                                                                       0%                                                                                                 2 (100%)                                                 0%                           0%                           \-                                   \-                                                                                                                                                                                                                                                                                          \-                                                                                                                                                                                           \[[@B133-antibiotics-09-00500]\]
  2013, Austria                                 Lingscheid              doripenem                                   3                                    1 (33%)                                            0%                                                                                                                                                                                                                                               \-                             in vitro (CB, TK)                                      1 (33%)                                                                                             \-                                                                                                 \-                                                       0%                           \-                           \-                                   The authors reported FICI ranging from 0.5 to 4, without distinction between additive and indifferent effect.                                                                                                                                                                               \[[@B139-antibiotics-09-00500]\]                                                                                                                                                             
  *P. aeruginosa*                               2020, USA               Mullane                                     meropenem                            30                                                 \-                                                                                                                                                                                                                                               14 (47%)                       30 (100%)                                              in vitro (CB, TK)                                                                                   5 (17%)                                                                                            9 (30%)                                                  16 (53%)                     0%                           0%                                   0%                                                                                                                                                                                                                                                                                          \-                                                                                                                                                                                           \[[@B129-antibiotics-09-00500]\]
  2019, USA                                     Avery                   meropenem                                   153                                  \-                                                 NA (at least 71)                                                                                                                                                                                                                                 153 (100%)                     in vitro (ET)                                          29 (19%)                                                                                            55 (35%)                                                                                           69 (45%)                                                 0%                           \-                           21 (13%)                             \-                                                                                                                                                                                                                                                                                          \[[@B33-antibiotics-09-00500]\]                                                                                                                                                              
  2019, Brazil                                  Albiero                 meropenem                                   19                                   MBL (52%)                                          17 (89%)                                                                                                                                                                                                                                         16 (84%)                       in vitro (CB)                                          15 (88%)                                                                                            3 (15%)                                                                                            1 (5%)                                                   0%                           15 (88%)                     7 (43%)                              \-                                                                                                                                                                                                                                                                                          \[[@B147-antibiotics-09-00500]\]                                                                                                                                                             
  2019, USA                                     Flamm                   meropenem                                   5                                    \-                                                 \-                                                                                                                                                                                                                                               \-                             in vitro (CB, TK)                                      1 (20%)                                                                                             3 (60%)                                                                                            1 (20%)                                                  0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B38-antibiotics-09-00500]\]                                                                                                                                                              
  2019, Brazil                                  Perdigão Neto           meropenem                                   1                                    OXA, fosA (100%)                                   1 (100%)                                                                                                                                                                                                                                         1 (100%)                       in vitro (CB, TK)                                      1 (100%)                                                                                            0%                                                                                                 0%                                                       0%                           1 (100%)                     1 (100%)                             \-                                                                                                                                                                                                                                                                                          \[[@B143-antibiotics-09-00500]\]                                                                                                                                                             
  2018, USA                                     Drusano                 meropenem                                   1                                    \-                                                 \-                                                                                                                                                                                                                                               \-                             in vitro (hollow-fiber infection model)                1 (100%)                                                                                            0%                                                                                                 0%                                                       0%                           \-                           \-                                   Combination therapy was able to counterselect resistance emergence.                                                                                                                                                                                                                         \[[@B148-antibiotics-09-00500]\]                                                                                                                                                             
  2017, Spain                                   Hamou-Segarra           imipenem                                    4                                    \-                                                 1 (25%)                                                                                                                                                                                                                                          \-                             in vitro (TK)                                          4 (100%)                                                                                            0%                                                                                                 0%                                                       0%                           \-                           \-                                   FOS and imipenem (IMI) alone lead to bacterial regrowth, while no regrowth was observed with the combination FOS + IMI.                                                                                                                                                                     \[[@B149-antibiotics-09-00500]\]                                                                                                                                                             
  2015, Thailand                                Kunakonvichaya          imipenem, meropenem, doripenem              70                                   \-                                                 \-                                                                                                                                                                                                                                               70 (100%)                      in vitro (CB, TK)                                      IMI: 38%; MER: 40%; DOR: 45%                                                                        \-                                                                                                 \-                                                       \-                           \-                           \-                                   FOS in association with a carbapenem was observed to reduce also biofilm formation.                                                                                                                                                                                                         \[[@B150-antibiotics-09-00500]\]                                                                                                                                                             
  2013, Brazil                                  dos Santos              imipenem                                    4                                    \-                                                 4 (100%)                                                                                                                                                                                                                                         2 (50%)                        in vitro (CB)                                          4 (100%)                                                                                            0%                                                                                                 0%                                                       0%                           3 (75%)                      1 (50%)                              \-                                                                                                                                                                                                                                                                                          \[[@B48-antibiotics-09-00500]\]                                                                                                                                                              
  2013, Austria                                 Lingscheid              doripenem                                   18                                   \-                                                 \-                                                                                                                                                                                                                                               \-                             in vitro (CB, TK)                                      0%                                                                                                  0%                                                                                                 18 (100%)                                                0%                           \-                           \-                                   The authors reported FICI ranging from 0.5 to 4, without distinction between additive and indifferent effect, and considered the combination \"indifferent\" against all isolates.                                                                                                          \[[@B139-antibiotics-09-00500]\]                                                                                                                                                             
  2012, Greece                                  Samonis                 imipenem, meropenem, doripenem              15                                   \-                                                 1 (1%)                                                                                                                                                                                                                                           9 (60%)                        in vitro (ET)                                          IMI: 7 (46%); MER: 8 (53%); DOR: 11 (73%)                                                           IMI: 8 (53%); MER: 7 (46%); DOR: 4 (26%)                                                           0%                                                       0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B86-antibiotics-09-00500]\]                                                                                                                                                              
  2005, Thailand                                Pruekprasert            imipenem                                    29                                   \-                                                 \-                                                                                                                                                                                                                                               \-                             in vitro (CB)                                          11 (38%)                                                                                            4 (14%)                                                                                            12 (41%)                                                 2 (7%)                       \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B22-antibiotics-09-00500]\]                                                                                                                                                              
  2002, Japan                                   Okazaki                 imipenem, meropenem                         30                                   \-                                                 15 (50%)                                                                                                                                                                                                                                         IMI: 29 (96%); MER: 27 (90%)   in vitro (efficacy time index)                         IMI: 22 (73%); MER: 26 (86%)                                                                        IMI: 0%; MER: 2 (6%)                                                                               IMI: 8 (26%); MER: 2 (6%)                                0%                           IMI: 2 (13%); MER: 3 (20%)   IMI: 21 (72%); MER: 16 (59%)         \-                                                                                                                                                                                                                                                                                          \[[@B39-antibiotics-09-00500]\]                                                                                                                                                              
  1999, Japan                                   Hayami                  meropenem                                   26                                   \-                                                 NA (at least 13)                                                                                                                                                                                                                                 NA (at least 5)                in vitro (CB, TK)                                      3 (11%)                                                                                             15 (57%)                                                                                           8 (30%)                                                  0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B130-antibiotics-09-00500]\]                                                                                                                                                             
  1997, France                                  Tessier                 imipenem                                    40                                   \-                                                 20 (50%)                                                                                                                                                                                                                                         9 (22%)                        in vitro (CB)                                          0%                                                                                                  15 (37%)                                                                                           25 (62%)                                                 0%                           17 (85%)                     8 (88%)                              Although the combination had a synergistic effect on no tested strains, it is of clinical relevance as it restored FOS and IMI susceptibility in almost all R isolates.                                                                                                                     \[[@B131-antibiotics-09-00500]\]                                                                                                                                                             
  *A. baumannii*                                2019, USA               Flamm                                       meropenem                            5 (*A. baumannii-calcoaceticus* species complex)   \-                                                                                                                                                                                                                                               \-                             \-                                                     in vitro (CB, TK)                                                                                   1 (20%)                                                                                            3 (60%)                                                  0%                           0%                           \-                                   \-                                                                                                                                                                                                                                                                                          For 1 isolate the efficacy of FOS + MER remained indeterminate.                                                                                                                              \[[@B38-antibiotics-09-00500]\]
  2018, China                                   Zhu                     imipenem                                    21                                   \-                                                 20 (95%)                                                                                                                                                                                                                                         21 (100%)                      in vitro (CB)                                          12 (57%)                                                                                            3 (14.3%)                                                                                          6 (28%)                                                  0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B151-antibiotics-09-00500]\]                                                                                                                                                             
  2018, Thailand                                Singkham-In             imipenem, meropenem                         23                                   OXA (100%)                                         23 (100%)                                                                                                                                                                                                                                        23 (100%)                      in vitro (CB, TK)                                      IMI: 65%; MER: 0%                                                                                   IMI: 30.4%; MER: 87%                                                                               IMI: 4%; MER: 13%                                        0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B152-antibiotics-09-00500]\]                                                                                                                                                             
  2016, Brazil                                  Leite                   imipenem, meropenem                         20                                   OXA (100%), IMP (15%)                              20 (100%)                                                                                                                                                                                                                                        20 (100%)                      in vitro (CB, TK)                                      IMI: 0%; MER: 0%                                                                                    IMI: 4 (20%); MER: 0%                                                                              IMI: 16 (80%); MER: 100%                                 0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B83-antibiotics-09-00500]\]                                                                                                                                                              
  1996, Spain                                   Martinez-Martinez       imipenem                                    34                                   \-                                                 34 (100%)                                                                                                                                                                                                                                        NA (at least 7)                in vitro (CB)                                          1 (3%)                                                                                              \-                                                                                                 \-                                                       0%                           \-                           \-                                   The Authors reported only the number of isolates on which the combination had a synergistic or an antagonistic effect.                                                                                                                                                                      \[[@B132-antibiotics-09-00500]\]                                                                                                                                                             
  *S. aureus*                                   2019, Spain             Coronado-Álvarez                            imipenem                             4                                                  MRSA (50%)                                                                                                                                                                                                                                       \-                             \-                                                     in vitro (TK)                                                                                       4 (100%)                                                                                           0%                                                       0%                           0%                           \-                                   \-                                                                                                                                                                                                                                                                                          \-                                                                                                                                                                                           \[[@B63-antibiotics-09-00500]\]
  2015, Spain                                   del Río                 imipenem                                    10 (in vitro); 2 (in vivo)           MRSA (100%)                                        1 (10%)                                                                                                                                                                                                                                          4 (40%)                        in vitro (TB); in vivo (rabbit, endocarditis)          in vitro: 9 (90%); in vivo: 2 (100%)                                                                in vitro: 1 (10%)                                                                                  0%                                                       0%                           \-                           \-                                   \% of sterile vegetations: FOS alone 0%, IMI alone 7%, FOS + IMI 73%.                                                                                                                                                                                                                       \[[@B28-antibiotics-09-00500]\]                                                                                                                                                              
  2013, Austria                                 Lingscheid              doripenem                                   39                                   MRSA (100%)                                        0%                                                                                                                                                                                                                                               \-                             in vitro (CB, TK)                                      37 (94%)                                                                                            \-                                                                                                 \-                                                       0%                           \-                           \-                                   The authors reported FICI ranging from 0.5 to 4, without distinction between additive and indifferent effect.                                                                                                                                                                               \[[@B139-antibiotics-09-00500]\]                                                                                                                                                             
  2012, Spain                                   Garrigós                imipenem                                    1                                    MRSA (100%)                                        0%                                                                                                                                                                                                                                               0%                             in vitro (TK); in vivo (rat, foreign-body infection)   0%                                                                                                  in vitro: 1 (100%)                                                                                 in vitro: 0%; in vivo: 1 (100%)                          0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B37-antibiotics-09-00500]\]                                                                                                                                                              
  2011, Spain                                   Pachón-Ibáñez           imipenem                                    1                                    GISA (100%)                                        0%                                                                                                                                                                                                                                               100%                           in vitro (TK); in vivo (mouse, peritonitis)            in vitro: 1 (100%); in vivo: 1 (100%)                                                               0%                                                                                                 0%                                                       0%                           \-                           \-                                   FOS + IMI reached statistical difference when compared to IMI as single therapy in the mouse model.                                                                                                                                                                                         \[[@B36-antibiotics-09-00500]\]                                                                                                                                                              
  2003, Japan                                   Nakazawa                imipenem, panipenem                         32                                   MRSA (100%)                                        29 (91%)                                                                                                                                                                                                                                         28 (88%)                       in vitro (efficacy time index)                         IMI: 16 (50%); PAN: 21 (66%)                                                                        IMI: 3 (9%); PAN: 8 (25%)                                                                          IMI: 13 (41%); PAN: 3 (9%)                               0%                           \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B18-antibiotics-09-00500]\]                                                                                                                                                              
  1987, France                                  Quentin                 imipenem                                    5                                    \-                                                 1 (20%)                                                                                                                                                                                                                                          1 (20%)                        in vitro (TK)                                          1 (20%)                                                                                             0%                                                                                                 3 (60%)                                                  1 (20%)                      \-                           \-                                   \-                                                                                                                                                                                                                                                                                          \[[@B35-antibiotics-09-00500]\]                                                                                                                                                              
  *S. aureus + S. epidermidis*                  2001, Austria           Grif                                        meropenem                            5 *S. aureus* + 2 *S. epidermidis*                 MRSA (25%), GISA (25%)                                                                                                                                                                                                                           \-                             \-                                                     in vitro (CB, TK)                                                                                   *S. aureus*: 5 (100%)                                                                              0%                                                       *S. epidermidis*: 2 (100%)   0%                           \-                                   \-                                                                                                                                                                                                                                                                                          \-                                                                                                                                                                                           \[[@B43-antibiotics-09-00500]\]
  1992, Austria                                 Guggenbichler           imipenem                                    1 *S. aureus* + 2 *S. epidermidis*   \-                                                 \-                                                                                                                                                                                                                                               \-                             in vitro (TK)                                          3 (100%)                                                                                            0%                                                                                                 0%                                                       0%                           \-                           \-                                   The study was conducted on catheters infected in laboratory. Bacterial regrowth was observed in catheters treated with FOS or IMI alone, but did not occurred when the drugs were tested in combination.                                                                                    \[[@B153-antibiotics-09-00500]\]                                                                                                                                                             
  *Staphylococcus* spp. + *Enterococcus* spp.   1986, Italy             Debbia                                      imipenem                             76                                                 \-                                                                                                                                                                                                                                               \-                             \-                                                     in vitro (CB, TK)                                                                                   54 (71%)                                                                                           0%                                                       22 (29%)                     0%                           \-                                   \-                                                                                                                                                                                                                                                                                          \% reported are those obtained with CB. Results of TK showed higher rates of synergism, but in the present Table are considered the results of CB as not all isolates were tested with TK.   \[[@B154-antibiotics-09-00500]\]
  *E. faecalis*                                 2011, Italy             Farina                                      imipenem                             27                                                 \-                                                                                                                                                                                                                                               2 (7%)                         0%                                                     in vitro (ET)                                                                                       0%                                                                                                 0%                                                       10 (37%)                     17 (62%)                     \-                                   \-                                                                                                                                                                                                                                                                                          The Authors did not distinguish between additive and indifferent effect, and defined the effect of FOS + IMI indifferent.                                                                    \[[@B128-antibiotics-09-00500]\]
  *S. pneumoniae*                               1994, France            Doit                                        imipenem                             26                                                 \-                                                                                                                                                                                                                                               0%                             0%                                                     in vitro (TK)                                                                                       0%                                                                                                 26 (100%)                                                0%                           0%                           \-                                   \-                                                                                                                                                                                                                                                                                          \-                                                                                                                                                                                           \[[@B134-antibiotics-09-00500]\]
  *N. gonorrhoeae*                              2015, The Netherlands   Wind                                        ertapenem                            4                                                  \-                                                                                                                                                                                                                                               \-                             \-                                                     in vitro (ET)                                                                                       0%                                                                                                 3 (75%)                                                  1 (25%)                      0%                           \-                                   \-                                                                                                                                                                                                                                                                                          \-                                                                                                                                                                                           \[[@B54-antibiotics-09-00500]\]

antibiotics-09-00500-t004_Table 4

###### 

Studies on combination between fosfomycin and aztreonam. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strain             Year and Country   Author   Number of Isolates   Known Resistance Mechanisms or Determinants (%)                                                                                                                                                                                                                             FOS-Resistant (%)   Aztreonam-Resistant (%)          In Vitro (Methods)/In Vivo (Animal and Site of Infection)   Synergistic Effect (%)   Additive Effect (%)   Indifferent Effect (%)   Antagonistic Effect (%)   FOS Susceptibility Restoration (%)   Aztreonam Susceptibility Restoration (%)                           Comments                                                                                                                                  Reference
  ------------------ ------------------ -------- -------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- -------------------------------- ----------------------------------------------------------- ------------------------ --------------------- ------------------------ ------------------------- ------------------------------------ ------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  Enterobacterales   2019, USA          Avery    48                   48 not specified between: 8 *E. coli*: KPC (25%), NDM (75%), ESBL (62%); 35 *Klebsiella* spp: KPC (45%), NDM (40%); OXA (14%), VIM (8.%), ESBL (88%), fosA (44%); 2 *Citrobacter* spp: KPC (50%), NDM (50%), ESBL (50%), 4 *E. cloacae*: KPC (75%), NDM (25%), ESBL (75%)   20 (40%)            48 (100%)                        in vitro (ET)                                               4 (8%)                   13 (27%)              31 (64%)                 0%                        0%                                   0%                                                                 Data on synergism reported without distinction for bacterial strains. % of FOS-R isolates estimated on the basis of the reported MIC50.   \[[@B11-antibiotics-09-00500]\]
  2019, USA          Flamm              20       \-                   \-                                                                                                                                                                                                                                                                          \-                  in vitro (CB, TK)                5 (25%)                                                     5 (25%)                  1 (5%)                0%                       \-                        \-                                   For 9 isolates the efficacy of FOS + ATM remained indeterminate.   \[[@B38-antibiotics-09-00500]\]                                                                                                           
  *E. coli*          2014, Sweden       Hickam   2                    ESBL, OXA (50%)                                                                                                                                                                                                                                                             0%                  1 (50%)                          in vitro (CB, TK)                                           2 (100%)                 0%                    0%                       0%                        \-                                   \-                                                                 \-                                                                                                                                        \[[@B120-antibiotics-09-00500]\]
  *K. pneumoniae*    2014, Sweden       Hickam   1                    ESBL, OXA (100%)                                                                                                                                                                                                                                                            0%                  1 (100%)                         in vitro (CB, TK)                                           0%                       1 (100%)              0%                       0%                        \-                                   \-                                                                 \-                                                                                                                                        \[[@B120-antibiotics-09-00500]\]
  *P. aeruginosa*    2019, USA          Avery    103                  \-                                                                                                                                                                                                                                                                          NA (at least 71)    103 (100%)                       in vitro (ET)                                               16 (15.5%)               68 (66%)              19 (18%)                 0%                        \-                                   21 (13%)                                                           \-                                                                                                                                        \[[@B33-antibiotics-09-00500]\]
  2019, USA          Flamm              5        \-                   \-                                                                                                                                                                                                                                                                          \-                  in vitro (ET)                    1 (20%)                                                     3 (60%)                  0%                    0%                       \-                        \-                                   For 1 isolate the efficacy of FOS + ATM remained indeterminate.    \[[@B38-antibiotics-09-00500]\]                                                                                                           
  2002, Japan        Okazaki            30       \-                   15 (50%)                                                                                                                                                                                                                                                                    29 (96%)            in vitro (efficacy time index)   23 (76.%)                                                   3 (10%)                  4 (13%)               0%                       4 (26%)                   6 (20%)                              \-                                                                 \[[@B39-antibiotics-09-00500]\]                                                                                                           

antibiotics-09-00500-t005_Table 5

###### 

Studies on combination between fosfomycin and quinolones. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strain                                         Year and Country    Author                                       Quinolone        Number of Isolates                               Known Resistance Mechanisms or Determinants (%)   FOS-Resistant (%)   Quinolone-Resistant (%)                         In Vitro (Methods)/In Vivo (Animal and Site of Infection)   Synergistic Effect (%)           Additive Effect (%)   Indifferent Effect (%)   Antagonistic Effect (%)   FOS Susceptibility Restoration (%)   Quinolone Susceptibility Restoration (%)                                                                                                                     Comments                                                                                                                                       Reference
  ---------------------------------------------- ------------------- -------------------------------------------- ---------------- ------------------------------------------------ ------------------------------------------------- ------------------- ----------------------------------------------- ----------------------------------------------------------- -------------------------------- --------------------- ------------------------ ------------------------- ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  Enterobacterales                               2019, USA           Flamm                                        Levofloxacin     20                                               7 MDR (of which 29% ESBL and 29% KPC-producer)    \-                  \-                                              in vitro (CB)                                               30%                              60%                   10%                      0%                        \-                                   \-                                                                                                                                                           \-                                                                                                                                             \[[@B38-antibiotics-09-00500]\]
  *E. coli*                                      2020, Egypt         El-Wafa                                      Ciprofloxacin    8                                                \-                                                100%                100%                                            in vitro (CB, TK)                                           3 (37%)                          \-                    \-                       \-                        3 (100%)                             3 (100%)                                                                                                                                                     Triple combination (FOS/IMP/CIP o FOS/CIP/TOB) increased synergism against all isolates.                                                       \[[@B42-antibiotics-09-00500]\]
  2019, USA                                      Wang                Ciprofloxacin                                8                \-                                               25%                                               25%                 in vitro (ET, biofilm)                          2 (25%)                                                     \-                               6 (75%)               \-                       0%                        0%                                   \-                                                                                                                                                           \[[@B155-antibiotics-09-00500]\]                                                                                                               
  2019, India                                    Sugathan            Ciprofloxacin                                50               biofilm producers (100%)                         0%                                                98%                 in vitro (CB, TK)                               3 (6%)                                                      20 (40%)                         27 (54%)              0%                       \-                        0%                                   The optimal combination of fosfomycin with N-acetylcystein produces the reduction of *E. coli* sessile cell viability and biofilm formation up to 60--73%.   \[[@B137-antibiotics-09-00500]\]                                                                                                               
  *S. flexneri*                                  2019, China         Liu                                          Ciprofloxacin    80                                               \-                                                43 (54%)            100%                                            in vitro (CB, TK); in vivo (*Galleria mellonella*)          31 (38%)                         0%                    49 (61)%                 0%                        65 (81%)                             3 (4%)                                                                                                                                                       \-                                                                                                                                             \[[@B156-antibiotics-09-00500]\]
  *P. aeruginosa*                                2019, USA           Wang                                         Ciprofloxacin    7                                                \-                                                0%                  14%                                             in vitro (ET, biofilm)                                      4 (57%)                          \-                    3 (42%)                  \-                        \-                                   0%                                                                                                                                                           \-                                                                                                                                             \[[@B155-antibiotics-09-00500]\]
  2019, USA                                      Flamm               Levofloxacin                                 5                7 MDR (of which 29% ESBL and 29% KPC-producer)   \-                                                \-                  in vitro (CB)                                   1 (20%)                                                     4 (80%)                                                0%                       \-                        \-                                   \-                                                                                                                                                           \[[@B38-antibiotics-09-00500]\]                                                                                                                
  2016, Australia                                Walsh               Ciprofloxacin                                4                \-                                               75%                                               50%                 in vitro (TK)                                   21% (23/108)                                                15% (16/108)                     38% (41/108)          \-                       \-                        \-                                   The total number of experiments was 108 (9 combinations of FOS + CIP at different concentrations, in 3 different times).                                     \[[@B76-antibiotics-09-00500]\]                                                                                                                
  2013, Brazil                                   Dos Santos          Ciprofloxacin                                2                MDR (50%)                                        100%                                              50%                 in vitro (CB, TK)                               2 (100%)                                                    \-                               \-                    \-                       2 (100%)                  0%                                   \-                                                                                                                                                           \[[@B48-antibiotics-09-00500]\]                                                                                                                
  2007, Japan                                    Mikuniya            Prulifloxacin, ciprofloxacin, levofloxacin   1                biofilm forming (100%)                           \-                                                \-                  in vivo (rat, UTI)                              1 (100%)                                                    \-                               \-                    \-                       \-                        \-                                   \*After 3 consecutive days' co-administration.                                                                                                               \[[@B40-antibiotics-09-00500]\]                                                                                                                
  2007, Japan                                    Yamada              Ciprofloxacin                                74               \-                                               \-                                                \-                  in vitro (CB)                                   20 (27%)                                                    \-                               54 (73%)              0%                       \-                        \-                                   \-                                                                                                                                                           \[[@B157-antibiotics-09-00500]\]                                                                                                               
  2005, Japan                                    Micuniya            Ciprofloxacin, Ulifloxacin, Levofloxacin     1                \-                                               100%                                              100%                in vitro (ATP bioluminescence assay)            \-                                                          100%                             \-                    \-                       0%                        0%                                   \-                                                                                                                                                           \[[@B46-antibiotics-09-00500]\]                                                                                                                
  2002, Japan                                    Monden              Ofloxacin                                    4                \-                                               3 (75%)                                           1 (25%)             in vitro (biofilm)                              3 (75%)                                                     \-                               \-                    \-                       \-                        \-                                   \-                                                                                                                                                           \[[@B158-antibiotics-09-00500]\]                                                                                                               
  2001, Japan                                    Okazaki             Levofloxacin                                 30               MDR (50%)                                        13/30 (43%)                                       21/30 (70%)         in vitro (Efficacy time index)                  3/30 (1%)                                                   17/30 (56%)                      \-                    10/30 (33)%              \-                        \-                                   ETI \< 0.5 antagonism; 0.5 ≤ ETI \<1 indifferent; 1 ≤ ETI \< 8 additive; ETI ≥ 8 synergistic                                                                 \[[@B39-antibiotics-09-00500]\]                                                                                                                
  1999, Japan                                    Hayami              Ciprofloxacin                                26               \-                                               \-                                                \-                  in vitro (CB, TK)                               10(38%)                                                     15 (57%)                         1 (3%)                0%                       \-                        \-                                   \-                                                                                                                                                           \[[@B130-antibiotics-09-00500]\]                                                                                                               
  1997, France                                   Bugnon              Pefloxacin                                   2                \-                                               \-                                                \-                  in vivo (rabbit, endocarditis)                  \-                                                          \-                               \-                    100%                     \-                        \-                                   \-                                                                                                                                                           \[[@B41-antibiotics-09-00500]\]                                                                                                                
  1997, France                                   Tessier             Ciprofloxacin                                40               MDR (100%)                                       23 (57%)                                          19 (47%)            in vitro (CB)                                   6 (15%)                                                     32 (80%)                         2 (5%)                \-                       16 (70%)                  12 (63%)                             \-                                                                                                                                                           \[[@B131-antibiotics-09-00500]\]                                                                                                               
  1995, Japan                                    Kumon               Ofloxacin                                    1                \-                                               \-                                                \-                  in vitro (TK)                                   1 (100%)                                                    \-                               \-                    \-                       \-                        \-                                   \-                                                                                                                                                           \[[@B159-antibiotics-09-00500]\]                                                                                                               
  1994, France                                   Xiong               Ciprofloxacin                                2                MDR (50%)                                        0%                                                50%                 in vitro (CB); in vivo (rabbit, endocarditis)   2 (100%) early thp; 1 (50%) Late thp                        0% early thp; 1 (50%) Late thp   \-                    \-                       \-                        \-                                   in vivo results.                                                                                                                                             \[[@B160-antibiotics-09-00500]\]                                                                                                               
  1994, France                                   Xiong               Pefloxacin                                   2                MDR (50%)                                        0%                                                50%                 in vitro (CB); in vivo (rabbit, endocarditis)   1 (50%) early thp; 1 (50%) late thp                         1 (50%) early thp                1 (50%) late thp      \-                       \-                        \-                                   in vivo results.                                                                                                                                             \[[@B160-antibiotics-09-00500]\]                                                                                                               
  1989, Germany                                  Vogt                Ciprofloxacin                                25               \-                                               1 (4%)                                            2 (8%)              in vitro (TK)                                   20%                                                         \-                               \-                    \-                       \-                        \-                                   \-                                                                                                                                                           \[[@B161-antibiotics-09-00500]\]                                                                                                               
  1988, USA                                      Figueredo           Ciprofloxacin                                \-               \-                                               \-                                                \-                  in vitro (CB)                                   60% (EV) 17% (OS)                                           \-                               \-                    0%                       \-                        \-                                   \-                                                                                                                                                           \[[@B162-antibiotics-09-00500]\]                                                                                                               
  1987, Germany                                  Ullmann             Ciprofloxacin                                37               \-                                               \-                                                \-                  in vitro (CB)                                   29 (78%)                                                    8 (22%)                          0%                    0%                       100%                      \-                                   \-                                                                                                                                                           \[[@B45-antibiotics-09-00500]\]                                                                                                                
  *A. baumannii*                                 1996, Spain         Martinez-Martinez                            Ciprofloxacin    34                                               \-                                                100%                100%                                            in vitro (CB)                                               1 (3%)                           \-                    \-                       0%                        \-                                   \-                                                                                                                                                           \-                                                                                                                                             \[[@B132-antibiotics-09-00500]\]
  *A. baumannii-A. calcoaceticus* spp. complex   2019, USA           Flamm                                        Levofloxacin     5                                                7 MDR (29% ESBL and 29% KPC-producer)             \-                  \-                                              in vitro (CB)                                               0%                               4 (80%)               1 (20%)                  0%                        \-                                   \-                                                                                                                                                           \-                                                                                                                                             \[[@B38-antibiotics-09-00500]\]
  Gram negative                                  1977, Spain         Daza                                         Nalidixic acid   100                                              \-                                                100%                \-                                              in vitro (CB)                                               0%                               \-                    100%                     0%                        \-                                   \-                                                                                                                                                           *Klebsiella* spp., *Pseudomonas* spp., *E. coli*, *Serratia* spp., *Proteus* spp., *Enterobacter* spp., *Acinetobacter* spp., *Levinea* spp.   \[[@B66-antibiotics-09-00500]\]
  *Staphylococcus* spp.                          2003, Japan         Nakazawa                                     Ofloxacin        32                                               MRSA (100%)                                       \-                  \-                                              in vitro (efficacy time index)                              3 (9%)                           2 (6%)                27 (84%)                 \-                        \-                                   \-                                                                                                                                                           synergism = high efficacy; additive = efficacy; indifferent = invalid                                                                          \[[@B18-antibiotics-09-00500]\]
  2001, Austria                                  Grif                Moxifloxacin                                 7                MRSA (100%)                                      \-                                                \-                  in vitro (CB)                                   100%                                                        \-                               \-                    \-                       \-                        \-                                   \-                                                                                                                                                           \[[@B43-antibiotics-09-00500]\]                                                                                                                
  1997, Italy                                    Ferrara             Sparfloxacin                                 16               MRSA (100%)                                      \>50%                                             ∼100%               in vitro (TK)                                   0%                                                          \-                               \-                    \-                       \-                        \-                                   \-                                                                                                                                                           \[[@B123-antibiotics-09-00500]\]                                                                                                               
  1988, France                                   Thauvin             Pefloxacin                                   1                MRSA (100%)                                                                                                            in vivo (rat, endocarditis)                     100%                                                        \-                               \-                    \-                       \-                        \-                                   \-                                                                                                                                                           \[[@B44-antibiotics-09-00500]\]                                                                                                                
  1987, France                                   Weber               Ofloxacin                                    8                MRSA (37%)                                       \-                                                \-                  in vitro (TK)                                   2 (25%)                                                     6 (75%)                          \-                    \-                       \-                        \-                                   \-                                                                                                                                                           \[[@B163-antibiotics-09-00500]\]                                                                                                               
  1987, Germany                                  Ullmann             Ciprofloxacin                                20               \-                                               \-                                                \-                  in vitro (CB)                                   19 (95%)                                                    1 (5%)                           \-                    \-                       \-                        \-                                   *S. aureus*.                                                                                                                                                 \[[@B45-antibiotics-09-00500]\]                                                                                                                
  1987, France                                   Quentin             Pefloxacin                                   6                \-                                               16%                                               0%                  in vitro (TK)                                   0%                                                          0%                               100%                  0%                       \-                        \-                                   *S. aureus*. Indifferent effect.                                                                                                                             \[[@B35-antibiotics-09-00500]\]                                                                                                                
  *S.epidermidis*                                1997, Italy         Ferrara                                      Sparfloxacin     12                                               MRSE (100%)                                       \>50%               ∼100%                                           in vitro (TK)                                               6/12 (50%)                       \-                    \-                       \-                        \-                                   \-                                                                                                                                                           \-                                                                                                                                             \[[@B123-antibiotics-09-00500]\]
  1987, France                                   Quentin             Pefloxacin                                   2                \-                                               50%                                               \-                  in vitro (TK)                                   0%                                                          0%                               100%                  0%                       \-                        \-                                   Indifferent effect.                                                                                                                                          \[[@B35-antibiotics-09-00500]\]                                                                                                                
  *N. gonorrhoeae*                               2014, Netherlands   Wind                                         Moxifloxacin     4                                                \-                                                \-                  \-                                              in vitro (ET)                                               0%                               \-                    \-                       \-                        \-                                   \-                                                                                                                                                           \-                                                                                                                                             \[[@B54-antibiotics-09-00500]\]

antibiotics-09-00500-t006_Table 6

###### 

Studies on combination between fosfomycin and aminoglycosides. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strain                 Year and Country          Author                                Aminoglycoside                                                                                                                                                                                                           Number of Isolates                                                                               Known Resistance Mechanisms or Determinants (%)                                                                                                                                                                                                                            FOS-Resistant (%)                        Aminoglycoside-Resistant (%)                                               In Vitro (Methods)/In Vivo (Animal and Site of Infection)                Synergistic Effect (%)                                             Additive Effect (%)                                                Indifferent Effect (%)   Antagonistic Effect (%)   FOS Susceptibility Restoration (%)   Aminoglycoside Susceptibility Restoration (%)                                                                                                                                                                                                                              Comments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Reference
  ---------------------- ------------------------- ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------ ------------------------------------------------------------------ ------------------------ ------------------------- ------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  Enterobacterales       2019, USA                 Avery                                 Tobramycin                                                                                                                                                                                                               45                                                                                               45 not specified between: 8 *E. coli*: KPC (25%), NDM (75%), ESBL (62%); 35 *Klebsiella* spp: KPC (45%), NDM (40%); OXA (14%), VIM (8%), ESBL (88%), fosA (44%); 2 *Citrobacter* spp: KPC (50%), NDM (50%), ESBL (50%), 4 *E. cloacae*: KPC (75%), NDM (25%), ESBL (75%)   20/49 (40%)                              45 (100%)                                                                  in vitro (ET)                                                            2 (4%)                                                             7 (15%)                                                            36 (80%)                 0%                        \-                                   \-                                                                                                                                                                                                                                                                         Data on synergism reported without distinction for bacterial strains. Percentages of FOS-R isolates estimated on the basis of the reported MIC50.                                                                                                                                                                                                                                                                                                                                                                                            \[[@B11-antibiotics-09-00500]\]
  2019, USA              Flamm                     Gentamicin                            20                                                                                                                                                                                                                       \-                                                                                               \-                                                                                                                                                                                                                                                                         \-                                       in vitro (CB, TK)                                                          6 (30%)                                                                  13 (65%)                                                           1 (5%)                                                             0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B38-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1978, Spain            Olay                      Streptomycin, gentamicin, kanamycin   Streptomycin: 18 *E. coli*. Gentamicin: 30 *E. coli*, 24 *Klebsiella* spp., 39 *S. marcescens*, 33 *Proteus* spp. Kanamycin: 21 *E. coli*, 12 *Klebsiella* spp., 16 *Proteus* spp., 5 *E. cloacae*, 22 *S. marcescens*   \-                                                                                               \-                                                                                                                                                                                                                                                                         \-                                       in vitro (CB)                                                              streptomycin: 0%; gentamicin: 16 (12%); kanamycin: 21 (27%)              streptomycin: 9 (50%); gentamicin: 52 (41%); kanamycin: 37 (48%)   streptomycin: 9 (50%); gentamicin: 58 (46%); kanamycin: 18 (23%)   0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B14-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  *E. coli*              2020, Egypt               El-Wafa                               tobramycin                                                                                                                                                                                                               8                                                                                                \-                                                                                                                                                                                                                                                                         3 (37.5%)                                8 (100%)                                                                   in vitro (CB, TK)                                                        2 (25%)                                                            0%                                                                 0%                       0%                        2 (66%)                              2 (25%)                                                                                                                                                                                                                                                                    For 6 isolates the efficacy of FOS + TOB remained indeterminate.                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \[[@B42-antibiotics-09-00500]\]
  2019, USA              Wang                      Gentamicin                            8                                                                                                                                                                                                                        \-                                                                                               0%                                                                                                                                                                                                                                                                         2/8 (25%)                                in vitro (ET, biofilm)                                                     75% (6/8)                                                                0%                                                                 (2/8) 25%                                                          0%                       \-                        1/2 50%                              \-                                                                                                                                                                                                                                                                         \[[@B155-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2019, India            Sugathan                  Amikacin                              50                                                                                                                                                                                                                       \-                                                                                               0%                                                                                                                                                                                                                                                                         26 (52%)                                 in vitro (TK)                                                              29 (58%)                                                                 21 (42%)                                                           0%                                                                 0%                       0% (all S)                22 (84%)                             The Authors also studied the efficacy of combination of FOS + AMK and found it reduced significantly biofilm formation.                                                                                                                                                    \[[@B137-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2013, Switzerland      Corvec                    Gentamicin                            1                                                                                                                                                                                                                        CTX-M15, ESBL                                                                                    0%                                                                                                                                                                                                                                                                         0%                                       in vitro (TK); in vivo (foreign-body infection model)                      0%                                                                       100%                                                               0%                                                                 0%                       \-                        \-                                   Cure rate of FOS plus gentamicin 42%.                                                                                                                                                                                                                                      \[[@B73-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2011, Greece           Samonis                   Netilmicin                            20                                                                                                                                                                                                                       ESBL                                                                                             0%                                                                                                                                                                                                                                                                         35%                                      in vitro (ET)                                                              25% (5/20)                                                               \-                                                                 \-                                                                 \-                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B86-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1977, Poland           Borowski                  Streptomycin                          10                                                                                                                                                                                                                       \-                                                                                               \-                                                                                                                                                                                                                                                                         \-                                       in vitro (CB)                                                              7 (70%)                                                                  3 (30%)                                                            0%                                                                 0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B121-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  *K. pneumoniae*        2020, Turkey              Erturk Sengel                         Amikacin                                                                                                                                                                                                                 17                                                                                               OXA-48, NDM                                                                                                                                                                                                                                                                41%                                      76%                                                                        in vitro (CB)                                                            29%                                                                29%                                                                24%                      0%                        \-                                   \-                                                                                                                                                                                                                                                                         Combination of FOS plus amikacin seems not a good choice for NDM producing strains.                                                                                                                                                                                                                                                                                                                                                                                                                                                          \[[@B142-antibiotics-09-00500]\]
  2018, China            Yu                        Amikacin                              3                                                                                                                                                                                                                        \-                                                                                               0%                                                                                                                                                                                                                                                                         \-                                       in vitro (TK)                                                              100% (3/3)                                                               0%                                                                 0%                                                                 0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B164-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2017, China            Yu                        Amikacin                              3                                                                                                                                                                                                                        KPC-2                                                                                            0%                                                                                                                                                                                                                                                                         33%                                      in vitro (TK)                                                              66%                                                                      0%                                                                 33%                                                                0%                       \-                        \-                                   FOS (8 g q8h)/AMK (15 mg/kg qd) most bactericidal activity, but resistance occurred.                                                                                                                                                                                       \[[@B50-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2017, China            Yu                        Amikacin                              136                                                                                                                                                                                                                      KPC (100%)                                                                                       78 (57%)                                                                                                                                                                                                                                                                   80 (58%)                                 in vitro (CB, TK)                                                          7 (5%)                                                                   109 (80%)                                                          20 (14%)                                                           0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B89-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2015, Spain            Rodriguez-Avial et al.    Plazomicin                            4 (CB); 2 (TK)                                                                                                                                                                                                           Carbapenemase-producing strains (KPC, VIM)                                                       100%                                                                                                                                                                                                                                                                       NA                                       in vitro (CB, TK)                                                          25--100%                                                                 50--0%                                                             25--0%                                                             0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B51-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2014, USA              Montgomery                Amikacyn                              20                                                                                                                                                                                                                       KPC-2 (20%), KPC-3 (15%)                                                                         \-                                                                                                                                                                                                                                                                         100%                                     in vitro (agar diluition, antibiotic potentation study in A:F 5:2 ratio)   100%                                                                     \-                                                                 \-                                                                 0%                       \-                        \-                                   Synergy defined: reduction of FOS and AMK MIC when used in combination.                                                                                                                                                                                                    \[[@B52-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2011, Greece           Samonis                   Netilmicin                            65                                                                                                                                                                                                                       serine carbapenem-producing (50/65); ESBL (14/65); MBL (1/65)                                    98%                                                                                                                                                                                                                                                                        87%                                      in vitro (ET)                                                              41% (27/65) overall. In ESBL 42% (6/14). In serine enzymes 42% (21/50)   \-                                                                 \-                                                                 \-                       \-                        54% (25/46)                          \-                                                                                                                                                                                                                                                                         \[[@B86-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2011, Greece           Souli                     gentamicin                            17                                                                                                                                                                                                                       KPC (100%)                                                                                       4 (23%)                                                                                                                                                                                                                                                                    7 (41%)                                  in vitro (TK)                                                              0%                                                                       0%                                                                 15/15 (100%)                                                       \-                       \-                        \-                                   Efficacy of FOS + GEN was not evaluated in 2 isolates.                                                                                                                                                                                                                     \[[@B53-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1977, Spain            Daza                      Tobramicin                            23                                                                                                                                                                                                                       \-                                                                                               \-                                                                                                                                                                                                                                                                         \-                                       in vitro (CB)                                                              2/23 (8%)                                                                \-                                                                 \-                                                                 0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B66-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  *M. morganii*          1977, Spain               Daza                                  Gentamicin                                                                                                                                                                                                               2                                                                                                \-                                                                                                                                                                                                                                                                         \-                                       \-                                                                         in vitro (CB)                                                            50% (1/2)                                                          \-                                                                 \-                       0%                        \-                                   \-                                                                                                                                                                                                                                                                         \-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \[[@B66-antibiotics-09-00500]\]
  *P. aeruginosa*        2019, USA                 Wang                                  Gentamicin                                                                                                                                                                                                               7                                                                                                \-                                                                                                                                                                                                                                                                         25%                                      1/7 (14%)                                                                  in vitro (ET, biofilm)                                                   4 (57%)                                                            0%                                                                 3 (42%)                  0%                        \-                                   0%                                                                                                                                                                                                                                                                         \-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \[[@B155-antibiotics-09-00500]\]
  2019, USA              Avery                     tobramycin                            42                                                                                                                                                                                                                       \-                                                                                               NA (at least 71)                                                                                                                                                                                                                                                           42 (27%)                                 in vitro (ET)                                                              8 (19%)                                                                  13 (31%)                                                           21 (50%)                                                           0%                       \-                        8 (19%)                              \-                                                                                                                                                                                                                                                                         \[[@B33-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2019, New Zealand      Li Bassi                  Amikacin                              15                                                                                                                                                                                                                       Strains resistant to nebulized fosfomycin and amikacin (100%)                                    \-                                                                                                                                                                                                                                                                         \-                                       in vivo (pigs, pneumonia)                                                  0%                                                                       0%                                                                 100%                                                               0%                       \-                        \-                                   No difference in *P. aeruginosa* lung tissue concentration, bronchoalveolar lavage concentration and lung hystopathology score when amikacin and FOS were administered by aerosol alone or in combination therapy.                                                         \[[@B165-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2019, USA              Flamm                     gentamicin, amikacin                  5                                                                                                                                                                                                                        \-                                                                                               \-                                                                                                                                                                                                                                                                         \-                                       in vitro (CB, TK)                                                          0%                                                                       genta: 4 (80%); amika: 4 (80%)                                     genta: 1 (20%); amika: 1 (20%)                                     0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B38-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2018, Spain            Diez-Aguilar              Tobramycin                            6                                                                                                                                                                                                                        \-                                                                                               100%                                                                                                                                                                                                                                                                       67%                                      in vitro (CB)                                                              83%                                                                      17%                                                                0%                                                                 0%                       \-                        \-                                   Synergy tested in biofilm.                                                                                                                                                                                                                                                 \[[@B166-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2015, Australia        Walsh                     Tobramycin                            3                                                                                                                                                                                                                        \-                                                                                                                                                                                                                                                                                                                                                                          1/4 (25%)                                in vitro (TK)                                                              18% (15/81)                                                              25% (20/81)                                                        \-                                                                 \-                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B76-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2015, Spain            Diez-Aguilar              Tobramycin                            8                                                                                                                                                                                                                        mexZ mutation (25%), ANT(2')-I enzyme (37.5%),                                                   100%                                                                                                                                                                                                                                                                       37%                                      in vitro (TK)                                                              25%                                                                      0%                                                                 75%                                                                0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B166-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2014, USA              Montgomery                Amikacin                              21                                                                                                                                                                                                                       GES-1, OXA-2 plus OXA-10 plus VIM-2, OXA 14, VIM-4 (each, 4.8%), VIM-2 (19%)                     \-                                                                                                                                                                                                                                                                         100%                                     in vitro (agar dilution, antibiotic potentation study in A:F 5:2 ratio)    100%                                                                     \-                                                                 \-                                                                 \-                       \-                        \-                                   Synergy defined: reduction of FOS and AMK MIC when used in combination.                                                                                                                                                                                                    \[[@B52-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2013, Brazil           Ferrari dos Santos Lima   Tobramycin                            2                                                                                                                                                                                                                        IMP-R (100%)                                                                                     100%                                                                                                                                                                                                                                                                       100%                                     in vitro (broth microdilution, CB)                                         100%                                                                     0%                                                                 0%                                                                 0%                       100%                      0%                                   Authors do NOT report FOS and AMG MIC (they referred to CLSI criteria except for FOS-Eucast S ≤ 32 µg/mL); FOS MIC restoration 32.                                                                                                                                         \[[@B48-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2013, USA              Anderson                  Tobramycin                            1                                                                                                                                                                                                                        \-                                                                                               \-                                                                                                                                                                                                                                                                         \-                                       in vitro (effects on biofilms on CF airway epithelial cells)               \-                                                                       100%                                                               0%                                                                 0%                       \-                        \-                                   FOS:TOBRA (4:1) formulas for inhalation treatment; results suggest that fosfomicon enhanced the activity of tobramycin (much less level of tobramycin needed). FOS alone does NOT result in biofilm inhibition, TOBRA alone require HIGHER doses for biofilm inhibition.   \[[@B49-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2012, UK/USA           McCaughey                 Tobramycin                            15                                                                                                                                                                                                                       \-                                                                                               \-                                                                                                                                                                                                                                                                         \-                                       in vitro (agar dilution, TK)                                               100%                                                                     \-                                                                 \-                                                                 0%                       \-                        \-                                   Synergism defined as FOS:TOBRA bactericidal activity; Time kill studies in a subset of isolates; biofilm studies were also performed.                                                                                                                                      \[[@B167-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2011, Greece           Samonis                   Netilmicin                            15                                                                                                                                                                                                                       MDR                                                                                              93%                                                                                                                                                                                                                                                                        13%                                      in vitro (ET)                                                              13% (2/15)                                                               \-                                                                 \-                                                                 \-                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B86-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2009, China            Cai                       Amikacin                              20                                                                                                                                                                                                                       \-                                                                                               \-                                                                                                                                                                                                                                                                         NA (MIC90 32)                            in vitro (CB); in vivo (rat, biofilm-infected model)                       80%                                                                      15%                                                                \-                                                                 0%                       \-                        MIC90 decrease of 64-fold            F + T (lowest FICI amikacina and isepamicina) had synergistic effect on planctonic *P. aeruginosa*.                                                                                                                                                                        \[[@B168-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2009, China            Cai                       Gentamicin                            20                                                                                                                                                                                                                       \-                                                                                               \-                                                                                                                                                                                                                                                                         NA (MIC90 16)                            in vitro (CB); in vivo (rat, biofilm-infected model)                       70%                                                                      15%                                                                \-                                                                 0%                       \-                        MIC90 decrease of 8-fold             F + T (lowest FICI amikacina and isepamicina) had synergistic effect on planctonic *P. aeruginosa*.                                                                                                                                                                        \[[@B168-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2009, China            Cai                       Netilmicin                            20                                                                                                                                                                                                                       \-                                                                                               \-                                                                                                                                                                                                                                                                         NA (MIC90 16)                            in vitro (CB); in vivo (rat, biofilm-infected model)                       65%                                                                      20%                                                                \-                                                                 0%                       \-                        MIC90 decrease of 8-fold             F + T (lowest FICI amikacina and isepamicina) had synergistic effect on planctonic *P. aeruginosa*.                                                                                                                                                                        \[[@B168-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2009, China            Cai                       Tobramycin                            20                                                                                                                                                                                                                       \-                                                                                               \-                                                                                                                                                                                                                                                                         NA (MIC90 8)                             in vitro (CB); in vivo (rat, biofilm-infected model)                       60%                                                                      20%                                                                \-                                                                 0%                       \-                        MIC90 decrease of 2-fold             F + T (lowest FICI amikacina and isepamicina) had synergistic effect on planctonic *P. aeruginosa*.                                                                                                                                                                        \[[@B168-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2005, Thailand         Pruekprasert              gentamicin                            22                                                                                                                                                                                                                       \-                                                                                               \-                                                                                                                                                                                                                                                                         \-                                       in vitro (CB)                                                              1 (4%)                                                                   9 (42%)                                                            6 (27%)                                                            6 (27%)                  \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B22-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2002, Japan            Okazaki                   gentamicin                            30                                                                                                                                                                                                                       \-                                                                                               15 (50%)                                                                                                                                                                                                                                                                   19 (63%)                                 in vitro (efficacy time index)                                             0%                                                                       9 (30%)                                                            21 (70%)                                                           0%                       0%                        15 (50%)                             \-                                                                                                                                                                                                                                                                         \[[@B39-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1999, Japan            Hayami                    amikacin                              26                                                                                                                                                                                                                       \-                                                                                               NA (at least 13)                                                                                                                                                                                                                                                           NA (\< 5)                                in vitro (CB, TK)                                                          0%                                                                       10 (38%)                                                           16 (61%)                                                           0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B130-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  1991, Nigeria          Chinwuba                  Gentamicin                            8                                                                                                                                                                                                                        \-                                                                                               \-                                                                                                                                                                                                                                                                         0%                                       in vitro (CB, TK)                                                          0%                                                                       0%                                                                 100%                                                               0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B169-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  1997, France           Tessier                   amikacin                              40                                                                                                                                                                                                                       \-                                                                                               23 (57%)                                                                                                                                                                                                                                                                   13 (32%)                                 in vitro (CB)                                                              3 (7%)                                                                   21 (52%)                                                           16 (40%)                                                           0%                       18 (78%)                  11 (84%)                             Although the combination had a synergistic effect on no tested strains, it is of clinical relevance as it restored FOS and AMK susceptibility in many resistant strains.                                                                                                   \[[@B131-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  1978, Spain            Olay                      gentamicin, kanamycin                 77 gentamicin, 15 kanamycin                                                                                                                                                                                              \-                                                                                               \-                                                                                                                                                                                                                                                                         \-                                       in vitro (CB)                                                              gentamicin: 55 (71%); kanamycin: 4 (26%)                                 gentamicin: 17 (22%); kanamycin: 8 (53%)                           gentamicin: 5 (6%); kanamycin: 3 (20%)                             0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B14-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  *A. baumannii*         2019, USA                 Flamm                                 gentamicin, amikacin                                                                                                                                                                                                     5 (*A. baumannii*-*calcoaceticus* species complex)                                               \-                                                                                                                                                                                                                                                                         \-                                       \-                                                                         in vitro (CB, TK)                                                        genta: 2 (40%); amika: 2 (40%)                                     genta: 3 (60%); amika: 3 (60%)                                     0%                       0%                        \-                                   \-                                                                                                                                                                                                                                                                         \-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \[[@B38-antibiotics-09-00500]\]
  2016, Brazil           Leite                     gentamicin, amikacin                  20                                                                                                                                                                                                                       OXA (100%), IMP (15%)                                                                            20 (100%)                                                                                                                                                                                                                                                                  genta: 11 (55%); amika: 19 (95%)         in vitro (CB, TK)                                                          0%                                                                       genta: 2 (10%); amika: 0%                                          genta: 18 (90%); amika: 20 (100%)                                  0%                       \-                        \-                                   \"2-well\" method showed synergistic activity in about 20% of tested strain, but the Authors considered it not fully reliable and concluded the association had an indifferent effect.                                                                                     \[[@B83-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  2014, USA              Montgomery                Amikacyn                              21                                                                                                                                                                                                                       OXA-23 plus OXA-51 (23.8%); OXA-24 plus OXA-51 (9.5%), OXA-51, OXA-51 plus OXA-58 (each, 4.8%)   \-                                                                                                                                                                                                                                                                         100%                                     in vitro (agar dilution, antibiotic potentation study in A:F 5:2 ratio)    100%                                                                     \-                                                                 \-                                                                 0%                       \-                        \-                                   Synergism defined as reduction of FOS and AMK MIC when used in combination.                                                                                                                                                                                                \[[@B52-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1996, Spain            Martinez-Martinez         amikacin, tobramycin                  34                                                                                                                                                                                                                       \-                                                                                               34 (100%)                                                                                                                                                                                                                                                                  amika: 31 (91%); tobra: 33 (97.%)        in vitro (CB)                                                              amika: 15 (44%); tobra: 11 (32%)                                         \-                                                                 \-                                                                 0%                       \-                        \-                                   The authors reported only synergistic and antagonistic effect rates.                                                                                                                                                                                                       \[[@B132-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Gram-negative          1977, Spain               Daza                                  Tobramycin                                                                                                                                                                                                               75                                                                                               \-                                                                                                                                                                                                                                                                         \-                                       \-                                                                         in vitro (CB)                                                            0%                                                                 0%                                                                 100%                     0%                        \-                                   \-                                                                                                                                                                                                                                                                         33 *Klebsiella* spp., 21 *P. aeruginosa*, 3 *P. cepacia*, 12 *E.coli*,11 *S. marcescens*, 9 *Enterobacter* spp., 8 *Proteus* spp., 2 *A. calcoaceticus*, 1 *L. malonatica*, 5 *K. pneumoniae oxytoca*, 5 *K. Ozenae*, 5 *E. aerogenes*, 2 *E. hafniae*, 1 *E. cloacae*, 1 *E. liquefaciens*, 4 *P. mirabilis*, 2 *P. rettgeri*                                                                                                                                                                                                               \[[@B66-antibiotics-09-00500]\]
  1977, Spain            Daza                      Gentamicin                            75                                                                                                                                                                                                                       \-                                                                                               \-                                                                                                                                                                                                                                                                         \-                                       in vitro (CB)                                                              0%                                                                       0%                                                                 100%                                                               0%                       \-                        \-                                   \[[@B66-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  *S. aureus*            2017, Spain               Lopez Diaz                            Plazomicin                                                                                                                                                                                                               12 (BC); 5 (TK)                                                                                  MRSA Strains carrying aminoglycosides-modifying enzymes (100%)                                                                                                                                                                                                             56%                                      \-                                                                         in vitro (CB, TK)                                                        33.3--0%                                                           66--100%                                                           0%                       0%                        \-                                   \-                                                                                                                                                                                                                                                                         \-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \[[@B170-antibiotics-09-00500]\]
  2012, UK/USA           McCaughey                 Tobramycin                            5                                                                                                                                                                                                                        MRSA                                                                                             100%                                                                                                                                                                                                                                                                       \-                                       in vitro (agar dilution, TK)                                               60%                                                                      \-                                                                 \-                                                                 0%                       \-                        \-                                   Synergism defined as F:T bactericidal activity; Time kill studies in a subset of isolates; biofilm studies were also performed                                                                                                                                             \[[@B167-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2005, Japan            Morikawa                  Arbekacin                             1                                                                                                                                                                                                                        MRSA                                                                                             100%                                                                                                                                                                                                                                                                       100% MIC 0.5 (no available breakpoint)   in vivo (rat, carboxymethyl cellulose pouch infection model)               100%                                                                     \-                                                                 \-                                                                 \-                       \-                        \-                                   NOT available arbikacin EUCAST breakpoints; Synergistic effect was evaluated by i) morphological and histological studies showing dramatic change in biofilm and inflammatory response and by ii) decrease in the number of viable bacteria in vivo.                       \[[@B171-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  1994, Japan            Kono                      Arbekacin                             96                                                                                                                                                                                                                       MRSA                                                                                             38%                                                                                                                                                                                                                                                                        \-                                       in vitro                                                                   66% (60/90)                                                              \-                                                                 \-                                                                 0%                       \-                        \-                                   Better results of FOS-arbekacin combination in FOS susceptible strains.                                                                                                                                                                                                    \[[@B172-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  1987, Spain            Rodriguez                 Gentamicin                            1                                                                                                                                                                                                                        MRSA                                                                                             0%                                                                                                                                                                                                                                                                         0%                                       in vivo (endocarditis in 10 rabbits)                                       100% (1/1) 0% n. of rabbits' death (0/10)                                0%                                                                 0%                                                                 0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B61-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1985, USA              Alvarez                   Gentamicin                            148                                                                                                                                                                                                                      MRSA                                                                                             \-                                                                                                                                                                                                                                                                         \-                                       in vitro (microtiter technique in a 1:1 ratio)                             (10/148) 7%                                                              0%                                                                 90% (134/148)                                                      (4/148) 3%               \-                        \-                                   Synergy was indicated if the MICs of both drugs decreased by at least one-fourth. If the MIC of one drug owed a fourfold or greater increase, it was assumed to be an indication of antagonism.                                                                            \[[@B12-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  1978, Spain            Olay                      streptomycin, gentamicin, kanamycin   18 streptomycin, 29 gentamicin, 21 kanamycin                                                                                                                                                                             \-                                                                                               \-                                                                                                                                                                                                                                                                         \-                                       in vitro (CB)                                                              streptomycin: 1 (5%); gentamicin: 0%; kanamycin: 9 (43%)                 streptomycin: 10 (55%); gentamicin: 3 (10%); kanamycin: 7 (33%)    streptomycin: 7 (38%); gentamicin: 26 (89%); kanamycin: 5 (23%)    0%                       \-                        \-                                   \-                                                                                                                                                                                                                                                                         \[[@B14-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  *Streptococcus* spp.   1978, Spain               Olay                                  streptomycin                                                                                                                                                                                                             16                                                                                               \-                                                                                                                                                                                                                                                                         \-                                       \-                                                                         in vitro (CB)                                                            0%                                                                 9 (56%)                                                            7 (43%)                  0%                        \-                                   \-                                                                                                                                                                                                                                                                         \-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \[[@B14-antibiotics-09-00500]\]
  *E. faecium*           2019, Thailand            Hemapanpairoa                         Gentamicin                                                                                                                                                                                                               8                                                                                                VRE (100%)                                                                                                                                                                                                                                                                 100%                                     13%                                                                        in vitro (ET for FOS, broth microdilution for gentamicin)                63%                                                                13%                                                                25%                      0%                        63%                                  \-                                                                                                                                                                                                                                                                         Synergistic activity assessed as a fourfold reduction of MIC when FOS combined with gentamicin 1 mcg/mL.                                                                                                                                                                                                                                                                                                                                                                                                                                     \[[@B55-antibiotics-09-00500]\]
  *N. gonorrhoeae*       2015, The Netherlands     Wind                                  gentamicin                                                                                                                                                                                                               4                                                                                                \-                                                                                                                                                                                                                                                                         \-                                       \-                                                                         in vitro (ET)                                                            0%                                                                 1 (25%)                                                            3 (75%)                  0%                        \-                                   \-                                                                                                                                                                                                                                                                         \-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \[[@B54-antibiotics-09-00500]\]
  Miscellaneous          2009, USA                 MacLeod                               Tobramycin                                                                                                                                                                                                               27 (4 *S. aureus*, 17 *P. aeruginosa*, 5 *E.coli*, 1 *H. influenzae*)                            \-                                                                                                                                                                                                                                                                         \-                                       \-                                                                         in vitro (CB, TK); in vivo (rat, pneumonia)                              7% (1 *P. aeruginosa*, 1 *E.coli*)                                 \-                                                                 93%                      0%                        \-                                   \-                                                                                                                                                                                                                                                                         In vitro (agar plate dilution, broth microdilution, CB ON a SUBSET of ISOLATES, TK) and in vivo (rat bacterial pneumonia). NB: CB for 27 total strains: 4 *S. aureus*, 17 *P. aeruginosa*, 5 *E. coli*, 1 *H. influenzae*. FOS:TOBRA 4:1 was rapidly bactericidal and exhibited concentration -bactericidal killing in TK, with excellent activity against *S. aureus* and *H. influenzae*, but poor activity against *S. maltophilia*, *B. cepacia*; it was active against *M. catarrhalis*, *E. coli*, *Klebsiella* and *S. pneumoniae*.   \[[@B173-antibiotics-09-00500]\]

antibiotics-09-00500-t007_Table 7

###### 

Studies on combination between fosfomycin and macrolides. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strain                      Year and Country    Author         Macrolide        Number of Isolates                              Known Resistance Mechanisms or Determinants (%)   FOS-Resistant (%)   Macrolide-Resistant (%)   In Vitro (Methods)/In Vivo (Animal and Site of Infection)             Synergistic Effect (%)   Additive Effect (%)   Indifferent Effect (%)       Antagonistic Effect (%)   FOS Susceptibility Restoration (%)   Macrolide Susceptibility Restoration (%)                                                                                                                                                                                                                                                                                                                                                        Comments                                                                                                                                                                                                                                                                                                                                                                                        Reference
  --------------------------- ------------------- -------------- ---------------- ----------------------------------------------- ------------------------------------------------- ------------------- ------------------------- --------------------------------------------------------------------- ------------------------ --------------------- ---------------------------- ------------------------- ------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------
  *E. coli*                   1978, Spain         Olay           Erythromycin     14                                              \-                                                \-                  \-                        in vitro (CB)                                                         42%                      29%                   28%                          0%                        \-                                   \-                                                                                                                                                                                                                                                                                                                                                                                              Authors considered Synergistic effect when MIC of both antimicrobials was at least fourfold lower over initial MIC; partial synergy when MIC of one antimicrobials was at least fourfold lower and MIC of the other one 2 times lower over initial MIC; Indifferent effect when MIC of both antimicrobials was 2 times lower; antagonism when MIC of both increased 4 times over initial MIC.   \[[@B14-antibiotics-09-00500]\]
  *Klebsiella spp*.           1978, Spain         Olay           Erythromycin     44                                              \-                                                \-                  \-                        in vitro (CB)                                                         50%                      23%                   27%                          0%                        \-                                   \-                                                                                                                                                                                                                                                                                                                                                                                              Authors considered Synergistic effect when MIC of both antimicrobials was at least fourfold lower over initial MIC; partial synergy when MIC of one antimicrobials was at least fourfold lower and MIC of the other one 2 times lower over initial MIC; Indifferent effect when MIC of both antimicrobials was 2 times lower; antagonism when MIC of both increased 4 times over initial MIC.   \[[@B14-antibiotics-09-00500]\]
  *E. cloacae*                1978, Spain         Olay           Erythromycin     16                                              \-                                                \-                  \-                        in vitro (CB)                                                         62%                      38%                   0%                           0%                        \-                                   \-                                                                                                                                                                                                                                                                                                                                                                                              Authors considered Synergistic effect when MIC of both antimicrobials was at least fourfold lower over initial MIC; partial synergy when MIC of one antimicrobials was at least fourfold lower and MIC of the other one 2 times lower over initial MIC; Indifferent effect when MIC of both antimicrobials was 2 times lower; antagonism when MIC of both increased 4 times over initial MIC.   \[[@B14-antibiotics-09-00500]\]
  *Proteus spp. (Indole +)*   1978, Spain         Olay           Erythromycin     13                                              \-                                                \-                  \-                        in vitro (CB)                                                         53%                      46%                   0%                           0%                        \-                                   \-                                                                                                                                                                                                                                                                                                                                                                                              Authors considered Synergistic effect when MIC of both antimicrobials was at least fourfold lower over initial MIC; partial synergy when MIC of one antimicrobials was at least fourfold lower and MIC of the other one 2 times lower over initial MIC; Indifferent effect when MIC of both antimicrobials was 2 times lower; antagonism when MIC of both increased 4 times over initial MIC.   \[[@B14-antibiotics-09-00500]\]
  *P. aeruginosa*             1982, Japan         Kasai          Midecamycin      2                                               \-                                                0%                  2 (100%)                  in vitro (TK)/in vivo (Mice, peritonitis or subcutaneous infection)   0%                       2 (100%)              0%                           0%                        \-                                   \-                                                                                                                                                                                                                                                                                                                                                                                              In all in vivo experiment survival rates of mice that received MDM + FOS was statistically significant higher then when FOS or MDM were administrated alone, proving synergistic effect.                                                                                                                                                                                                        \[[@B59-antibiotics-09-00500]\]
  1978, Spain                 Olay                Erythromycin   29               \-                                              \-                                                \-                  in vitro (CB)             38%                                                                   59%                      3%                    0%                           \-                        \-                                   Authors considered Synergistic effect when MIC of both antimicrobials was at least fourfold lower over initial MIC; partial synergy when MIC of one antimicrobials was at least fourfold lower and MIC of the other one 2 times lower over initial MIC; Indifferent effect when MIC of both antimicrobials was 2 times lower; antagonism when MIC of both increased 4 times over initial MIC.   \[[@B14-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                 
  *S. aureus*                 1978, Spain         Olay           Erythromycin     34                                              \-                                                \-                  \-                        in vitro (CB)                                                         26%                      68%                   6%                           0%                        \-                                   \-                                                                                                                                                                                                                                                                                                                                                                                              Authors considered Synergistic effect when MIC of both antimicrobials was at least fourfold lower over initial MIC; partial synergy when MIC of one antimicrobials was at least fourfold lower and MIC of the other one 2 times lower over initial MIC; Indifferent effect when MIC of both antimicrobials was 2 times lower; antagonism when MIC of both increased 4 times over initial MIC.   \[[@B14-antibiotics-09-00500]\]
  *S. epidermidis*            2009, Austria       Presterl       Azithromycin     11                                              \-                                                2 (18%)             5 (45%)                   in vitro (Microtitre plate assay on Biofilm culture)                  \-                       \-                    \-                           \-                        \-                                   \-                                                                                                                                                                                                                                                                                                                                                                                              Combination of azithromycin with any of the tested antimicrobial agents did not reduce the biofilm ODr compared to the ODr of biofilms treated with single agents                                                                                                                                                                                                                               \[[@B58-antibiotics-09-00500]\]
  *S. pseudointermedius*      2014, Canada        DiCicco        Clarithromycin   8                                               MRSP (100%)                                       5 (62%)             8 (100%)                  in vitro (Microtitre plate assay)                                     5 (62%)                  2 (25%)               0%                           0%                        \-                                   \-                                                                                                                                                                                                                                                                                                                                                                                              FICI for 1 strains was reported as \"Not available\".                                                                                                                                                                                                                                                                                                                                           \[[@B60-antibiotics-09-00500]\]
  *Streptococcus spp*.        1978, Spain         Olay           Erythromycin     26                                              \-                                                \-                  \-                        in vitro (CB)                                                         15%                      27%                   57%                          0%                        \-                                   \-                                                                                                                                                                                                                                                                                                                                                                                              Authors considered Synergistic effect when MIC of both antimicrobials was at least fourfold lower over initial MIC; partial synergy when MIC of one antimicrobials was at least fourfold lower and MIC of the other one 2 times lower over initial MIC; Indifferent effect when MIC of both antimicrobials was 2 times lower; antagonism when MIC of both increased 4 times over initial MIC.   \[[@B14-antibiotics-09-00500]\]
  *N. gonorrhoeae*            2015, Switzerland   Hauser         Azithromycin     8 (4 TK)                                        AZT-HLR (12,%)                                    0%                  1 (12%)                   in vitro (CB, TK)                                                     CK: 0%; TK: 0%           CK: 0%; TK: 0%        CK: 8 (100%); TK: 4 (100%)   CK: 0%; TK: 0%            \-                                   \-                                                                                                                                                                                                                                                                                                                                                                                              Only 4 strains were tested with TKA. Authors used *Enterobacterales* FOS breakpoint as presumptive breakpoint for *N. gonorrhoeae* (EUCAST: S ≤ 32 mg/L; CLSI: S ≤ 64 mg/L).                                                                                                                                                                                                                    \[[@B57-antibiotics-09-00500]\]
  2015, Netherlands           Wind                Azithromycin   4                Azithromycin and Ceftriaxone Resistant (100%)   \-                                                \-                  in vitro (ET)             0%                                                                    0%                       4 (100%)              \-                           \-                        \-                                   \-                                                                                                                                                                                                                                                                                                                                                                                              \[[@B54-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                                                                 

antibiotics-09-00500-t008_Table 8

###### 

Studies on combination between fosfomycin and glycopeptides. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strain                                                           Year and Country   Author                    Glycopeptide                               Number of Isolates                                                                           Known Resistance Mechanisms or Determinants (%)                              FOS-Resistant (%)                             Glycpeptide-Resistant (%)                                               In Vitro (Methods)/In Vivo (Animal and Site of Infection)   Synergistic Effect (%)                                                                                                        Additive Effect (%)                                                                                                           Indifferent Effect (%)                                                                               Antagonistic Effect (%)   FOS Susceptibility Restoration (%)    Glycopeptide Susceptibility Restoration (%)                                                                                                                                                                                                                                               Comments                                                                                                                                                                                                                                                                                                                 Reference
  ---------------------------------------------------------------- ------------------ ------------------------- ------------------------------------------ -------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- --------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------- ------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------
  *A baumannii*                                                    2016, Brazil       Leite                     Vancomycin                                 20                                                                                           OXA-23 (50%), OXA-143 (35%), IMP-type (15%), depletion of OMP 43 kDa (20%)   19 (95%)                                      Natural resistance                                                      in vitro (CB, TK)                                           0%                                                                                                                            0%                                                                                                                            CB: 20 (100%)                                                                                        0%                        0%                                    Breakpoints not available                                                                                                                                                                                                                                                                 TK showed indifference in all strains.                                                                                                                                                                                                                                                                                   \[[@B83-antibiotics-09-00500]\]
  *S. aureus*                                                      2018, China        Xu                        Vancomycin                                 3                                                                                            \-                                                                           1 (33%)                                       0%                                                                      in vitro (CB)                                               0%                                                                                                                            2 (66%)                                                                                                                       1 (33%)                                                                                              0%                        1 (100%)                              No resistant isolates                                                                                                                                                                                                                                                                     In vitro concentrations - VAN (0.5, 1, 2 mg/L); FOS (32, 64 mg/L).                                                                                                                                                                                                                                                       \[[@B174-antibiotics-09-00500]\]
  2017, Spain                                                      Coronado-Alvarez   Vancomycin                4                                          Methicillin resistance (50%)                                                                 \-                                                                           \-                                            in vitro (TK)                                                           0%                                                          4 (100%)                                                                                                                      0%                                                                                                                            0%                                                                                                   \-                        \-                                    The study also evaluated 15 patients with bacteremia caused by MRSA were treated with FOS in combination with VAN. Of these, 7 patients (46.7%) had negative blood cultures after 48 h of combination therapy.                                                                            \[[@B63-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                          
  2012, Taiwan                                                     Tang               Vancomycin, teicoplanin   8                                          Methicillin resistance (100%)                                                                2 (6%)                                                                       VAN: 0%; TEC: 0%                              in vitro (TK)                                                           VAN: 8 (100%)                                               0%                                                                                                                            TEC: 8 (100%)                                                                                                                 0%                                                                                                   0%                        No resistant isolates                 Synergistic concentrations were 64 mg/L for FOS and 2 mg/L for VAN, at 24 h. Indifference was detected with 8 mg/L for TEC at 24 h. Significant reduction of colony count in biofilm model when FOS was in combination with either VAN and TEC after 5 days.                              \[[@B69-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                          
  2011, Taiwan                                                     Tang               Vancomycin                5                                          Methicillin resistance (100%)                                                                0%                                                                           0%                                            in vitro (TK)                                                           5 (100%)                                                    0%                                                                                                                            0%                                                                                                                            0%                                                                                                   No resistant isolates     No resistant isolates                 All strains had borderline MIC values for VAN (2 mg/L). In vitro synergistic concentrations were 2 mg/L for VAN and 64 mg/L for FOS.                                                                                                                                                      \[[@B175-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                         
  2010, Spain                                                      Pachon-Ibanez      Vancomycin                1                                          hGISA (100%)                                                                                 0%                                                                           0%                                            in vitro (TK); in vivo (*mouse, peritonitis*)                           1 (100%)                                                    0%                                                                                                                            0%                                                                                                                            0%                                                                                                   No resistant isolate      No resistant isolate                  Resistant (4 mg/L) sub-population frequency: 3.6 × 10^−6^ CFU/mL; in vitro synergistic concentrations were 1--2--4 mg/L for FOS and 1--2 mg/L for VAN at 24 h. In vivo combination was significant and effective in reducing bacteremia rates in 57% (n = 8 out of 14) of mice treated.   \[[@B36-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                          
  2005, Italy                                                      Pistella           Vancomycin, teicoplanin   7                                          Methicillin resistance (100%)                                                                5 (71%)                                                                      VAN: 3 (42%); TEC: 6 (85.7%)                  in vitro (TK)                                                           VAN: 7 (100%); TEC: 0%                                      VAN: 0%; TEC: 7 (100%)                                                                                                        0%                                                                                                                            0%                                                                                                   7 (100%)                  0%                                    Synergistic concentrations were 8 mg/L for FOS and 1 × MIC for VAN (1, 2 or 4 mg/L respectively) at 24 h.                                                                                                                                                                                 \[[@B176-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                         
  1987, Spain                                                      Rodriguez          Vancomycin                1                                          Methicillin resistance (100%)                                                                0%                                                                           0%                                            in vitro (TK); in vivo (*rabbit*, endocarditis)                         1 (100%)                                                    0%                                                                                                                            0%                                                                                                                            0%                                                                                                   No resistant isolates     No resistant isolates                 In vitro synergism at 24 and 48 h. Fixed concentrations of FOS at 8 mg/L and VAN at 1 mg/L. In vivo combination was successful in 10 rabbits (100%) showing sterile vegetations.                                                                                                          \[[@B61-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                          
  1985, Spain                                                      Alvarez            Vancomycin                148                                        Methicillin resistance (100%)                                                                15 (10%)                                                                     1 (1%)                                        in vitro (CB)                                                           0%                                                          0%                                                                                                                            145 (98%)                                                                                                                     3 (2%)                                                                                               \-                        \-                                    1 strain was resistant to VAN (MIC \> 32 mg/L).                                                                                                                                                                                                                                           \[[@B12-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                          
  *S. aureus, S. epidermidis*                                      2014, China        Shi                       Vancomycin                                 3 (2 *S. aureus*, 1 *S. epidermidis*)                                                        Methicillin resistance (67%)                                                 3 (100%)                                      0%                                                                      in vitro (TK); in vivo (biofilm in rats' tissues)           3 (100%)                                                                                                                      0%                                                                                                                            0%                                                                                                   0%                        0%                                    No resistant isolates                                                                                                                                                                                                                                                                     In vitro synergistic concentrations at 1 mg/L for VAN and 64 mg/L for FOS at 6h and 24 h. In vivo significative reduction of biofilm formation in rats' tissues (4, 100%).                                                                                                                                               \[[@B62-antibiotics-09-00500]\]
  2001, Austria                                                    Grif               Vancomycin                7 (5 *S. aureus*; 2 *S. epidermidis*)      *S. aureus*: GISA 1 (20%), MRSA 1 (20%)                                                      \-                                                                           0%                                            in vitro (CB, TK)                                                       0%                                                          0%                                                                                                                            CB: *S. epidermidis* 2 (100%); *S. aureus* 5 (71%)                                                                            CB: *S. epidermidis* 0%; *S. aureus* 2 (28%)                                                         \-                        \-                                    TK showed indifference for all strains, with fixed concentration of FOS at 40 mg/L and VAN at 10 mg/L.                                                                                                                                                                                    \[[@B43-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                          
  1989, Germany                                                    Gatermann          Vancomycin                33 (15 *S. aureus*; 18 *S. epidermidis*)   \-                                                                                           \-                                                                           \-                                            in vitro (CB)                                                           *S. aureus*: 1 (6%); *S. epidermidis*: 1 (5%)               *S. aureus*: 8 (53%); *S. epidermidis*: 7 (39%)                                                                               *S. aureus*: 6 (40%); *S. epidermidis*: 9 (50%)                                                                               *S. aureus*: 0%; *S. epidermidis*: 1 (5%)                                                            \-                        \-                                    Synergistic concentrations not specified.                                                                                                                                                                                                                                                 \[[@B177-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                         
  *E. faecalis, E. faecium*, *S. aureus*, *S. epidermidis*, CONS   1986, Italy        Debbia                    Teicoplanin                                76 strains: 30 *E. faecalis*, 6 *E. faecium*, 20 *S. aureus*, 10 *S. epidermidis*, 10 CoNS   Methicillin resistance (50% of *S. aureus*)                                  \-                                            \-                                                                      in vitro (CB, TK)                                           CB: 20 (67%) *E. faecalis*; 4 (67%) *E. faecium*; 6 (60%) *S. aureus*; 6 (60%) MRSA; 1 (10%) *S. epidermidis*; 6 (60%) CONS   CB: 10 (33%) *E. faecalis*; 2 (33%) *E. faecium*; 4 (40%) *S. aureus*; 4 (40%) MRSA; 9 (90%) *S. epidermidis*; 4 (40%) CONS   0%                                                                                                   0%                        \-                                    \-                                                                                                                                                                                                                                                                                        Synergistic concentrations not specified. 46 strains were tested also by TK. TK results-Synergism: 11 (92%) *E. faecalis*; 4 (100%) *E. faecium*; 6 (100%) *S. aureus*; 8 (100%) MRSA; 6 (75%) *S. epidermidis*; 8 (100%) CoNS. Additive effect: 1 (8%) *E. faecalis*; 2 (25%) *S. epidermidis*.                         \[[@B178-antibiotics-09-00500]\]
  *S. pneumoniae*                                                  2006, Spain        Ribes                     Vancomycin                                 2                                                                                            Resistance to penicillin (50%) and ceftriaxone (100%)                        0%                                            0%                                                                      in vitro (TK); in vivo (rabbit, menigitis)                  1 (50%)                                                                                                                       1 (50%)                                                                                                                       0%                                                                                                   0%                        No resistant isolates                 No resistant isolates                                                                                                                                                                                                                                                                     In vitro synergism at 24 h, at concentrations achievable in CSF. In vivo combination significant and effective in eradicating meningitis with sterile blood cultures (8, 100%).                                                                                                                                          \[[@B24-antibiotics-09-00500]\]
  1994, France                                                     Doit               Vancomycin                26                                         Isolates not susceptible to penicillin (100%)                                                0%                                                                           0%                                            in vitro (TK)                                                           0%                                                          0%                                                                                                                            100%                                                                                                                          0%                                                                                                   No resistant isolates     No resistant isolates                 Fixed concentrations of FOS at 40 mg/L and VAN at 3 mg/L.                                                                                                                                                                                                                                 \[[@B134-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                         
  *S. epidermidis*                                                 1990, France       Gaillanrd                 Vancomycin                                 1                                                                                            \-                                                                           0%                                            0%                                                                      in vitro (TK)                                               1 (100%)                                                                                                                      0%                                                                                                                            0%                                                                                                   0%                        No resistant isolates                 No resistant isolates                                                                                                                                                                                                                                                                     Synergism at 4 h. Fixed concentrations of FOS at 12.5 mg/L and VAN at 7.5 mg/L. Effective to reduce biofilm formation (1; 100%).                                                                                                                                                                                         \[[@B179-antibiotics-09-00500]\]
  1990, Germany                                                    Simon              Vancomycin, teicoplanin   20                                         Methicillin resistant (100%)                                                                 10 (50%)                                                                     VAN: 0%; TEC: 2 (10%)                         in vitro (CB)                                                           VAN: 4 (20%); TEC: 9 (45%)                                  VAN: 5 (25%); TEC: 6 (30%)                                                                                                    VAN: 11 (55%); TEC: 5 (25%)                                                                                                   VAN: 0%; TEC: 0%                                                                                     \-                        VAN: no resistant isolates; TEC: NS   Synergistic concentrations at 0.5 X MIC for FOS, TEC and VAN. Good efficacy in artificial biofilm model when isolates were fully susceptible to FOS.                                                                                                                                      \[[@B180-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                         
  *E. faecalis - E. faecium*                                       2013, Taiwan       Tang                      Vancomycin, teicoplanin                    19 strains: 9 *E. faecalis*; 10 *E. faecium*                                                 Vancomycin resistant (100%)                                                  5 (55%) *E. faecalis*; 7 (70%) *E. faecium*   VAN: 19 (100%) both; TEC: 1 (11%) *E. faecalis*; 6 (60%) *E. faecium*   in vitro (TK)                                               VAN: 3 (33%) *E. faecalis*, 3 (30%) *E. faecium*; TEC: 8 (89%) *E. faecalis*, 3 (30%) *E. faecium*                            0%                                                                                                                            VAN: 6 (67%) *E. faecalis*, 7 (70%) *E. faecium*; TEC: 1 (11%) *E. faecalis*, 7 (70%) *E. faecium*   0%                        0%                                    VAN: 3 (33%) *E. faecalis*; 3 (30%) *E. faecium*; TEC: 0%                                                                                                                                                                                                                                 Synergistic concentrations were 64 mg/L for FOS, 4 mg/L for VAN and 8 mg/L for TEC, at 24 h. FOS-TEC had synergistic effect against biofilm-producing *E. faecalis* (4; 44%) and one *E. faecium* (1; 10%) isolates. FOS-VAN had synergistic effect against only one biofilm-producing *E. faecalis* isolate (1; 11%).   \[[@B13-antibiotics-09-00500]\]

antibiotics-09-00500-t009_Table 9

###### 

Studies on combination between fosfomycin and tetracyclines. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strain             Year and Country    Author         Tetracycline   Number of Isolates   Known Resistance Mechanisms or Determinants (%)                                                                      FOS-Resistant (%)   Tetracycline-Resistant (%)       In Vitro (Methods)/In Vivo (Animal and site of Infection)   Synergistic Effect (%)      Additive Effect (%)    Indifferent Effect (%)   Antagonistic Effect (%)   FOS Susceptibility Restoration (%)   Tetracycline Susceptibility Restoration (%)                                                                                                                                                          Comments                                                                                                                                                                                                                                                                                                                                                Reference
  ------------------ ------------------- -------------- -------------- -------------------- -------------------------------------------------------------------------------------------------------------------- ------------------- -------------------------------- ----------------------------------------------------------- --------------------------- ---------------------- ------------------------ ------------------------- ------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------
  Enterobacterales   2019, USA           Flamm          Minocycline    20                   7/30 MDR strains (*A. baumannii*, *Enterobacterales* e *P. aeruginosa*) included 2 ESBL e 2 KPC *Enterobacterales*   \-                  \-                               in vitro (CB)                                               4 (20%)                     13 (65%)               1 (5%)                   0%                        \-                                   \-                                                                                                                                                                                                   Authors considered Partial Sinergy when FICI was between 0.5--1 and Additive effect for FICI = 1. Results for 2/20 strains (10%) were indeterminate.                                                                                                                                                                                                    \[[@B38-antibiotics-09-00500]\]
  1977, Spain        Daza                Tetracycline   100            \-                   100 (100%)                                                                                                           \-                  in vitro (CB)                    2 (2%)                                                      \-                          98%                    0%                       \-                        \-                                   Authors considered Synergistic effect when MIC was at least fourfold lower over initial MIC.                                                                                                         \[[@B66-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                         
  *P. aeruginosa*    2019, USA           Flamm          Minocycline    5                    7/30 MDR strains (*A. baumannii*, *Enterobacterales* e *P. aeruginosa*)                                              \-                  \-                               in vitro (CB)                                               2 (40%)                     3 (60%)                0%                       0%                        \-                                   \-                                                                                                                                                                                                   Authors considered Partial Sinergy when FICI was between 0.5--1 and Additive effect for FICI = 1.                                                                                                                                                                                                                                                       \[[@B38-antibiotics-09-00500]\]
  *A. baumannii*     2013, China         Zhang          Minocycline    25                   Pan-Drug-Resistant (100%)                                                                                            100%                See Comments                     in vitro (CB)                                               12%                         56%                    32%                      0%                        0%                                   100%                                                                                                                                                                                                 Mean MIC for Minocycline was 16, MIC range 4-16. Authors used CLSI breakpoint for MIN (S ≤ 4 mg/L).                                                                                                                                                                                                                                                     \[[@B65-antibiotics-09-00500]\]
  *S. aureus*        2012, Taiwan        Tang           Minocycline    33 (8 TK)            MRSA (100%)                                                                                                          6%                  61%                              in vitro (TK, Biofilm MTT-staining method)                  \-                          \-                     \-                       \-                        \-                                   \-                                                                                                                                                                                                   Only 8 strains were tested with TK. Biofilm cultures were 94% MIN resistant and 94% FOS resistant. Cases of synergism were observed with FOS+MIN combination. Percentages or other data were not reported by authors. Combination of FOS + MIN determined a statistically significant reduction on ODRs in biofilm cultures compared to single drugs.   \[[@B69-antibiotics-09-00500]\]
  2011, China        Sun                 Minocycline    87             MRSA (100%)          35 (40%)                                                                                                             13 (14%)            in vitro (CB)                    76 (87%)                                                    \-                          11 (12%)               0%                       100%                      92%                                  Authors considered Indifferent effect for FICI between 0,5 and 4. CLSI breakpoint was used for MIN (S ≤ 4 mg/L) and *E. faecalis* FOS breakpoint as presumptive breakpoint for MRSA (S ≤ 64 mg/L).   \[[@B70-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                         
  2003, Japan        Nakazawa            Minocycline    32             MRSA (100%)          29 (91%)                                                                                                             26 (81%)            in vitro (Efficacy Time Index)   10 (31%)                                                    1 (3%)                      21 (65%)               \-                       \-                        \-                                   \-                                                                                                                                                                                                   \[[@B18-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                         
  *E. faecalis*      2013, Taiwan        Tang           Minocycline    9                    VRE (100%)                                                                                                           56%                 89%                              in vitro (TK, Biofilm Model)                                TKA: 2 (22%); BM: 1 (11%)   \-                     \-                       \-                        \-                                   \-                                                                                                                                                                                                   Additive, Indifferent and antagonistic effect were not evaluated.                                                                                                                                                                                                                                                                                       \[[@B13-antibiotics-09-00500]\]
  *E. faecium*       2013, Taiwan        Tang           Minocycline    10                   VRE (100%)                                                                                                           70%                 80%                              in vitro (TK, Biofilm Model)                                TKA: 4 (40%); BM: 1 (10%)   \-                     \-                       \-                        \-                                   \-                                                                                                                                                                                                   Additive, Indifferent and antagonistic effect were not evaluated.                                                                                                                                                                                                                                                                                       \[[@B13-antibiotics-09-00500]\]
  2012, USA          Descourouez         Minocycline    32             VRE (100%)           9%                                                                                                                   See Comments        in vitro (TK)                    0%                                                          0%                          100%                   0%                       \-                        \-                                   The authors considered MIC ≤ 64 mg/L as FOS breakpoint. Most of strains were minocycline resistant (MIC range 4--32, mean MIC 16 mg/L).                                                              \[[@B67-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                         
  2019, USA          Davis               Doxycycline    24             VRE (100%)           96%                                                                                                                  8%                  in vitro (ET, TK)                CK: 11 (46%); TK: 10 (41%)                                  CK: 13 (54%); TK: 4 (16%)   CK: 0%; TK: 10 (41%)   CK: 0%; TK 0%            \-                        \-                                   Authors used CLSI breakpoint for DOX (S ≤ 4 mg/L) and *E. faecalis* FOS breakpoint as presumptive breakpoint for *E. faecium* (S ≤ 64 mg/L).                                                         \[[@B68-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                                                                         
  *N. gonorrhoeae*   2015, Netherlands   Wind           Minocycline    4                    Azithromycin and Ceftriaxone Resistant (100%)                                                                        \-                  \-                               in vitro (ET)                                               0%                          0%                     4 (100%)                 \-                        \-                                   \-                                                                                                                                                                                                   \-                                                                                                                                                                                                                                                                                                                                                      \[[@B54-antibiotics-09-00500]\]

antibiotics-09-00500-t010_Table 10

###### 

Studies on combination between fosfomycin and polymyxins. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strain                                         Year and Country    Author                Polymyxin                Number of Isolates                                       Known Resistance Mechanisms or Determinants (%)    FOS-Resistant (%)          Polymyxin-ResIstant (%)                                 In Vitro (Methods)/In Vivo (Animal and Site of Infection)   Synergistic Effect (%)   Additive Effect (%)   Indifferent Effect (%)   Antagonistic Effect (%)   FOS Susceptibility Restoration (%)   Polymyxin Susceptibility Restoration (%)                                                                                                                                                                                                      Comments                                                          Reference
  ---------------------------------------------- ------------------- --------------------- ------------------------ -------------------------------------------------------- -------------------------------------------------- -------------------------- ------------------------------------------------------- ----------------------------------------------------------- ------------------------ --------------------- ------------------------ ------------------------- ------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------
  Enterobacterales                               2019, USA           Flamm                 Colistin                 20                                                       carbapenem-resistant (5%), KPC (10%), ESBL (10%)   \-                         \-                                                      in vitro (CB, TK)                                           1 (5%)                   5 (25%)               8 (40%)                  0%                        \-                                   \-                                                                                                                                                                                                                                            For 6 isolates the effect of the combination was indeterminate.   \[[@B38-antibiotics-09-00500]\]
  2015, UK                                       Albur               Colistin              6                        NDM-1 (100%)                                             3 (50%)                                            0%                         in vitro (TK)                                           3 (50%)                                                     0%                       3 (50%)               0%                       \-                        \-                                   The combination was synergistic against FOS-S isolates. Against FOS-R isolates, an additive effect was observed after 12h, but then regrowth occurred.                                                                                        \[[@B181-antibiotics-09-00500]\]                                  
  *E. coli*                                      2013, Switzerland   Corvec                Colistin                 1                                                        CTX-M15, ESBL (100%)                               0%                         0%                                                      in vitro (TK), in vivo (foreign-body infection model)       1 (100%)                 0%                    0%                       0%                        \-                                   \-                                                                                                                                                                                                                                            \-                                                                \[[@B73-antibiotics-09-00500]\]
  2011, France                                   Berçot              Colistin              1                        NDM-1                                                    0%                                                 0%                         in vitro (CB, TK)                                       0%                                                          1 (100%)                 0%                    0%                       \-                        \-                                   *E. coli* J53                                                                                                                                                                                                                                 \[[@B85-antibiotics-09-00500]\]                                   
  2011, Greece                                   Samonis             Colistin              20                       ESBL (100%)                                              0%                                                 0%                         in vitro (ET)                                           3 (15%)                                                     \-                       \-                    0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B86-antibiotics-09-00500]\]                                   
  *E. cloacae*                                   2011, France        Berçot                Colistin                 2                                                        NMD-1                                              1 (50%)                    0%                                                      in vitro (CB, TK)                                           0%                       2 (100%)              0%                       0%                        \-                                   \-                                                                                                                                                                                                                                            \-                                                                \[[@B85-antibiotics-09-00500]\]
  *K. pneumoniae*                                2020, Turkey        Buket Erturk Sengel   Colistin                 17                                                       KPC (OXA-48, NDM) (100%)                           41%                        65%                                                     in vitro (CB, TK)                                           7 (41%)                  3 (18%)               5 (29%)                  2 (12%)                   \-                                   \-                                                                                                                                                                                                                                            \-                                                                \[[@B142-antibiotics-09-00500]\]
  2019, India                                    Bakthavatchalam     Colistin              50                       CR-Kp, NDM, OXA-43 (100%)                                24 (48%)                                           14 (30%)                   in vitro (TK)                                           8 (16%)                                                     0%                       42 (84%)              0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B141-antibiotics-09-00500]\]                                  
  2020, Sweden                                   Wistrand-Yuen       Polymyxin B           5 (4 used for FOS+PMB)   KPC-2, KPC-3, NMD-1, OXA-48, VIM-1 (100%)                3 (60%)                                            2 (40%)                    in vitro (TK)                                           5 (31%)                                                     2 (12%)                  \-                    \-                       \-                        \-                                   Synergistic rate inferred from 4 isolates monitored at different times. If evaluated only after 24 h, syn: 40%; add 20%.                                                                                                                      \[[@B182-antibiotics-09-00500]\]                                  
  2019, France                                   Crémieux            Colistin              1                        carbapenem-resistant (100%)                              0%                                                 0%                         in vitro (TK); in vivo (rabbit, osteomyelitis)          1 (100%)                                                    0%                       0%                    0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B71-antibiotics-09-00500]\]                                   
  2018, China                                    Wang                Colistin              4                        carbapenem-resistant (100%)                              2 (50%)                                            0% (75% heteroresistant)   in vitro (TK)                                           31 (43%)                                                    8 (11%)                  33 (46%)              0%                       \-                        \-                                   3 isolates showed heteroresistance: the total number of experiments was 72 (3 different colistin concentrations tested in 6 different times).                                                                                                 \[[@B183-antibiotics-09-00500]\]                                  
  2018, China                                    Yu                  Colistin              3                        KPC (100%)                                               1 (33%)                                            3 (100%)                   in vitro (TK)                                           2 (66%)                                                     1 (33%)                  0%                    0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B164-antibiotics-09-00500]\]                                  
  2017, Taiwan                                   Ku                  Colistin              9                        ESBL-producing KP (5/9 carbapenem-R, 4/9 carbapenem-S)   4 (45%)                                            1 (11%)                    in vitro (TK)                                           5 (55%)                                                     0%                       4 (45%)               0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B84-antibiotics-09-00500]\]                                   
  2017, China                                    Yu                  Colistin              3                        KPC2 (100%)                                              0%                                                 1 (33%)                    in vitro (TK)                                           3 (100%)                                                    0%                       0%                    0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B50-antibiotics-09-00500]\]                                   
  2017, China                                    Yu                  Colistin              136                      KPC-Kp (100%)                                            78 (57%)                                           1 (1%)                     in vitro (CB, TK)                                       5 (3%)                                                      109 (80%)                22 (16%)              0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B89-antibiotics-09-00500]\]                                   
  2018, USA                                      Bulman              Polymyxin B           2                        KPC-2 (100%)                                             0%                                                 0%                         in vitro (TK); in vivo (hollow-fibre infection model)   2 (100%)                                                    \-                       \-                    \-                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B75-antibiotics-09-00500]\]                                   
  2014, Sweden                                   Tängdeén            Colistin              4                        VIM (50%), NDM (50%)                                     2 (50%)                                            0%                         in vitro (TK)                                           3 (75%)                                                     0%                       1 (25%)               0%                       \-                        \-                                   Synergism in 1 VIM- and 2 NDM-producing isolates, although NDM-producing isolates were FOS-R.                                                                                                                                                 \[[@B146-antibiotics-09-00500]\]                                  
  2013, Turkey                                   Evren               Colistin              12                       OXA-48 (100%)                                            11 (92%)                                           2 (17%)                    in vitro (CB)                                           0%                                                          0%                       0%                    12 (100%)                \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B74-antibiotics-09-00500]\]                                   
  2011, France                                   Berçot              Colistin              3                        NDM-1 (100%)                                             0%                                                 0%                         in vitro (CB, TK)                                       0%                                                          1 (33%)                  2 (66%)               0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B85-antibiotics-09-00500]\]                                   
  2011, Greece                                   Samonis             Colistin              50                       carbapenem-resistant (100%)                              3%                                                 25%                        in vitro (ET)                                           18 (36%)                                                    \-                       \-                    0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B86-antibiotics-09-00500]\]                                   
  2011, Greece                                   Samonis             Colistin              14                       ESBL (100%)                                              3%                                                 25%                        in vitro (ET)                                           1 (7%)                                                      \-                       \-                    0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B86-antibiotics-09-00500]\]                                   
  2011, Greece                                   Souli               Colistin              17                       KPC-2 (100%)                                             4 (23%)                                            7 (41%)                    in vitro (TK)                                           2 (12%)                                                     0%                       15 (88%)              0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B53-antibiotics-09-00500]\]                                   
  *K. oxytoca*                                   2011, France        Berçot                Colistin                 1                                                        NDM-1                                              0%                         0%                                                      in vitro (CB, TK)                                           0%                       100%                  0%                       0%                        \-                                   \-                                                                                                                                                                                                                                            \-                                                                \[[@B85-antibiotics-09-00500]\]
  *P. rettgeri*                                  2011, France        Berçot                Colistin                 1                                                        NDM-1                                              0%                         100%                                                    in vitro (CB, TK)                                           0%                       0%                    100%                     0%                        \-                                   \-                                                                                                                                                                                                                                            \-                                                                \[[@B85-antibiotics-09-00500]\]
  *P. aeruginosa*                                2019, USA           Flamm                 Colistin                 5                                                        \-                                                 \-                         \-                                                      in vitro (CB, TK)                                           0%                       1 (20%)               4 (80%)                  0%                        \-                                   \-                                                                                                                                                                                                                                            \-                                                                \[[@B38-antibiotics-09-00500]\]
  2016, Australia                                Walsh               Polymyxin B           4                        MDR (75%)                                                50%                                                50%                        in vitro (TK)                                           19 (18%)                                                    27 (25%)                 \-                    \-                       \-                        \-                                   FOS in combination with polymyxin B increased bacterial killing, but did not suppress emergence of FOS resistance. The total number of experiments was 108 (9 combinations of FOS + CIP at different concentrations, in 3 different times).   \[[@B76-antibiotics-09-00500]\]                                   
  2011, Greece                                   Samonis             Colistin              15                       MDR (100%)                                               6%                                                 0%                         in vitro (ET)                                           2 (13%)                                                     \-                       \-                    0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B86-antibiotics-09-00500]\]                                   
  2015, China                                    Di                  Colistin              87                       CRPA (100%)                                              75%                                                4% (5/87)                  in vitro (CB, TK)                                       19 (21%)                                                    29 (33)%                 39 (44%)              0%                       \-                        3 (60%)                              \-                                                                                                                                                                                                                                            \[[@B184-antibiotics-09-00500]\]                                  
  *A. baumannii-A. calcoaceticus spp. Complex*   2019, USA           Flamm                 Colistin                 5                                                        MDR (20%)                                          \-                         \-                                                      in vitro (CB, TK)                                           2 (40%)                  1 (20%)               1 (20%)                  0%                        \-                                   \-                                                                                                                                                                                                                                            For 1 isolate the effect of the combination was indeterminate.    \[[@B38-antibiotics-09-00500]\]
  *A. baumannii*                                 2020, South Korea   Su Ku                 Colistin                 1                                                        OXA-23 (100%)                                      100%                       0%                                                      in vitro (TK); in vivo (mouse, nasal inoculation)           1 (100%)                 0%                    0%                       0%                        \-                                   \-                                                                                                                                                                                                                                            \-                                                                \[[@B72-antibiotics-09-00500]\]
  2019, Turkey                                   Sertcelik           Colistin              23                       carbapenem-resistant (100%)                              100%                                               26%                        in vitro (CB)                                           1 (4%)                                                      10 (43%)                 12 (52%)              0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B185-antibiotics-09-00500]\]                                  
  2019, China                                    Bian                Colistin              9                        carbapenem-resistant (100%)                              \-                                                 0%                         in vitro (CB, TK)                                       1 (11%)                                                     \-                       \-                    \-                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B186-antibiotics-09-00500]\]                                  
  2018, China                                    Zhu                 Colistin              21                       \-                                                       100%                                               61% (13/21)                in vitro (CB)                                           0%                                                          2 (9%)                   19 (90%)              0%                       \-                        \-                                   The authors reported 8 isolates to be colistin-R, but only 3 isolates had MIC \> 2.                                                                                                                                                           \[[@B151-antibiotics-09-00500]\]                                  
  2018, Thailand                                 Leelasupasri        Colistin              15                       carbapenem-resistant (100%)                              100%                                               0%                         in vitro (CB, ET)                                       4 (26%)                                                     7 (46%)                  4 (26%)               0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B187-antibiotics-09-00500]\]                                  
  2017, Thailand                                 Lertsrisatit        Colistin              17                       CoR-AB; carbapenemase-producing; efflux-pump (100%)      100%                                               100%                       in vitro (CB, ET)                                       \-                                                          \-                       \-                    0%                       \-                        \-                                   Treatment in vivo (patients) with COL + FOS lead to death (2/2).                                                                                                                                                                              \[[@B188-antibiotics-09-00500]\]                                  
  2016, China                                    Fan                 Colistin              12                       XDR (100%)                                               100%                                               0%                         in vivo (mouse, thigh-infection)model                   1 (8%)                                                      \-                       \-                    0%                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B189-antibiotics-09-00500]\]                                  
  2016, Brazil                                   Leite               Colistin              20                       OXA-23, OXA-143 (100%)                                   100%                                               35% (7/20)                 in vitro (CB, TK, 2-well)                               0%                                                          \-                       \-                    \-                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B83-antibiotics-09-00500]\]                                   
  2015, China                                    Wei                 Colistin              50                       XDR (100%)                                               94%                                                50%                        in vitro (CB)                                           25 (50%)                                                    0%                       22 (44%)              3 (6%)                                                                                  Synergism (FICI: =\< 0.5). Indifference (FICI: 0.5--4). Antagonism (FICI: \>= 4).                                                                                                                                                             \[[@B190-antibiotics-09-00500]\]                                  
  2013, China                                    Zhang               Polymyxin B           25                       PDR (100%)                                               100%                                               100%                       in vitro (TK)                                           4 (16%)                                                     11 (44%)                 10 (40%)              0%                       0%                        25 (100%)                            \-                                                                                                                                                                                                                                            \[[@B65-antibiotics-09-00500]\]                                   
  2011, Thailand                                 Santimaleeworagun   Colistin              8                        carbapenem-resistant (100%)                              0%                                                 \-                         in vitro (CB, TK)                                       13%                                                         \-                       \-                    \-                       \-                        \-                                   \-                                                                                                                                                                                                                                            \[[@B99-antibiotics-09-00500]\]                                   
  *N. gonorrhoeae*                               2014, Netherlands   Wind                  Colistin                 4                                                        \-                                                 \-                         \-                                                      in vitro (ET)                                               0%                       \-                    \-                       \-                        \-                                   \-                                                                                                                                                                                                                                            \-                                                                \[[@B54-antibiotics-09-00500]\]

antibiotics-09-00500-t011_Table 11

###### 

Studies on combination between fosfomycin and daptomycin. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strains                                      Year and Country     Author                      Number of Isolates           Known Resistance Mechanisms or Determinants (%)   FOS-Resistant (%)   Daptomycin-Resistant (%)                               In Vitro (Methods)/In Vivo (Animal and Site of Infection)   Synergistic Effect (%)                 Additive Effect (%)   Indifferent Effect (%)           Antagonistic Effect (%)               FOS Susceptibility Restoration (%)   Daptomycin Susceptibility Restoration (%)                                                                                                                                                                                                                                                  Comments                                                                                                                                                                              Reference
  -------------------------------------------- -------------------- --------------------------- ---------------------------- ------------------------------------------------- ------------------- ------------------------------------------------------ ----------------------------------------------------------- -------------------------------------- --------------------- -------------------------------- ------------------------------------- ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  *S. aureus*                                  2019, Taiwan         Lee                         100                          MRSA (100%)                                       15 (15%)            0%                                                     in vitro (CB)                                               37 (37%)                               44 (44%)              19 (19%)                         0%                                    \-                                   \-                                                                                                                                                                                                                                                                                         All isolates had MIC daptomycin = 1 (previously selected among 1353 isolates).                                                                                                        \[[@B191-antibiotics-09-00500]\]
  2019, Spain                                  Coronado-Alvarez     4                           MRSA (50%)                   \-                                                \-                  in vitro (TK)                                          4 (100%)                                                    0%                                     0%                    0%                               \-                                    \-                                   The authors also performed a retrospective review of 75 patients with severe Gram-positive infections and found that DAP + FOS (30) was the most effective combination.                                                                                                                    \[[@B63-antibiotics-09-00500]\]                                                                                                                                                       
  2018, Spain                                  Garcìa-de-la-Mària   5 (in vitro); 1 (in vivo)   MRSA (100%)                  0%                                                0%                  in vitro (TK), in vivo (rabbit, endocarditis)          in vitro: 5 (100%); in vivo: 1 (100%)                       0%                                     0%                    0%                               \-                                    \-                                   \-                                                                                                                                                                                                                                                                                         \[[@B79-antibiotics-09-00500]\]                                                                                                                                                       
  2017, Turkey                                 Aktas                25                          MRSA (100%)                  11 (44%)                                          0%                  in vitro (CB)                                          25 (100%)                                                   0%                                     0%                    0%                               \-                                    \-                                   \-                                                                                                                                                                                                                                                                                         \[[@B80-antibiotics-09-00500]\]                                                                                                                                                       
  2015, Austria                                Lingscheid           1                           MRSA (100%)                  0%                                                0%                  in vivo (rats, implant-associated osteomyelitis)       1 (100%)                                                    0%                                     0%                    0%                               \-                                    \-                                   \-                                                                                                                                                                                                                                                                                         \[[@B81-antibiotics-09-00500]\]                                                                                                                                                       
  2013, Spain                                  Garrigós             1                           MRSA (100%)                  0%                                                0%                  in vitro (TK), in vivo (rat, foreign-body infection)   in vitro: 0%; in vivo: 1 (100%)                             0%                                     in vitro: 1 (100%)    0%                               \-                                    \-                                   \-                                                                                                                                                                                                                                                                                         \[[@B37-antibiotics-09-00500]\]                                                                                                                                                       
  2012, Spain                                  Miró                 14                          MRSA (35%); GISA (14%)       0%                                                1 (7%)              in vitro (TK)                                          11 (79%)                                                    3 (21%)                                0%                    0%                               \-                                    \-                                   The combination was bactericidal against 8 (57%) isolates. The authors also reported the case reports of 3 patients with *S. aureus* (1 MSSA, 2 MRSA) endocarditis successfully treated with high-dose DAP (10/kg/day) + FOS.                                                              \[[@B192-antibiotics-09-00500]\]                                                                                                                                                      
  2011, Austria                                Poeppl               1                           MRSA (100%)                  0%                                                0%                  in vivo (rats, osteomyelitis)                          0%                                                          0%                                     1 (100%)              0%                               \-                                    \-                                   FOS and FOS + DAP were significantly superior to placebo and to DAP alone. FOS + DAP was not more effective than FOS alone.                                                                                                                                                                \[[@B193-antibiotics-09-00500]\]                                                                                                                                                      
  *E. faecalis*                                2019, China          Zheng                       4 (TK) + 4 (biofilm assay)   \-                                                1 (12%)             2 (25%)                                                in vitro (TK, biofilm assay)                                TK: 4 (100%). Biofilm assay: 3 (75%)   0%                    TK: 0%. Biofilm assay: 1 (25%)   0%                                    \-                                   \-                                                                                                                                                                                                                                                                                         TK performed on 4 linezolid-R isolates. Biofilm assay performed on 4 linezolid-S isolates. DAP + FOS demonstrated significantly more anti-biofilm activities then DAP or FOS alone.   \[[@B194-antibiotics-09-00500]\]
  1992, USA                                    Rice                 1                           \-                           0                                                 1 (100%)            in vitro (TK), in vivo (rats, endocarditis)            in vitro: 1 (100%)                                          in vitro: 0%; in vivo: 1 (100%)        0%                    0%                               \-                                    in vitro: 1 (100%)                   The isolate was highly R to gentamicin. DAP + FOS sterilized more valves (59% VS 35%) than DAP alone. Despite this, the combination in vivo was considered \"additive\" because it was not possible to demonstrate a statistically significant superiority in comparison with DAP alone.   \[[@B82-antibiotics-09-00500]\]                                                                                                                                                       
  1989, USA                                    Rice                 21                          \-                           0                                                 0                   in vitro (TK)                                          21 (100%)                                                   0%                                     0%                    0%                               \-                                    \-                                   All isolates were highly R to gentamicin. The bactericidal effect of DAP alone was not increased by the addition of FOS.                                                                                                                                                                   \[[@B195-antibiotics-09-00500]\]                                                                                                                                                      
  *E. faecium*                                 2013, USA            Descourouez                 4                            VRE (100%)                                        0%                  0%                                                     in vitro (TK)                                               4 (100%)                               0%                    0%                               0% \[[@B196-antibiotics-09-00500]\]   \-                                   \-                                                                                                                                                                                                                                                                                         The combination resulted strongly bactericidal.                                                                                                                                       \[[@B67-antibiotics-09-00500]\]
  *Staphylococcus* spp., *Enterococcus* spp.   1988, Italy          Debbia                      50                           \-                                                \-                                                                         in vitro (CB, TK)                                           CB: 80%TK: 95%                         0%                    CB: 20%TK: 5%                    0%                                    \-                                   \-                                                                                                                                                                                                                                                                                         A total of 50 strains was tested with CB, and only 20 strains were tested with TK.                                                                                                    \[[@B197-antibiotics-09-00500]\]

antibiotics-09-00500-t012_Table 12

###### 

Studies on combination between fosfomycin and tigecycline. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strain              Year and Country    Author          Number of Isolates                         Known Resistance Mechanisms or Determinants (%)                                                                  FOS-Resistant (%)   Tigecycline-Resistant (%)                    In Vitro (Methods)/In Vivo (Animal and Site of Infection)   Synergistic Effect (%)              Additive Effect (%)          Indifferent Effect (%)        Antagonistic Effect (%)   FOS Susceptibility Restoration (%)   Tigecycline Susceptibility Restoration (%)                                                                                                                                                                                    Comments                                                                                                                                                                                                                  Reference
  ------------------- ------------------- --------------- ------------------------------------------ ---------------------------------------------------------------------------------------------------------------- ------------------- -------------------------------------------- ----------------------------------------------------------- ----------------------------------- ---------------------------- ----------------------------- ------------------------- ------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------
  Enterobacterales    2019, USA           Flamm           20                                         7/30 MDR strains (*A. baumannii*, Enterobacterales e *P. aeruginosa*) included 2 ESBL e 2 KPC Enterobacterales   \-                  \-                                           in vitro (CB)                                               5 (25%)                             10 (50%)                     5 (25%)                       0%                        \-                                   \-                                                                                                                                                                                                                            Authors considered Partial Sinergy when FICI was between 0.5--1 and Additive effect for FICI = 1.                                                                                                                         \[[@B38-antibiotics-09-00500]\]
  2017, Taiwan        Ku                  9               ESBL KP producing (100%)                   4 (44,4%)                                                                                                        4 (44%)             in vitro (TK)                                6 (66%)                                                     0%                                  3 (33%)                      0%                            \-                        \-                                   \-                                                                                                                                                                                                                            \[[@B84-antibiotics-09-00500]\]                                                                                                                                                                                           
  2011, France        Berçot              9               NDM-1 KPC (100%)                           2 (22%)                                                                                                          3 (33%)             in vitro (CB)                                0%                                                          \-                                  9 (100%)                     0%                            \-                        \-                                   Authors considered Indifferent effect for FICI between 0.5 and 4.                                                                                                                                                             \[[@B85-antibiotics-09-00500]\]                                                                                                                                                                                           
  *E. coli*           2013, Switzerland   Corvec          1                                          Bj HDE-1 (100%) (ESBL and Ciprofloxacin resistant)                                                               0%                  0%                                           in vitro (TK); in vivo (Guinea pigs, cage infection)        TK: 0%; in vivo: 0%                 TK: 100%; in vivo: 0%        TK: 0%; in vivo: 100%         0%                        \-                                   \-                                                                                                                                                                                                                            \-                                                                                                                                                                                                                        \[[@B73-antibiotics-09-00500]\]
  2011, Greece        Samonis             20              ESBL (100%)                                0%                                                                                                               1 (5%)              in vitro (ET)                                5 (25%)                                                     \-                                  15 (75%)                     0%                            \-                        \-                                   Authors considered Indifferent effect for FICI between 0.5 and 4. In vivo experiment: bacterial count using FOS + TIG combination was reduced ≥ 2 log over single antimicrobials                                              \[[@B86-antibiotics-09-00500]\]                                                                                                                                                                                           
  *K. pneumoniae*     2019, China         Huang           30                                         KPC (100%)                                                                                                       19 (63%)            11 (36%)                                     in vitro (ET, CB)                                           ET: 5 (16%); CK: 4 (13%)            ET: 9 (30%); CK: 11 (36%)    ETt: 16 (53%); CK: 15 (50%)   0%                        ET: 14/19 (73%); CK: 6/15 (40%)      ET: 5/11 (45%); CK: 7/13 (53,%)                                                                                                                                                                                               ET and CB showed different rates of FOS and TIG resistance and different rates of susceptibility restoration; otherwise the 2 methods had similar resulted in establishing synergistic, additive or indifferent effect.   \[[@B88-antibiotics-09-00500]\]
  2019, Greece        Papoutsaki          11              KPC (100%)                                 35%                                                                                                              96%                 in vitro (ET, TK)                            ET: 16/33 (48%); TKA: 1/22 (4%)                             ET: 17/33 (51%); TKA: 21/22 (95%)   0%                           0%                            \-                        \-                                   ET was performed three times with different methods: a) Etest/Agar method; b) Cross formation method; c) MIC/MIC ratio method. TK was performed two times: a) TIG 1,3 mg/L + FOS 0,5xMIC and b) TIG 1,3 mg/L + FOS 30 mg/L.   \[[@B87-antibiotics-09-00500]\]                                                                                                                                                                                           
  2017, China         Yu                  136             KPC (100%)                                 78 (57%)                                                                                                         25 (18%)            in vitro (CB, TK)                            CK: 2 (1%); TKA: 0%                                         CK: 113 (83%); TKA: 3 (75%)         CK: 19 (14%); TKA: 1 (25%)   CK: 2 (1%); TKA: 0%           \-                        \-                                   Only 4 strains were tested with TK.                                                                                                                                                                                           \[[@B89-antibiotics-09-00500]\]                                                                                                                                                                                           
  2013, Turkey        Evren               12              OXA-48 (100%)                              11 (92%)                                                                                                         5 (41%)             in vitro (CB)                                4 (33%)                                                     6 (50%)                             2 (16%)                      0%                            \-                        \-                                   Authors considered Indifferent effect for FICI between 0.5 and 4. In vivo experiment: bacterial count using FOS + TIG combination was reduced ≥ 2 log over single antimicrobials                                              \[[@B74-antibiotics-09-00500]\]                                                                                                                                                                                           
  2011, Greece        Samonis             65              Serine-KPC (77%) - MBL (1%) - ESBL (21%)   1 (1%)                                                                                                           10 (15%)            in vitro (ET)                                18 (27%)                                                    \-                                  47 (72%)                     0%                            \-                        \-                                   Authors considered Indifferent effect for FICI between 0.5 and 4. In vivo experiment: bacterial count using FOS + TIG combination was reduced ≥ 2 log over single antimicrobials                                              \[[@B86-antibiotics-09-00500]\]                                                                                                                                                                                           
  *P. aeruginosa*     2011, Greece        Samonis         15                                         MDR (100%)                                                                                                       1 (6%)              15 (100%)                                    in vitro (ET)                                               2 (13%)                             \-                           13 (86%)                      0%                        \-                                   \-                                                                                                                                                                                                                            Authors considered Indifferent effect for FICI between 0.5 and 4. In vivo experiment: bacterial count using FOS + TIG combination was reduced ≥ 2 log over single antimicrobials                                          \[[@B86-antibiotics-09-00500]\]
  *A. baumannii*      2019, USA           Flamm           5                                          7/30 MDR strains (*A. baumannii*, Enterobacterales e *P. aeruginosa*)                                            \-                  \-                                           in vitro (CB)                                               0%                                  4 (80%)                      1 (20%)                       0%                        \-                                   \-                                                                                                                                                                                                                            Authors considered Partial Sinergy when FICI was between 0.5--1 and Additive effect for FICI = 1.                                                                                                                         \[[@B38-antibiotics-09-00500]\]
  2016, Netherlands   Leite               20              Colistin-Resistant (65%)                   20 (100%)                                                                                                        5%                  in vitro (CB, 2-Well Method)                 0%                                                          \-                                  \-                           \-                            \-                        \-                                   Any synergistic effect was reported. Additive, Indifferent and antagonistic effect were not evaluated.                                                                                                                        \[[@B83-antibiotics-09-00500]\]                                                                                                                                                                                           
  *S. aureus*         2018, Italy         Simonetti       15                                         MRSA (100%)                                                                                                      0                   0%                                           in vitro (CB); in vivo (mice, wound infection)              12 (80%)                            \-                           3 (20%)                       0%                        \-                                   \-                                                                                                                                                                                                                            Authors considered Indifferent effect for FICI between 0.5 and 4. In vivo experiment: bacterial count using FOS + TIG combination was reduced ≥ 2 log over single antimicrobials.                                         \[[@B90-antibiotics-09-00500]\]
  2012, Taiwan        Tang                33 (8 TK)       MRSA (100%)                                6%                                                                                                               0%                  in vitro (TK, Biofilm MTT-staining method)   0%                                                          \-                                  100%                         0%                            \-                        \-                                   Only 8 strains were tested with Time--kill Assay. Biofilm cultures were 100% TIG resistant and 94% FOS resistant. No FICI were reported by authors, no synergistic effect was seen on any strains.                            \[[@B69-antibiotics-09-00500]\]                                                                                                                                                                                           
  *E. faecalis*       2018, Italy         Simonetti       15                                         \-                                                                                                               0%                  0%                                           in vitro (CB); in vivo (mice, wound infection)              12 (80%)                            \-                           3 (20%)                       0%                        \-                                   \-                                                                                                                                                                                                                            Authors considered Indifferent effect for FICI between 0.5 and 4. In vivo experiment: bacterial count using FOS + TIG combination was reduced ≥ 2 log over single antimicrobials.                                         \[[@B90-antibiotics-09-00500]\]
  2013, Taiwan        Tang                9               VRE (100%)                                 56%                                                                                                              0%                  in vitro (TK, Biofilm Model)                 TKA: 3 (33%); BM: 5 (56%)                                   \-                                  \-                           \-                            \-                        \-                                   Additive, Indifferent and antagonistic effect were not evaluated.                                                                                                                                                             \[[@B13-antibiotics-09-00500]\]                                                                                                                                                                                           
  *E. faecium*        2019, Thailand      Hemapampairoa   12                                         VRE (100%)                                                                                                       12 (100%)           3 (25%)                                      in vitro (CB)                                               1 (8%)                              9 (75%)                      2 (16)%                       0%                        \-                                   \-                                                                                                                                                                                                                            \-                                                                                                                                                                                                                        \[[@B55-antibiotics-09-00500]\]
  2018, Italy         Simonetti           15              \-                                         0%                                                                                                               0%                  in vitro (CB)                                10 (66)%                                                    \-                                  5 (33%)                      0%                            \-                        \-                                   Authors considered Indifferent effect for FICI between 0.5 and 4.                                                                                                                                                             \[[@B90-antibiotics-09-00500]\]                                                                                                                                                                                           
  2013, Taiwan        Tang                10              VRE (100%)                                 70%                                                                                                              0%                  in vitro (TK, Biofilm Model)                 TKA: 3 (30%); BM: 1 (10%)                                   \-                                  \-                           \-                            \-                        \-                                   Additive, Indifferent and antagonistic effect were not evaluated.                                                                                                                                                             \[[@B13-antibiotics-09-00500]\]                                                                                                                                                                                           
  *N. gonorrhoeae*    2015, Netherlands   Wind            4                                          Azithromycin and Ceftriaxone Resistant (100%)                                                                    \-                  \-                                           in vitro (ET)                                               0%                                  0%                           4 (100%)                      \-                        \-                                   \-                                                                                                                                                                                                                            \-                                                                                                                                                                                                                        \[[@B54-antibiotics-09-00500]\]

antibiotics-09-00500-t013_Table 13

###### 

Studies on combination between fosfomycin and linezolid. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strain             Year and Country   Author          Number of Isolates                                Known Resistance Mechanisms or Determinants (%)   FOS-Resistant (%)   Linezolid-Resistant (%)                                               In Vitro (Methods)/In Vivo (Animal and Site of Infection)   Synergistic Effect (%)      Additive Effect (%)        Indifferent Effect (%)   Antagonistic Effect (%)   FOS Susceptibility Restoration (%)   Linezolid Susceptibility Restoration (%)                                                                                                                                                                                                                                                         Comments                                                                                                                                                                                                                                                                                                   Reference
  ------------------ ------------------ --------------- ------------------------------------------------- ------------------------------------------------- ------------------- --------------------------------------------------------------------- ----------------------------------------------------------- --------------------------- -------------------------- ------------------------ ------------------------- ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  *S. aureus*        2018, China        Chen            11 (3 TK)                                         MRSA (50%)                                        0%                  0%                                                                    in vitro (CB, TK)                                           CK: 8 (72%); TK: 3 (100%)   CK: 3 (27%); TK: 0%        CK: 0%; TK: 0%           CK: 0%; TK: 0%            \-                                   \-                                                                                                                                                                                                                                                                                               Only 3 strains were tested with TK. For the same 3 strains, the authors also evaluated. Post-Antibiotic Effect (PAE) of LZD alone and in combination with FOS. PAE of LZD + FOS seemed to be increased with the increase in time of exposure, even if no statistically significant difference was found.   \[[@B198-antibiotics-09-00500]\]
  2018, Spain        Coronado-Alvarez   2               MRSA (100%)                                       \-                                                \-                  in vitro (TK)                                                         2 (100%)                                                    0%                          0%                         0%                       \-                        \-                                   Synergy was defined as a reduction \> 3 log CFU/mL over antimicrobial agent alone, additive effect was defined as areduction \< 3 log CFU/mL. Synergistic effect was demonstrated only when 4 x MIC LZD + 2 x MIC FOS were used; 1 × MIC LZD + 2 × MIF FOS regimen showed Additive effect.       \[[@B63-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                            
  2016, China        Chai               3 (1 TK)        MRSA (100%)                                       2 (66%)                                           0%                  in vitro (CB, TK)                                                     CK: 3 (100%); TK: 1 (100%)                                  CK: 0%; TK: 0%              CK: 0%; TK: 0%             CK: 0%; TK: 0%           \-                        \-                                   Only 1 strain was tested with Time--kill Assay. The authors also evaluated in vitro and in vivo efficacy of LIN + FOS on MRSA biofilm (all 3 strains), demonstrating a synergistic effect only in vitro when using 1/2 MIC LZD + 1/2 MIC FOS and not with lower concentrations.                  \[[@B94-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                            
  2014, China        Xu-Hong            102             MRSA (100%)                                       \*\*MIC range 16-128 mg/L                         0%                  in vitro (CB)                                                         100 (98%)                                                   \-                          2 (2%)                     0%                       100%                      100%                                 The authors considered Indifferent effect for FICI between 0.5 and 4. Fosfomycin MIC range in combination was 2-32 mg/L, LZD MIC in combination was 0,125--1 mg/L.                                                                                                                               \[[@B199-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                           
  2012, Taiwan       Tang               33 (8 TK)       MRSA (100%)                                       6%                                                0%                  in vitro (TK, Biofilm MTT-staining method)                            \-                                                          \-                          \-                         \-                       \-                        \-                                   Only 8 strains were tested with Time--kill Assay. Biofilm cultures were 100% LZD resistant and 94% FOS resistant. Combination of FOS + LZD determined a statistically significant reduction on ODRs in biofilm cultures.                                                                         \[[@B69-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                            
  2010, Spain        Pachón-Ibáñez      1               GISA 100% (Gentamicin Intermediate *S. aureus*)   \-                                                \-                  in vitro (TK); in vivo (Murine peritonitis model)                     1 (100%)                                                    0%                          0%                         0%                       \-                        \-                                   In vivo experiment on mice showed a higher rate of blood culture negativization when using FOS + LZD therapy (57%) then using FOS or LZD alone (43% and 27% respectively).                                                                                                                       \[[@B36-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                            
  2006, Spain        Sahuquillo Arce    5 (4 TK)        \-                                                0%                                                0%                  in vitro (CB, TK)                                                     CK: 4 (80%); TK: 4 (100%)                                   CK: 1 (20%); TK: 0%         CK: 0%; TK: 0%             CK: 0%; TK: 0%           \-                        \-                                   Synergistic effect at CB was confirmed with TK on 4 strains.                                                                                                                                                                                                                                     \[[@B200-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                           
  2001, Austria      Grif               5 (1 TK)        MRSA (60%)                                        0%                                                0%                  in vitro (CB, TK, TEM)                                                CK: 5 (100%); TK: 0%                                        \-                          CK: 0%; TK: (1) 100%       CK: 0%; TK: 0%           \-                        \-                                   The authors did not consider additive effect. They also performed Transmission Electron Microscopy, demonstrating profound morphological alteration of 2 strains when using FOS + LZD, which were not seen using FOS or LZD alone.                                                               \[[@B43-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                            
  2018, China        Li                 4               MRSA (50%)                                        0%                                                0%                  in vitro (CB, TK); in vivo (*Galleria melonella* Survival Assay)      CK: 4 (100%); TK: 4 (100%)                                  CK: 0%; TK: 0%              CK: 0%; TK: 0%             CK: 0%; TK: 0%           \-                        \-                                   TKA showed synergism, but bacteriostatic effect. In vivo experiment showed statistically significant higher efficacy of high-dose LZD + FOS combination, then high dose of FOS or LZD alone, but low-dose combination had no significant differences with monotherapy orhigh-dose combination.   \[[@B95-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                            
  *S. epidermidis*   2001, Austria      Grif            2                                                 \-                                                0%                  0%                                                                    in vitro (CB)                                               2 (100%)                    \-                         0%                       0%                        \-                                   \-                                                                                                                                                                                                                                                                                               The authors did not consider additive effect. They also performed Transmission Electron Microscopy, demonstrating profound morphological alteration of 2 strains when using FOS + LZD, which were not seen using FOS or LZD alone.                                                                         \[[@B43-antibiotics-09-00500]\]
  *E. faecalis*      2013, Taiwan       Tang            9                                                 VRE (100%)                                        56%                 0%                                                                    in vitro (TK, Biofilm Model)                                TKA: 0%; BM: 0%             \-                         \-                       \-                        \-                                   \-                                                                                                                                                                                                                                                                                               The authors did not consider additive, indifferent or antagonistic effect.                                                                                                                                                                                                                                 \[[@B13-antibiotics-09-00500]\]
  2019, China        Qi                 2               VRE (50%)                                         2 (100%)                                          0%                  in vitro (CB, TK, TEM)                                                CK: 0%; TK: 0%)                                             CK: 2 (100%); TK: 1 (50%)   CK: 0%; TK: 1 (50%)        CK: 0%; TK: 0%           2 (100%)                  2 (100%)                             Transmission Electron Microscopy, demonstrated more morphological alterations when using FOS + LZD, then using FOS or LZD alone.                                                                                                                                                                 \[[@B201-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                           
  *E. faecium*       2019, Thailand     Hemapampairoa   12                                                VRE (100%)                                        12 (100%)           0%                                                                    in vitro (CB)                                               3 (25%)                     9 (75%)                    0%                       0%                        \-                                   \-                                                                                                                                                                                                                                                                                               \-                                                                                                                                                                                                                                                                                                         \[[@B55-antibiotics-09-00500]\]
  2013, Taiwan       Tang               10              VRE (100%)                                        70%                                               80%                 in vitro (TK, Biofilm Model)                                          TKA: 1 (10%); BM: 0%                                        \-                          \-                         \-                       \-                        \-                                   The authors did not consider additive, indifferent or antagonistic effect.                                                                                                                                                                                                                       \[[@B13-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                            
  2012, USA          Descourouez        32              VRE (100%)                                        9%                                                3%                  in vitro (TK)                                                         See comments                                                See comments                0%                         0%                       \-                        \-                                   The authors considered MIC ≤ 64 mg/L as FOS breakpoint. FOS combined with LZD was either synergistic or additive yet bacteriostatic. Percentages of strains on which there was synergistic effect were not reported                                                                              \[[@B67-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                            
  2019, China        Qi                 4               VRE (75%)                                         4 (100%)                                          1 (25%)             in vitro (CB, TK, TEM); in vivo (Galleria Melonella Survival Assay)   CK: 2 (50%); TK: 2 (50%)                                    CK: 1 (25%); TK: 1 (25%)    CK: 1 (25%); TK: 1 (25%)   0%                       3 (75%)                   4 (100%)                             Transmission Electron Microscopy, demonstrated more morphological alterations when using FOS + LZD, then using FOS or LZD alone. In vivo experiment showed higher survival rates of larvae when using FOS + LZD then LZD alone, but similar rates using FOS alone.                               \[[@B201-antibiotics-09-00500]\]                                                                                                                                                                                                                                                                           

antibiotics-09-00500-t014_Table 14

###### 

Studies on combination between fosfomycin and rifampin. CB: checkerboard assay; TK: time--kill assay; ET: E-test.

  Strain                                    Year and Country    Author            Number of Isolates   Known Resistance Mechanisms or Determinants (%)   FOS-Resistant (%)               Rifampin-Resistant (%)                                      In Vitro (Methods)/In Vivo (Animal and Site of Infection)   Synergistic Effect (%)   Additive Effect (%)   Indifferent Effect (%)                             Antagonistic Effect (%)   FOS Susceptibility Restoration (%)   Rifampin Susceptibility Restoration (%)                                                                                                                                                                                                                      Comments                                                          Reference
  ----------------------------------------- ------------------- ----------------- -------------------- ------------------------------------------------- ------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ------------------------ --------------------- -------------------------------------------------- ------------------------- ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------- ----------------------------------
  *E. coli*                                 1978, Spain         Olay              17                   \-                                                \-                              \-                                                          in vitro (CB); in vivo (mouse, peritonitis)                 1 (5,9%)                 9 (52,9%)             7 (41,2%)                                          0%                        \-                                   \-                                                                                                                                                                                                                                                           \-                                                                \[[@B14-antibiotics-09-00500]\]
  *A. baumannii*                            2016, Brazil        Leite             20                   OXA-51, OXA-23, OXA-143 (100%)                    20 (100%)                       20 (100%)                                                   in vitro (CB, TK)                                           0%                       \-                    \-                                                 \-                        \-                                   \-                                                                                                                                                                                                                                                           \-                                                                \[[@B83-antibiotics-09-00500]\]
  *S. aureus*                               2018, Italy         Simonetti         16                   MRSA (100%)                                       0%                              2 (12%)                                                     in vitro (CB, TK); in vivo (mouse, wound infection)         16 (100%)                0%                    0%                                                 0%                        \-                                   \-                                                                                                                                                                                                                                                           \-                                                                \[[@B90-antibiotics-09-00500]\]
  2014, Switzerland                         Mihailescu          1                 MRSA (100%)          0%                                                0%                              in vitro (ET, TK); in vivo (foreign-body infection model)   in vitro: 1 (100%); in vivo: 100% at day 12                 0%                       0%                    0%                                                 \-                        \-                                   \-                                                                                                                                                                                                                                                           \[[@B96-antibiotics-09-00500]\]                                   
  2013, China                               Tang                8                 MRSA (100%)          0%                                                8 (100%)                        in vitro (biofilm assay)                                    4 (50%)                                                     \-                       \-                    \-                                                 \-                        \-                                   \-                                                                                                                                                                                                                                                           \[[@B91-antibiotics-09-00500]\]                                   
  2012, Spain                               Garrigos            1                 MRSA (100%)          \-                                                \-                              in vitro (TK); in vivo (rat, tissue cage infection)         in vivo: 1 (100%) at day 8 and day 11                       \-                       \-                    in vitro: 1 (100%)                                 \-                        \-                                   In vitro FOS antagonized the effect of RIF.                                                                                                                                                                                                                  \[[@B37-antibiotics-09-00500]\]                                   
  2012, Taiwan                              Tang                33                MRSA (100%)          6% (planktonic) 94% (biofilm)                     0% (planktonic) 79% (biofilm)   in vitro (TK)                                               0%                                                          \-                       \-                    \-                                                 \-                        \-                                   \-                                                                                                                                                                                                                                                           \[[@B69-antibiotics-09-00500]\]                                   
  2001, Austria                             Grif                5                 MRSA (100%)          \-                                                \-                              in vitro (CB, TK)                                           100%                                                        \-                       \-                    \-                                                 \-                        \-                                   \-                                                                                                                                                                                                                                                           \[[@B43-antibiotics-09-00500]\]                                   
  1987, France                              Quentin             6                 \-                   33%                                               0%                              in vitro (TK)                                               0%                                                          0%                       33%                   33%                                                \-                        \-                                   RIF antagonizes FOS. In particular, it antagonizes FOS against susceptible and intermediate isolates to RIF. The combination resulted indifferent against RIF-resistant isolates. For 2 isolates it was not possible to infer their susceptibility to RIF.   \[[@B35-antibiotics-09-00500]\]                                   
  1984, Germany                             Traub               6                 GRMR (100%)          0%                                                0%                              in vitro (CB); in vivo (mouse, peritonitis)                 \-                                                          \-                       2 (33%)               \-                                                 \-                        \-                                   \-                                                                                                                                                                                                                                                           \[[@B202-antibiotics-09-00500]\]                                  
  1978, Spain                               Olay                38                \-                   \-                                                \-                              in vitro (CB); in vivo (mouse, peritonitis)                 13 (34%)                                                    24 (63%)                 1 (2%)                \-                                                 \-                        \-                                   \-                                                                                                                                                                                                                                                           \[[@B14-antibiotics-09-00500]\]                                   
  *S. pneumoniae*                           1994, France        Doit              26                   \-                                                0%                              0%                                                          in vitro (TK)                                               0%                       0%                    100%                                               0%                        \-                                   \-                                                                                                                                                                                                                                                           \-                                                                \[[@B134-antibiotics-09-00500]\]
  *S. agalactiae, S. pyogenes, S. oralis*   2017, Germany       Gonzalez Moreno   3                    \-                                                33%                             0%                                                          in vitro (ET)                                               1 (100%) *S. oralis*     \-                    1 (100%) *S. agalactiae*; 1 (100%) *S. pyogenes*   \-                        \-                                   \-                                                                                                                                                                                                                                                           \-                                                                \[[@B9-antibiotics-09-00500]\]
  *E. feacalis*                             2018, Italy         Simonetti         16                   \-                                                0%                              2 (12%)                                                     in vitro (CB, TK); in vivo (mouse, wound infection)         12 (75%)                 0%                    4 (25%)\*                                          0%                        \-                                   \-                                                                                                                                                                                                                                                           \*The FICIs were interpreted as indifferent if \> 0.5 and \< 4.   \[[@B90-antibiotics-09-00500]\]
  2013, Taiwan                              Tang                9                 VRE (100%)           56%                                               11%                             in vitro (TK, biofilm)                                      TK: 3 (33%); biofilm: 9 (100%)                              \-                       \-                    0%                                                 \-                        \-                                   \-                                                                                                                                                                                                                                                           \[[@B13-antibiotics-09-00500]\]                                   
  *E. faecium*                              2018, Italy         Simonetti         15                   \-                                                0%                              2 (13%)                                                     in vitro (CB, TK); in vivo (mouse, wound infection)         11 (73%)                 0%                    4 (27%)\*                                          0%                        \-                                   \-                                                                                                                                                                                                                                                           \*The FICIs were interpreted as indifferent if \> 0.5 and \< 4.   \[[@B90-antibiotics-09-00500]\]
  2013, Taiwan                              Tang                10                VRE (100%)           70%                                               90%                             in vitro (TK)                                               TK: 2 (20%); biofilm: 4 (40%)                               \-                       \-                    \-                                                 \-                        \-                                   \-                                                                                                                                                                                                                                                           \[[@B13-antibiotics-09-00500]\]                                   
  *S. epidermidis*                          2011, Austria       Grif              2                    MRSA (100%)                                       \-                              \-                                                          in vitro (CB, TK)                                           2 (100%)                 \-                    \-                                                 \-                        \-                                   \-                                                                                                                                                                                                                                                           \-                                                                \[[@B43-antibiotics-09-00500]\]
  1987, France                              Quentin             3                 \-                   NA                                                NA                              in vitro (TK)                                               0%                                                          0%                       50%                   \-                                                 \-                        \-                                   For 1 isolate it was not possible to infer its susceptibility to RIF.                                                                                                                                                                                        \[[@B35-antibiotics-09-00500]\]                                   
  *N. gonorrhoeae*                          2015, Netherlands   Wind              4                    \-                                                \-                              \-                                                          in vitro (ET)                                               1 (25%)                  \-                    \-                                                 \-                        \-                                   \-                                                                                                                                                                                                                                                           \-                                                                \[[@B54-antibiotics-09-00500]\]

antibiotics-09-00500-t015_Table 15

###### 

Effect of FOS in combination with different antibiotics: overview.

  Antibiotic Class                                                                         Strains                               Number of Studies   Number of Isolates   Synergistic Effect (%)   Additive Effect (%)   Indifferent Effect (%)   Antagonistic Effect (%)                                                                                                                                                                                                                                        Comments
  ---------------------------------------------------------------------------------------- ------------------------------------- ------------------- -------------------- ------------------------ --------------------- ------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Penicillins, penicillins + β-lactamase inhibitors, penicillinase-resistant penicillins   Enterobacterales                      9                   267                  51                       19                    28                                                                                                                                                                                                                                                                                      One study \[[@B11-antibiotics-09-00500]\] reported high rates of indifferent effect of FOS + PIP/TAZ against PIP/TAZ-R isolates.
  *P. aeruginosa*                                                                          6                                     235                 15                   40                       45                                             \-                                                                                                                                                                                                                                                             
  *Acinetobacter* spp.                                                                     1                                     5                   60                   20                       0                                              \-                                                                                                                                                                                                                                                             
  *Staphylococcus* spp.                                                                    7                                     295                 42                   15                       33                                             \-                                                                                                                                                                                                                                                             
  *Streptococcus* spp.                                                                     6                                     119                 30                   55                       15                                             \-                                                                                                                                                                                                                                                             
  *Enterococcus* spp.                                                                      4                                     60                  25                   0                        42                    10                       Antagonistic effect observed in biofilms of some *E. faecalis* isolates.                                                                                                                                                                                       
  Cephalosporins, cephalosporins + β-lactamase inhibitors                                  Enterobacterales                      8                   251                  33                       33                    20                                                                                                                                                                                                                                                                                      One study \[[@B11-antibiotics-09-00500]\] reported high rates of indifferent effect of FOS + 4 different cephalosporins against cephalosporin-R isolates.
  *P. aeruginosa*                                                                          13                                    318                 36                   40                       23                    1                        Antagonistic effect against 4 *P. aeruginosa* isolates \[[@B22-antibiotics-09-00500]\].                                                                                                                                                                        
  *Acinetobacter* spp.                                                                     2                                     39                  8                    3                        3                                              Effect of the combination indeterminate on 33 isolates.                                                                                                                                                                                                        
  *Staphylococcus* spp.                                                                    12                                    284                 57                   12                       9                     1                        Great heterogeneity of results.                                                                                                                                                                                                                                
  *Streptococcus* spp.                                                                     6                                     63                  33                   59                       8                                              \-                                                                                                                                                                                                                                                             
  *Enterococcus* spp.                                                                      2                                     77                  78                   0                        22                                             \-                                                                                                                                                                                                                                                             
  *N. gonorrhoeae*                                                                         3                                     44                  0                    5                        95                                             \-                                                                                                                                                                                                                                                             
  Carbapenems                                                                              Enterobacterales                      23                  542                  43                       37                    19                                                                                                                                                                                                                                                                                      
  *P. aeruginosa*                                                                          15                                    445                 29                   25                       36                    1                        \-                                                                                                                                                                                                                                                             
  *Acinetobacter* spp.                                                                     5                                     103                 28                   17                       22                                             \-                                                                                                                                                                                                                                                             
  Gram + cocci                                                                             12                                    231                 56                   13                       22                    8                        *S. aureus, S. epidermidis, Enterococci* spp., *S. pneumoniae*. High rates of antagonistic effect reported on *E. faecalis* isolates.                                                                                                                          
  *N. gonorrhoeae*                                                                         1                                     4                   0                    75                       25                                             \-                                                                                                                                                                                                                                                             
  Monobactams                                                                              Enterobacterales                      4                   71                   15                       27                    45                                                                                                                                                                                                                                                                                      \-
  *P. aeruginosa*                                                                          3                                     138                 29                   54                       17                                             \-                                                                                                                                                                                                                                                             
  Quinolones                                                                               Enterobacterales                      6                   264                  17                       12                    69                                                                                                                                                                                                                                                                                      \-
  *P. aeruginosa*                                                                          18                                    263                 42                   36                       38                    5                        Synergism rates not concordant in all studies.                                                                                                                                                                                                                 
  *Acinetobacter* spp.                                                                     3                                     41                  2                    10                       7                                              \-                                                                                                                                                                                                                                                             
  *Staphylococcus* spp.                                                                    7                                     90                  37                   9                        34                                             \-                                                                                                                                                                                                                                                             
  *N. gonorrhoeae*                                                                         1                                     4                   0                    0                        100                                            \-                                                                                                                                                                                                                                                             
  Aminoglycosides                                                                          Enterobacterales                      19                  713                  20                       31                    36                                                                                                                                                                                                                                                                                      Synergism rates not concordant in all studies.
  *P. aeruginosa*                                                                          23                                    440                 43                   29                       27                    1                        Synergism rates not concordant in all studies.                                                                                                                                                                                                                 
  *Acinetobacter* spp.                                                                     5                                     102                 37                   5                        18                                             Synergism rates not concordant in all studies.                                                                                                                                                                                                                 
  *S. aureus*                                                                              8                                     301                 26                   4                        53                    1                        Antagonistic effect of FOS + gentamicin against 4 isolates \[[@B12-antibiotics-09-00500]\].                                                                                                                                                                    
  *Streptococcus* spp.                                                                     1                                     16                  0                    52                       48                                             \-                                                                                                                                                                                                                                                             
  *E. faecium*                                                                             1                                     8                   62                   13                       25                                             \-                                                                                                                                                                                                                                                             
  *N. gonorrhoeae*                                                                         1                                     4                   0                    25                       75                                             \-                                                                                                                                                                                                                                                             
  *H. influenzae*                                                                          1                                     1                   0                    0                        100                                            \-                                                                                                                                                                                                                                                             
  Glycopeptides                                                                            *A. baumannii*                        1                   20                   0                        0                     100                                                                                                                                                                                                                                                                                     \-
  *Staphylococcus* spp.                                                                    12                                    229                 17                   16                       65                    2                        In 2 studies \[[@B69-antibiotics-09-00500],[@B176-antibiotics-09-00500]\] VAN exhibited higher synergistic rates than TEC. Antagonistic effect with FOS + VAN against 5 isolates of *S. aureus* \[[@B12-antibiotics-09-00500],[@B43-antibiotics-09-00500]\].   
  *Enterococcus* spp.                                                                      2                                     55                  55                   22                       24                                             \-                                                                                                                                                                                                                                                             
  *S. pneumoniae*                                                                          2                                     28                  4                    4                        92                                             \-                                                                                                                                                                                                                                                             
  Macrolides                                                                               Enterobacterales                      1                   87                   53                       34                    14                                                                                                                                                                                                                                                                                      \-
  *N. gonorrhoeae*                                                                         2                                     12                  0                    0                        100                                            \-                                                                                                                                                                                                                                                             
  *P. aeruginosa*                                                                          2                                     31                  19                   79                       2                                              \-                                                                                                                                                                                                                                                             
  *S. aureus*                                                                              1                                     34                  26                   68                       6                                              \-                                                                                                                                                                                                                                                             
  *S. epidermidis*                                                                         1                                     11                  0                    0                        100                                            \-                                                                                                                                                                                                                                                             
  *S. pseudointermedius*                                                                   1                                     8                   62                   25                       12                                             \-                                                                                                                                                                                                                                                             
  *Streptococcus* spp.                                                                     1                                     26                  15                   27                       58                                             Only erythromycin was tested in combination with FOS. Against almost half of strains additive or, less frequently, synergistic effect was observed.                                                                                                            
  Tetracyclines                                                                            Enterobacterales                      2                   120                  5                        11                    84                                                                                                                                                                                                                                                                                      Indifferent effect when tetracycline was tested, but one study showed additive or synergistic effect when using minocycline + FOS combination \[[@B38-antibiotics-09-00500]\].
  *P. aeruginosa*                                                                          1                                     5                   40                   60                       0                                              \-                                                                                                                                                                                                                                                             
  *Acinetobacter* spp.                                                                     1                                     25                  12                   56                       32                                             In all experiment minocycline susceptibility restoration was observed \[[@B65-antibiotics-09-00500]\].                                                                                                                                                         
  *S. aureus*                                                                              3                                     152                 72                   1                        27                                             \-                                                                                                                                                                                                                                                             
  *Enterococcus* spp.                                                                      3                                     75                  24                   10                       20                                             Indifferent effect when minocycline was tested, but one study showed additive or synergistic effect when using doxicycline + FOS combination \[[@B68-antibiotics-09-00500]\].                                                                                  
  *N. gonorrhoeae*                                                                         1                                     4                   0                    0                        100                                            \-                                                                                                                                                                                                                                                             
  Polymyxins                                                                               Enterobacterales                      18                  381                  26                       35                    35                       4                                                                                                                                                                                                                                                              Antagonistic effect of FOS + colistin observed against 14 isolates of *K. pneumoniae*.
  *P. aeruginosa*                                                                          4                                     111                 27                   41                       31                                             \-                                                                                                                                                                                                                                                             
  *Acinetobacter* spp.                                                                     12                                    206                 19                   15                       32                    1                        Antagonistic effect of FOS + colistin observed against 3 isolates of *A. baumannii*.                                                                                                                                                                           
  *N. gonorrhoeae*                                                                         1                                     4                   0                    0                        100                                            \-                                                                                                                                                                                                                                                             
  Daptomycin                                                                               *Staphylococcus* spp.                 13                  186                  56                       31                    14                                                                                                                                                                                                                                                                                      \-
  *Enterococcus* spp.                                                                      5                                     49                  97                   0                        3                                              \-                                                                                                                                                                                                                                                             
  Tigecycline                                                                              Enterobacterales                      9                   313                  17                       44                    34                       1                                                                                                                                                                                                                                                              One in vivo study observed indifferent effect in 100% of cases against *E. coli* \[[@B73-antibiotics-09-00500]\] and one in vitro study reported 2 cases of antagonistic effect against *K. pneumoniae* isolates \[[@B89-antibiotics-09-00500]\].
  *P. aeruginosa*                                                                          1                                     15                  13                   0                        87                                             \-                                                                                                                                                                                                                                                             
  *Acinetobacter* spp.                                                                     2                                     25                  0                    16                       4                                              \-                                                                                                                                                                                                                                                             
  *S. aureus*                                                                              2                                     48                  21                   0                        79                                             Conflicting results (total indifference or almost total synergistic effect).                                                                                                                                                                                   
  *Enterococcus* spp.                                                                      3                                     61                  61                   0                        9                                              \-                                                                                                                                                                                                                                                             
  *N. gonorrhoeae*                                                                         1                                     4                   0                    0                        100                                            \-                                                                                                                                                                                                                                                             
  Linezolid                                                                                *Enterococcus* spp.                   4                   69                   17                       29                    6                                                                                                                                                                                                                                                                                       Synergistic effect was never observed for *E. faecalis* (2 studies) \[[@B13-antibiotics-09-00500],[@B201-antibiotics-09-00500]\].
  *S. aureus*                                                                              9                                     166                 74                   2                        2                                              \-                                                                                                                                                                                                                                                             
  *S. epidermidis*                                                                         1                                     2                   100                  0                        0                                              \-                                                                                                                                                                                                                                                             
  Rifampin                                                                                 *E. coli*                             1                   17                   6                        53                    41                                                                                                                                                                                                                                                                                      \-
  *A. baumannii*                                                                           1                                     20                  0                    0                        100                                            \-                                                                                                                                                                                                                                                             
  *S. aureus*                                                                              9                                     114                 35                   21                       4                     3                        Antagonistic effect of FOS + RIF against 3 isolates \[[@B35-antibiotics-09-00500],[@B37-antibiotics-09-00500]\].                                                                                                                                               
  *S. epidermidis*                                                                         2                                     5                   40                   0                        40                                             \-                                                                                                                                                                                                                                                             
  *Streptococcus* spp.                                                                     2                                     29                  3                    0                        97                                             \-                                                                                                                                                                                                                                                             
  *Enterococcus* spp.                                                                      2                                     50                  59                   0                        12                                             \-                                                                                                                                                                                                                                                             
  *N. gonorrhoeae*                                                                         1                                     4                   25                   0                        75                                             \-                                                                                                                                                                                                                                                             
  Metronidazole                                                                            Intestinal bacteria (not specified)   1                   NA                   \-                       \-                    \-                                                                                                                                                                                                                                                                                      \-
  *H. pylori*                                                                              1                                     24                  0                    21                       80                                             \-                                                                                                                                                                                                                                                             
  Spectinomycin                                                                            *N. gonorrhoeae*                      1                   4                    0                        0                     100                                                                                                                                                                                                                                                                                     \-
  Sulbactam                                                                                *A. baumannii*                        1                   8                    75                       0                     25                                                                                                                                                                                                                                                                                      \-
  Lincomycin                                                                               *S. aureus*                           1                   37                   81                       19                    0                                                                                                                                                                                                                                                                                       \-
  Nitroxoline                                                                              *P. aeruginosa*                       1                   8                    12                       0                     88                                                                                                                                                                                                                                                                                      \-
  Dalfopristin-Quinupristin                                                                *Staphylococcus* spp.                 2                   12                   100                      0                     0                                                                                                                                                                                                                                                                                       \-
  Fusidic acid                                                                             *S. aureus*                           3                   239                  63                       4                     33                                                                                                                                                                                                                                                                                      \-
  Chloramphenicol                                                                          Enterobacterales                      4                   468                  39                       34                    25                                                                                                                                                                                                                                                                                      \-
  *P. aeruginosa*                                                                          1                                     19                  53                   37                       10                                             \-                                                                                                                                                                                                                                                             
  *S. aureus*                                                                              1                                     48                  44                   37                       19                                             \-                                                                                                                                                                                                                                                             
  Nitrofurantoin                                                                           Enterobacterales                      1                   100                  0                        0                     100                                                                                                                                                                                                                                                                                     \-
  *Enterococcus* spp.                                                                      1                                     32                  0                    0                        100                                            \-                                                                                                                                                                                                                                                             
  Trimethoprim-Sulfamethoxazole                                                            Enterobacterales                      2                   120                  2                        5                     89                                                                                                                                                                                                                                                                                      \-
  *S. aureus*                                                                              1                                     148                 3                    0                        95                    3                        Antagonistic effect was reported for 4 isolates \[[@B12-antibiotics-09-00500]\].                                                                                                                                                                               

The Authors are grateful to Maria Crapulli for her precious help in finding articles available only in paper version.

The following are available online at <https://www.mdpi.com/2079-6382/9/8/500/s1>, Table S1: Studies on combination between fosfomycin and different antibiotics. CB: checkerboard assay; TK: time--kill assay; ET: E-test, Table S2: Studies on combination between fosfomycin and molecules other than antibiotics. CB: checkerboard assay; TK: time--kill assay.
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